Nivolumab in patients with advanced hepatocellular ca
open-label, non-comparative, phase 1/2 dose escalation

Lancet, The

389, 2492-2502

DOI: 10.1016/s0140-6736(17)31046-2

Citation Report

#	Article	IF	Citations
1	Immune oncology in hepatocellular carcinomaâ€"hype and hope. Lancet, The, 2017, 389, 2448-2449.	6.3	10
2	Nivolumab keeps HCC in check and opens avenues for checkmate. Nature Reviews Clinical Oncology, 2017, 14, 392-392.	12.5	19
3	Nivolumab: checkmate for hepatocellular carcinoma?. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 326-326.	8.2	3
4	Asiaâ€"Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International, 2017, 11, 317-370.	1.9	1,537
5	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 2017, 153, 812-826.	0.6	650
6	Antibodies Against Immune Checkpoint Molecules RestoreÂFunctions of Tumor-Infiltrating T Cells in HepatocellularÂCarcinomas. Gastroenterology, 2017, 153, 1107-1119.e10.	0.6	309
7	Regorafenib for the treatment of unresectable hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2017, 17, 567-576.	1.1	26
8	Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma. Digestive Diseases, 2017, 35, 618-622.	0.8	10
9	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. European Journal of Cancer, 2017, 86, 305-317.	1.3	22
10	<scp>IFI</scp>16 restoration in hepatocellular carcinoma induces tumour inhibition via activation of p53 signals and inflammasome. Cell Proliferation, 2017, 50, .	2.4	31
12	Endocrine side effects of cancer immunotherapy. Endocrine-Related Cancer, 2017, 24, T331-T347.	1.6	131
13	Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma. , 2017, , 51-68.		0
14	Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions. Therapeutic Advances in Gastroenterology, 2017, 10, 805-814.	1.4	13
15	Immunomodulatory Therapy of Inflammatory Liver Disease Using Selectin-Binding Glycopolymers. ACS Nano, 2017, 11, 9689-9700.	7.3	36
16	Learning the Roles of the Hepatic Adaptive Immune System in Hepatocellular Carcinomaâ€"Nature's Guide for Successful Cancer Immunotherapy. Seminars in Liver Disease, 2017, 37, 210-218.	1.8	3
17	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	2.1	62
18	PD-1 checkpoint inhibition: Toxicities and management. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 701-707.	0.8	57
19	An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2017, 18, 1467-1476.	0.9	23

#	Article	IF	Citations
20	Viral hepatitis and liver cancer. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160274.	1.8	265
21	Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. Clinical Cancer Research, 2017, 23, 7333-7339.	3.2	128
22	Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation?. Journal of Hepatology, 2017, 67, 893-895.	1.8	4
23	Programmed cell deathâ€1 (PDâ€1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cellâ€“intrinsic PDâ€1. Hepatology, 2017, 66, 1920-1933.	3.6	142
24	Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study. Journal of Hepatology, 2017, 66, S223-S224.	1.8	9
25	Translating 'â€“omics' results into precision medicine for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 571-572.	8.2	28
26	Lenalidomide as secondâ€line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. Alimentary Pharmacology and Therapeutics, 2017, 46, 722-730.	1.9	12
27	Lenvatinib in Advanced Hepatocellular Carcinoma. Liver Cancer, 2017, 6, 253-263.	4.2	43
28	Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer, 2017, 6, 360-374.	4.2	66
29	H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma. Cancer Research, 2017, 77, 6999-7013.	0.4	100
30	Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. Clinical and Translational Immunology, 2017, 6, e161.	1.7	51
31	Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma. American Journal of Gastroenterology, 2017, 112, 1895-1896.	0.2	52
32	Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. European Journal of Cancer, 2017, 87, 101-112.	1.3	56
33	Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2017, 44, 125-132.	1.1	61
34	New Era of the Management of Liver Diseases and Liver Cancer: State-of-the-Art Progress in 2017. Digestive Diseases, 2017, 35, 493-497.	0.8	1
35	Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature, 2017, 551, 340-345.	13.7	396
36	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. Future Oncology, 2017, 13, 1893-1905.	1.1	9
37	Cabozantinib in the treatment of hepatocellular carcinoma. Future Oncology, 2017, 13, 1915-1929.	1.1	10

#	Article	IF	Citations
38	Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. Oncology, 2017, 93, 135-146.	0.9	96
39	Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. Oncology, 2017, 93, 147-159.	0.9	83
40	Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma. Oncology, 2017, 93, 160-164.	0.9	56
41	Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. Liver Cancer, 2017, 6, 313-324.	4.2	21
42	Immune Checkpoint Inhibitors in Melanoma and HIV Infection. Open AIDS Journal, 2017, 11, 91-100.	0.1	12
43	Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers, 2017, 9, 127.	1.7	112
44	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. International Journal of Molecular Sciences, 2017, 18, 2642.	1.8	72
45	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology, 2017, 8, 1597.	2.2	225
46	The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2017, 18, 1175.	1.8	23
47	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. Frontiers in Immunology, 2017, 8, 1215.	2.2	80
48	Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 131-138.	1.8	45
49	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology and Oncology, 2017, 10, 146.	6.9	77
50	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
51	Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. Oncotarget, 2017, 8, 96649-96655.	0.8	22
52	Treatment options after sorafenib failure in patients with hepatocellular carcinoma. Clinical and Molecular Hepatology, 2017, 23, 273-279.	4.5	34
53	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncology, 2018, 14, 553-566.	1.1	22
54	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 222-234.	8.2	82
55	Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression. Hepatology Communications, 2018, 2, 148-151.	2.0	16

#	Article	IF	Citations
56	Genetic and Epigenetic Heterogeneity in Normal Liver Homeostasis and Its Implications for Liver Disease and Hepatocellular Cancer. Seminars in Liver Disease, 2018, 38, 041-050.	1.8	25
57	Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 40-54.	4.2	24
58	Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century. International Journal of Cancer, 2018, 143, 324-332.	2.3	5
59	Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends in Molecular Medicine, 2018, 24, 395-411.	3.5	58
60	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	1.5	169
61	Combination Cancer Immunotherapy in Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 20-27.	4.2	55
62	Patient prioritisation in HCC treatment: All (good) things come in threes. Journal of Hepatology, 2018, 68, 1311-1312.	1.8	3
63	The role of molecular enrichment on future therapies in hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 237-247.	1.8	95
64	Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. Current Problems in Cancer, 2018, 42, 8-11.	1.0	0
65	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. Journal of Immunotherapy, 2018, 41, 284-291.	1.2	11
66	Hepatocellular carcinoma: Prospects for natural killer cell immunotherapy. Hla, 2018, 92, 3-11.	0.4	10
67	A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity. Biochemical Pharmacology, 2018, 154, 127-135.	2.0	28
68	Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1222-1225.	0.4	29
69	Generalization and representativeness of phase III immune checkpoint blockade trials in nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 736-744.	0.8	31
70	Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatology Research, 2018, 48, 597-607.	1.8	58
71	Current and future directions of management of hepatitis B: steps toward a cure. Future Virology, 2018, 13, 189-209.	0.9	1
72	Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1. Immunity, 2018, 48, 621-623.	6.6	4
73	Targeting Wnt/Î²-Catenin Signaling for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2018, 39, 648-658.	4.0	159

#	Article	IF	Citations
74	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncology, The, 2018, 19, 682-693.	5.1	285
75	Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells. Immunity, 2018, 48, 773-786.e5.	6.6	150
76	Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology, 2018, 68, 1025-1041.	3.6	330
77	CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. Journal of Pathology, 2018, 245, 297-310.	2.1	25
78	Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver International, 2018, 38, 976-987.	1.9	166
79	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018, 68, 723-750.	3.6	3,096
80	Circulating tumor DNA detection in hepatocellular carcinoma. Annals of Oncology, 2018, 29, 1094-1096.	0.6	4
81	Sorafenib and hepatic arterial infusion chemotherapy: another failed combination. The Lancet Gastroenterology and Hepatology, 2018, 3, 376-377.	3.7	4
82	New trials and results in systemic treatment of HCC. Journal of Hepatology, 2018, 69, 525-533.	1.8	49
83	Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepatic Oncology, 2018, 5, HEP01.	4.2	30
84	The role of external beam radiotherapy in the treatment of hepatocellular cancer. Cancer, 2018, 124, 3476-3489.	2.0	26
85	Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 1-19.	4.2	89
86	Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies. Journal of Gastrointestinal Cancer, 2018, 49, 107-115.	0.6	27
87	Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiotherapy and Oncology, 2018, 129, 130-135.	0.3	69
88	Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nature Reviews Clinical Oncology, 2018, 15, 310-324.	12.5	412
89	Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. Cancer Chemotherapy and Pharmacology, 2018, 81, 679-686.	1.1	15
90	The immunology of hepatocellular carcinoma. Nature Immunology, 2018, 19, 222-232.	7.0	697
91	Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. Melanoma Research, 2018, 28, 155-158.	0.6	40

#	Article	IF	Citations
92	Lenvatinib: can a non-inferiority trial change clinical practice?. Lancet, The, 2018, 391, 1123-1124.	6.3	12
93	Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. The Lancet Gastroenterology and Hepatology, 2018, 3, 192-202.	3.7	75
94	Targeting tumorâ€infiltrating Ly6G⁺ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. International Journal of Cancer, 2018, 142, 1878-1889.	2.3	46
95	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist, 2018, 23, 410-421.	1.9	23
96	Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology, 2018, 48, 103-114.	0.6	192
97	Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. New England Journal of Medicine, 2018, 378, 158-168.	13.9	3,047
98	Hepatocellular carcinoma. Lancet, The, 2018, 391, 1301-1314.	6.3	3,878
99	Two large steps forward, one small step back. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 74-76.	8.2	18
100	Novel insights into mechanisms of disease progression. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 71-72.	8.2	23
101	The Basics of Cancer Immunotherapy. , 2018, , .		5
102	Immunotherapy for Other Malignancies. , 2018, , 125-142.		0
104	Immunotherapy of Hepatocellular Carcinoma. Oncology Research and Treatment, 2018, 41, 292-297.	0.8	27
105	Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. Future Oncology, 2018, 14, 2957-2967.	1.1	54
106	Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. OncoImmunology, 2018, 7, e1448332.	2.1	54
107	Dynamic human immune and tumour cells cross-talk in PDX-humanised mice warrants checkpoint inhibitor cancer immunotherapies assessment. Gut, 2018, 67, 1753-1754.	6.1	0
108	Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Future Oncology, 2018, 14, 2293-2302.	1.1	25
109	Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR. Clinical Cancer Research, 2018, 24, 3767-3780.	3.2	34
110	The immune contexture of hepatocellular carcinoma predicts clinical outcome. Scientific Reports, 2018, 8, 5351.	1.6	93

#	Article	IF	Citations
111	Hepatocellular Carcinoma With Portal Venous Invasion. JAMA Oncology, 2018, 4, 669.	3.4	1
112	Treatment of advanced hepatocellular carcinoma: beyond sorafenib. The Lancet Gastroenterology and Hepatology, 2018, 3, 218-220.	3.7	19
113	Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3509-E3518.	3.3	109
114	Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?. Hepatobiliary and Pancreatic Diseases International, 2018, 17, 93-94.	0.6	1
115	Regulation and Function of the PD-L1 Checkpoint. Immunity, 2018, 48, 434-452.	6.6	1,437
116	Cancer immunotherapy using checkpoint blockade. Science, 2018, 359, 1350-1355.	6.0	4,274
117	Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers. Seminars in Oncology, 2018, 45, 116-123.	0.8	9
118	Radiogenomics and IR. Journal of Vascular and Interventional Radiology, 2018, 29, 706-713.	0.2	7
119	Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncology, 2018, 14, 947-962.	1.1	9
120	Precision diagnosis and treatment of liver cancer in China. Cancer Letters, 2018, 412, 283-288.	3.2	226
121	Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?. Cancer Immunology, Immunotherapy, 2018, 67, 161-174.	2.0	24
122	Regorafenib for treatment of hepatocellular carcinoma. Hepatology, 2018, 67, 1162-1165.	3.6	10
123	Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?. Hepatology, 2018, 67, 826-828.	3.6	1
124	CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC. Gut, 2018, 67, 783-784.	6.1	7
125	Immune checkpoint blockade in infectious diseases. Nature Reviews Immunology, 2018, 18, 91-104.	10.6	407
126	Cholangiocarcinoma â€" evolving concepts and therapeutic strategies. Nature Reviews Clinical Oncology, 2018, 15, 95-111.	12.5	1,051
127	Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma. Journal of Hepatology, 2018, 68, 100-108.	1.8	35
128	Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes. FEBS Journal, 2018, 285, 752-762.	2.2	43

#	Article	IF	Citations
129	Targets for immunotherapy of liver cancer. Journal of Hepatology, 2018, 68, 157-166.	1.8	129
130	The Role of Transforming Growth Factor-Î² in Human Hepatocarcinogenesis: Mechanistic and Therapeutic Implications From an Integrative Multiomics Approach. Gastroenterology, 2018, 154, 17-20.	0.6	11
131	⁹⁰Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort. Journal of Nuclear Medicine, 2018, 59, 1042-1048.	2.8	54
132	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nature Reviews Urology, 2018, 15, 112-124.	1.9	73
133	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. Annual Review of Medicine, 2018, 69, 333-347.	5.0	38
135	Hepatocellular carcinoma in the era of immunotherapy. Current Problems in Cancer, 2018, 42, 40-48.	1.0	135
136	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	1.2	149
137	Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. Clinical Cancer Research, 2018, 24, 1518-1524.	3.2	194
138	Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers. World Journal of Gastrointestinal Oncology, 2018, 10, 221-227.	0.8	6
139	Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget, 2018, 9, 37721-37732.	0.8	16
140	Checkpoint inhibitor-associated autoimmunity. Best Practice and Research in Clinical Rheumatology, 2018, 32, 781-802.	1.4	13
142	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget, 2018, 9, 16701-16717.	0.8	44
143	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2018, 36, 1020-1044.	0.8	108
144	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Translational Gastroenterology and Hepatology, 2018, 3, 89-89.	1.5	30
145	Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2018, 7, 466-474.	0.7	14
146	Immunotherapy in pancreatic adenocarcinomaâ€"overcoming barriers to response. Journal of Gastrointestinal Oncology, 2018, 9, 143-159.	0.6	42
147	Immunotherapy in the Asiatic population: any differences from Caucasian population?. Journal of Thoracic Disease, 2018, 10, S1482-S1493.	0.6	42
148	Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. Journal of Gastrointestinal Oncology, 2018, 9, 377-389.	0.6	2

#	Article	IF	Citations
149	Understanding and quantifying the immune microenvironment in hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 107-107.	1.5	1
150	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. Journal of Gastrointestinal Oncology, 2018, 9, 1054-1062.	0.6	110
151	Systemic Therapy for Hepatocellular Carcinoma: Recent Advances. Acta Hepatologica Japonica, 2018, 59, 587-603.	0.0	3
152	Misconceptions Surrounding Hepatocellular Carcinoma. Clinical Liver Disease, 2018, 12, 154-159.	1.0	0
153	Hepatocellular carcinoma: one world, one cancerâ€"different guidelines?. Hepatobiliary Surgery and Nutrition, 2018, 7, 41-43.	0.7	4
154	Editorial: charting the future of hepatocellular carcinoma publications. Journal of Hepatocellular Carcinoma, 2018, Volume 5, 51-54.	1.8	0
155	17. Management of Hepatocellular Carcinoma: an Update. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1934-1943.	0.0	0
156	Biologic and Immunotherapy Developments in Advanced Hepatocellular Carcinoma. , 2018, , .		0
157	Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events. Journal of Patient-Reported Outcomes, 2018, 2, 35.	0.9	9
159	Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World Journal of Gastroenterology, 2018, 24, 5081-5094.	1.4	58
160	Impressive Response of Advanced Hepatocellular Carcinoma to Cisplatin Combined with Sorafenib, Nivolumab, and PG2 Immunomodulatory Injection: A Case Report. Journal of Clinical Case Reports, 2018, 08, .	0.0	1
162	Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. International Journal of Molecular Sciences, 2018, 19, 3505.	1.8	69
163	Patient-derived organoids: a promising model for personalized cancer treatment. Gastroenterology Report, 2018, 6, 243-245.	0.6	52
164	Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1â€6 hepatocellular carcinoma model. Cancer Science, 2018, 109, 3993-4002.	1.7	215
165	Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. International Journal of Molecular Sciences, 2018, 19, 3648.	1.8	32
166	Mechanism and prognostic value of indoleamine 2,3â€dioxygenase 1 expressed in hepatocellular carcinoma. Cancer Science, 2018, 109, 3726-3736.	1.7	29
167	Management of Hepatocarcinoma with Celecoxib and Pentoxifylline: Report of Three Cases. Clinical & Experimental Pharmacology, 2018, 08, .	0.3	0
168	Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology, 2018, 155, 1684-1686.	0.6	4

#	Article	IF	Citations
169	Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of HepatocellularÂCarcinoma. Gastroenterology, 2018, 155, 1936-1950.e17.	0.6	211
170	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). , 2018, 6, 114.		41
172	Immunotherapy for hepatocellular carcinoma: current status and future perspectives. ESMO Open, 2018, 3, e000455.	2.0	76
173	Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway. OncoTargets and Therapy, 2018, Volume 11, 8633-8642.	1.0	25
174	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics, 2018, 8, 5690-5702.	4.6	45
175	Staging systems of hepatocellular carcinoma: A review. Indian Journal of Gastroenterology, 2018, 37, 481-491.	0.7	88
176	The Case for Proton Beam Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1406-1407.	0.4	0
177	Emerging Role for Systemic Therapy in Earlier Stages of HCC. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1407.	0.4	1
178	Strategies of Combination Drug Delivery for Immune Checkpoint Blockades. Advanced Healthcare Materials, 2019, 8, e1801099.	3.9	32
179	Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. BMC Cancer, 2018, 18, 1250.	1.1	6
180	Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). Journal of Hepatocellular Carcinoma, 2018, Volume 5, 109-119.	1.8	15
181	Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Research, 2018, 78, 6717-6725.	0.4	155
182	Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2018, 10, 108-114.	0.8	25
183	Liver Allograft Failure After Nivolumab Treatmentâ€"A Case Report With Systematic Literature Research. Transplantation Direct, 2018, 4, e376.	0.8	98
184	Cytolytic Activity (CYT) Score Is a Prognostic Biomarker Reflecting Host Immune Status in Hepatocellular Carcinoma (HCC). Anticancer Research, 2018, 38, 6631-6638.	0.5	36
185	Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma. Current Hepatology Reports, 2018, 17, 385-391.	0.4	1
186	Stereotactic Ablative Radiotherapy (SABR/SBRT) for Hepatocellular Carcinoma. Current Hepatology Reports, 2018, 17, 392-398.	0.4	1
187	Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and) Tj ETQq1 1 0.784314 rgBT /Overlock	0.5	3

#	Article	IF	Citations
188	A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. OncoTargets and Therapy, 2018, Volume 11, 8529-8541.	1.0	26
189	Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World Journal of Gastroenterology, 2018, 24, 4436-4447.	1.4	105
190	Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver. Advanced Functional Materials, 2019, 29, 1805760.	7.8	13
191	Reply to: â€œIncidence of grade 3â€“4 liver injury under immune checkpoints inhibitors: A retrospective studyâ€. Journal of Hepatology, 2018, 69, 1397-1398.	1.8	2
192	Systemic treatment for hepatocellular carcinoma. Chronic Diseases and Translational Medicine, 2018, 4, 148-155.	0.9	8
193	Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study. Journal of Hepatology, 2018, 69, 1396-1397.	1.8	41
194	A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. Journal of Clinical Pathology, 2018, 71, 1078-1083.	1.0	33
195	Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. Cancers, 2018, 10, 367.	1.7	24
196	Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection. Viruses, 2018, 10, 531.	1.5	29
197	Knowns and Unknowns: the Safety and Efficacy of Cancer Immunotherapy in Chronic Liver Disease. Current Hepatology Reports, 2018, 17, 153-155.	0.4	11
198	Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9879-E9888.	3.3	67
199	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biology and Medicine, 2018, 15, 116.	1.4	52
200	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv238-iv255.	0.6	663
201	4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12. Molecular Therapy, 2018, 26, 2738-2750.	3.7	53
202	Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy. Seminars in Radiation Oncology, 2018, 28, 332-341.	1.0	16
203	Prostaglandin E2 facilitates Hepatitis B virus replication by impairing CTL function. Molecular Immunology, 2018, 103, 243-250.	1.0	11
204	Introduction. Seminars in Radiation Oncology, 2018, 28, 265-266.	1.0	0
205	Viral hepatitis, inflammation, and cancer: A lesson for autoimmunity. Journal of Autoimmunity, 2018, 95, 58-68.	3.0	31

#	Article	IF	Citations
206	Liver Toxicity with Cancer Checkpoint Inhibitor Therapy. Seminars in Liver Disease, 2018, 38, 366-378.	1.8	31
207	Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Seminars in Liver Disease, 2018, 38, 379-388.	1.8	62
208	Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies. Clinics, 2018, 73, e510s.	0.6	0
209	Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481880808.	1.4	10
210	Current State of Immunotherapy for HCCâ€"Supporting Data and Toxicity Management. Current Hepatology Reports, 2018, 17, 434-443.	0.4	2
211	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinomaâ€"a meta-analysis. European Journal of Cancer, 2018, 105, 1-9.	1.3	69
212	Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers, 2018, 10, 412.	1.7	138
213	Hepatocellular carcinoma: Where are we in 2018?. Current Problems in Surgery, 2018, 55, 450-503.	0.6	2
214	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIVÂor hepatitis B/C infection. European Journal of Cancer, 2018, 104, 137-144.	1.3	97
215	Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing. Oncology Letters, 2018, 16, 6003-6012.	0.8	8
216	Nivolumab for the treatment of hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 1169-1175.	1.1	99
217	Tim-3 expression and its role in hepatocellular carcinoma. Journal of Hematology and Oncology, 2018, 11, 126.	6.9	89
218	Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Experimental and Molecular Medicine, 2018, 50, 1-9.	3.2	216
219	Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature. Frontiers in Medicine, 2018, 5, 268.	1.2	49
220	Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI). Journal of Hepatocellular Carcinoma, 2018, Volume 5, 87-90.	1.8	12
221	Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1193-1199.	2.3	40
222	Molecular heterogeneity in hepatocellular carcinoma. Hepatic Oncology, 2018, 5, HEP10.	4.2	18
223	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Molecular Therapy, 2018, 26, 2553-2566.	3.7	20

#	Article	IF	Citations
224	Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 1069-1076.	1.1	25
225	Development of shellfish allergy after exposure to dual immune checkpoint blockade. Hepatic Oncology, 2018, 5, HEP02.	4.2	3
226	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. European Journal of Cancer, 2018, 103, 7-16.	1.3	63
227	Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. Future Oncology, 2018, 14, 3187-3198.	1.1	9
228	Changes in plasma interleukin-8 and tumor necrosis factor-Î± levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2018, 82, 857-864.	1.1	6
229	Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opinion on Biological Therapy, 2018, 18, 1061-1071.	1.4	27
230	Long-term remission in advanced stage hepatocellular carcinoma? AÂchance for cure?. Memo - Magazine of European Medical Oncology, 2018, 11, 185-192.	0.3	6
231	Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. Journal of Clinical and Translational Hepatology, 2018, 6, 1-10.	0.7	218
232	Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy, 2018, 10, 1077-1091.	1.0	6
233	Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-10.	1.0	34
234	Precision oncology in liver cancer. Annals of Translational Medicine, 2018, 6, 285-285.	0.7	22
235	Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data. Health Economics Review, 2018, 8, 18.	0.8	6
236	Impact of PDâ€Ł1, transforming growth factorâ€Î² expression and tumorâ€infiltrating CD8⁺ T cells on clinical outcome of patients with advanced thymic epithelial tumors. Thoracic Cancer, 2018, 9, 1341-1353.	0.8	20
237	Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterology Journal, 2018, 6, 970-973.	1.6	81
238	The Paradoxical Role of NKG2D in Cancer Immunity. Frontiers in Immunology, 2018, 9, 1808.	2.2	47
239	The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-4.	0.8	7
240	Management of Hepatocellular Carcinoma in Japan as a World-Leading Model. Liver Cancer, 2018, 7, 134-147.	4.2	56
241	Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. Journal of Gastrointestinal Cancer, 2018, 49, 227-236.	0.6	28

#	Article	IF	Citations
242	Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis, 2018, 7, 44.	2.1	31
244	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. Journal of Pain and Symptom Management, 2018, 56, 460-472.	0.6	14
245	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. Journal of Molecular Biology, 2018, 430, 2014-2029.	2.0	42
246	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. Oncologist, 2018, 23, 1171-1177.	1.9	29
247	Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2018, 41, 1799-1802.	0.9	45
248	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncology, The, 2018, 19, 940-952.	5.1	1,816
249	Shaping the landscape of immune oncology in hepatocellular carcinoma. Lancet Oncology, The, 2018, 19, 855-856.	5.1	2
250	Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy. Advances in Radiation Oncology, 2018, 3, 399-404.	0.6	22
252	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews, 2018, 68, 16-24.	3.4	124
253	Nivolumab for the treatment of colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 611-618.	1.1	52
254	Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. Gastrointestinal Tumors, 2018, 5, 38-46.	0.3	8
255	A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. Cancer Chemotherapy and Pharmacology, 2018, 82, 429-440.	1.1	35
257	Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patientsâ€™ selection. Critical Reviews in Oncology/Hematology, 2018, 129, 27-39.	2.0	39
258	Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-8.	0.8	97
259	Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Critical Reviews in Oncology/Hematology, 2018, 129, 44-53.	2.0	23
260	Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. Journal of Immunology Research, 2018, 2018, 1-8.	0.9	57
261	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 2018, 379, 54-63.	13.9	1,677
262	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma. Clinical Cancer Research, 2018, 24, 4650-4661.	3.2	63

#	Article	IF	Citations
263	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2018, 67, 1305-1315.	2.0	93
264	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death and Disease, 2018, 9, 620.	2.7	90
265	Molecular therapies and precision medicine for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2018, 15, 599-616.	12.5	1,308
266	Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. BMC Cancer, 2018, 18, 766.	1.1	42
267	Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease. Nutrients, 2018, 10, 977.	1.7	17
268	Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Reports, 2018, 24, 1363-1376.	2.9	288
269	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. Drug Design, Development and Therapy, 2018, Volume 12, 1645-1657.	2.0	19
270	Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer. Anticancer Research, 2018, 38, 4723-4729.	0.5	43
271	Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1â€“CH3 fusion protein. Cancer Immunology, Immunotherapy, 2018, 67, 1621-1634.	2.0	46
272	A Threeâ€Pronged Epigenetic Approach to the Treatment of Hepatocellular Carcinoma. Hepatology, 2018, 68, 1226-1228.	3.6	15
273	The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. Journal of Cancer, 2018, 9, 2302-2307.	1.2	23
274	Potentiating cancer vaccine efficacy in liver cancer. OncoImmunology, 2018, 7, e1488564.	2.1	26
275	Downregulation of lncRNA OGFRP1 inhibits hepatocellular carcinoma progression by AKT/mTOR and Wnt/β-catenin signaling pathways. Cancer Management and Research, 2018, Volume 10, 1817-1826.	0.9	39
276	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. Advanced Functional Materials, 2018, 28, 1802540.	7.8	92
277	Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. Journal of Hepatocellular Carcinoma, 2018, Volume 5, 61-73.	1.8	155
278	Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. Seminars in Liver Disease, 2018, 38, 242-251.	1.8	95
279	Review article: systemic treatment of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2018, 48, 598-609.	1.9	131
280	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatmentâ€”A Review From the Melanoma Perspective and Beyond. Frontiers in Immunology, 2018, 9, 1474.	2.2	174

#	Article	IF	Citations
281	Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook. Frontiers in Medicine, 2018, 5, 78.	1.2	38
282	Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Annals of Gastroenterological Surgery, 2018, 2, 289-303.	1.2	35
283	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
284	Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study. Biomedicines, 2018, 6, 46.	1.4	5
285	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. International Immunopharmacology, 2018, 62, 29-39.	1.7	860
286	Liquid biopsies for hepatocellular carcinoma. Translational Research, 2018, 201, 84-97.	2.2	29
287	The Role of Long Non-Coding RNAs in Hepatocarcinogenesis. International Journal of Molecular Sciences, 2018, 19, 682.	1.8	73
288	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq1 1 0.784314 rgBT /C		12
289	Differential Expression of Immune Inhibitory Checkpoint Signatures on Antiviral and Inflammatory T Cell Populations in Chronic Hepatitis B. Journal of Interferon and Cytokine Research, 2018, 38, 273-282.	0.5	13
290	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
291	Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opinion on Biological Therapy, 2018, 18, 905-910.	1.4	89
292	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Critical Reviews in Oncology/Hematology, 2018, 130, 13-26.	2.0	34
293	Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Medicine, 2018, 7, 2641-2653.	1.3	163
294	Immune checkpoint receptors: homeostatic regulators of immunity. Hepatology International, 2018, 12, 223-236.	1.9	43
295	VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer, 2018, 18, 511.	1.1	66
296	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
297	Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatology Research, 2018, 48, 622-634.	1.8	58
298	New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precision Clinical Medicine, 2018, 1, 21-28.	1.3	16

#	Article	IF	Citations
299	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines, 2018, 6, 87.	1.4	8
300	Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. Journal of Clinical Medicine, 2018, 7, 213.	1.0	24
301	Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C. Canadian Liver Journal, 2018, 1, 78-105.	0.3	3
302	Emerging therapies in advanced hepatocellular carcinoma. Experimental Hematology and Oncology, 2018, 7, 17.	2.0	85
303	Hepatitis B and C. Clinics in Liver Disease, 2018, 22, 703-722.	1.0	46
304	Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut, 2018, 67, 2056-2067.	6.1	179
305	Immune checkpoint therapy in liver cancer. Journal of Experimental and Clinical Cancer Research, 2018, 37, 110.	3.5	255
306	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist, 2018, 23, 991-997.	1.9	86
307	Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 536-554.	8.2	158
308	Exploring the role of oncolytic viruses in hepatobiliary cancers. Immunotherapy, 2018, 10, 971-986.	1.0	9
309	The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Scientific Reports, 2018, 8, 9105.	1.6	57
310	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. Mayo Clinic Proceedings, 2018, 93, 917-936.	1.4	4
311	Checkpoint blockade in esophagogastric cancer. Journal of Surgical Oncology, 2018, 118, 77-85.	0.8	9
312	Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure. Liver Cancer, 2018, 7, 205-208.	4.2	4
313	Oral chemotherapy for the treatment of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2018, 19, 993-1001.	0.9	13
314	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer, 2019, 8, 110-120.	4.2	46
315	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 29-39.	2.3	43
316	CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. Hepatology, 2019, 69, 143-159.	3.6	105

#	Article	IF	Citations
317	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 155-171.	4.2	25
318	Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut, 2019, 68, 916-927.	6.1	228
319	Animal models for hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 993-1002.	1.8	28
320	Characteristics of Immune Response to Tumorâ€Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma. Hepatology, 2019, 69, 653-665.	3.6	56
321	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68, 1065-1075.	6.1	195
322	Dual Targeting of Histone Methyltransferase G9a and DNAâ€Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. Hepatology, 2019, 69, 587-603.	3.6	81
323	Getting insights into hepatocellular carcinoma tumour heterogeneity by multiomics dissection. Gut, 2019, 68, 1913-1914.	6.1	5
325	Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. Alimentary Pharmacology and Therapeutics, 2019, 50, 872-884.	1.9	31
326	Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. Future Oncology, 2019, 15, 2449-2462.	1.1	11
327	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy, 2019, 11, 873-879.	1.0	12
328	DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade. Frontiers in Genetics, 2019, 10, 724.	1.1	12
329	Immunotherapy for hepatocellular carcinoma: Current and future. World Journal of Gastroenterology, 2019, 25, 2977-2989.	1.4	148
330	Prevention Strategies for Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 255-289.	0.4	2
331	Early alphaâ€foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver International, 2019, 39, 2184-2189.	1.9	55
332	Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 2416-2429.	1.4	66
333	Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib. Digestive and Liver Disease, 2019, 51, 1488-1490.	0.4	9
334	Serious immuneâ€related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head and Neck, 2019, 41, 4036-4050.	0.9	3
335	Experimental Models for Preclinical Research in Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 333-358.	0.4	7

#	Article	IF	Citations
336	Letter: programmed cell death proteinâ€1â€targeted immunotherapy for advanced hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2019, 50, 340-341.	1.9	1
337	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490.	4.2	57
338	The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver International, 2019, 39, 2008-2023.	1.9	56
339	Biology and significance of alphaâ€fetoprotein in hepatocellular carcinoma. Liver International, 2019, 39, 2214-2229.	1.9	327
340	A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 589-604.	8.2	2,482
341	Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by Î²-Catenin Activation. Cancer Discovery, 2019, 9, 1003-1005.	7.7	23
342	Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer, 2019, 8, 221-238.	4.2	51
343	Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?. Cancers, 2019, 11, 1078.	1.7	36
344	Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers, 2019, 11, 1085.	1.7	60
345	Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opinion on Biological Therapy, 2019, 19, 1165-1172.	1.4	40
346	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 617-630.	8.2	132
347	Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. Seminars in Diagnostic Pathology, 2019, 36, 434-440.	1.0	58
349	The alpha and ÃŸeta in phase II trials hepatocellular carcinoma â€•A tale of more than radiological response?. Liver International, 2019, 39, 1391-1393.	1.9	0
350	Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. ESMO Open, 2019, 4, e000464.	2.0	21
352	Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World Journal of Gastroenterology, 2019, 25, 3151-3167.	1.4	80
353	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology and Hepatology, 2019, 4, 721-730.	3.7	105
354	Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. Journal of Clinical and Experimental Hepatology, 2019, 9, 588-596.	0.4	43
355	Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. Targeted Oncology, 2019, 14, 541-550.	1.7	18

#	Article	IF	Citations
357	Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver International, 2019, 39, 1608-1621.	1.9	67
358	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1195.	3.4	431
359	Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease, 2019, 51, 1713-1719.	0.4	18
360	Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. Journal of Hepatology, 2019, 71, 900-907.	1.8	229
361	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Research and Treatment, 2019, 51, 510-518.	1.3	39
362	Proteomic profiling in liver cancer: another new page. Translational Gastroenterology and Hepatology, 2019, 4, 47-47.	1.5	8
363	Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. Clinical Oncology, 2019, 31, 560-569.	0.6	6
364	Hepatotoxicity of immune check point inhibitors: Approach and management. Digestive and Liver Disease, 2019, 51, 1074-1078.	0.4	32
365	Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunology Research, 2019, 7, 1390-1395.	1.6	54
366	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget, 2019, 10, 4018-4025.	0.8	118
367	Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer, 2019, 125, 3312-3319.	2.0	90
368	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Scientific Reports, 2019, 9, 10677.	1.6	37
369	Treatment of Hepatocellular Carcinoma: Time for a Paradigm Shift?. Radiology, 2019, 292, 760-761.	3.6	2
370	Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. , 2019, 7, 193.		304
371	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986269.	1.4	75
372	Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma. BioScience Trends, 2019, 13, 282-283.	1.1	5
373	Immunomodulatory TGF-Î² Signaling in Hepatocellular Carcinoma. Trends in Molecular Medicine, 2019, 25, 1010-1023.	3.5	157
374	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology, 2019, 157, 760-776.	0.6	141

#	Article	IF	Citations
375	Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatology International, 2019, 13, 521-533.	1.9	50
376	Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 119-129.	1.8	15
377	Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein. Nano Letters, 2019, 19, 5266-5276.	4.5	40
378	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. American Journal of Transplantation, 2019, 19, 3176-3184.	2.6	60
379	Treatment Lines in Hepatocellular Carcinoma. Visceral Medicine, 2019, 35, 266-272.	0.5	31
380	Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. Cancers, 2019, 11, 861.	1.7	25
381	Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. Cancers, 2019, 11, 873.	1.7	19
382	Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer, 2019, 125, 3603-3614.	2.0	121
383	Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Cellular Oncology (Dordrecht), 2019, 42, 705-715.	2.1	18
384	Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series. , 2019, 7, 162.		13
385	Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). OncoImmunology, 2019, 8, 1615817.	2.1	85
386	Comparison of the current international guidelines on the management of HCC. JHEP Reports, 2019, 1, 114-119.	2.6	30
387	Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma. Anticancer Research, 2019, 39, 3909-3916.	0.5	19
388	Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Medicine, 2019, 8, 4699-4708.	1.3	52
389	Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Frontiers in Oncology, 2019, 9, 345.	1.3	10
390	Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1686-1695.	7.7	75
391	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
392	Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Medicina (Lithuania), 2019, 55, 698.	0.8	54

#	Article	IF	Citations
393	Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nature Communications, 2019, 10, 4681.	5.8	229
394	Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma. American Journal of Health-System Pharmacy, 2019, 76, 1749-1752.	0.5	22
395	Heterogeneity of HBV-Specific CD8+ T-Cell Failure: Implications for Immunotherapy. Frontiers in Immunology, 2019, 10, 2240.	2.2	31
396	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers, 2019, 11, 1554.	1.7	73
397	Update on hepatocellular carcinoma: Pathologistsâ€™ review. World Journal of Gastroenterology, 2019, 25, 1653-1665.	1.4	100
398	Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. Expert Opinion on Investigational Drugs, 2019, 28, 941-949.	1.9	25
399	Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response. Clinical and Experimental Hepatology, 2019, 5, 256-264.	0.6	11
400	Cabozantinib for the treatment of hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 847-855.	1.1	12
401	Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells. Cancer Immunology Research, 2019, 7, 1813-1823.	1.6	85
402	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinomaâ€”Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers, 2019, 11, 1517.	1.7	30
403	Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report . OncoTargets and Therapy, 2019, Volume 12, 7355-7359.	1.0	30
404	Traf6 inhibitor boosts antitumor immunity by impeding regulatory T cell migration in Hepa1-6 tumor model. International Immunopharmacology, 2019, 77, 105965.	1.7	7
405	Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 151-166.	1.8	25
406	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers, 2019, 11, 1689.	1.7	44
407	Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell, 2019, 179, 829-845.e20.	13.5	897
408	Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 447.	3.5	149
409	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers, 2019, 11, 1721.	1.7	8
410	Immune checkpoint inhibitorâ€associated pituitaryâ€adrenal dysfunction: A systematic review and metaâ€analysis. Cancer Medicine, 2019, 8, 7503-7515.	1.3	35

#	Article	IF	Citations
411	Immunotherapy in head and neck cancer: The great challenge of patient selection. Critical Reviews in Oncology/Hematology, 2019, 144, 102829.	2.0	14
412	Heterogenous responses to nivolumab in a single metastatic nodule in hepatocellular carcinoma: role of salvage surgery. Hepatobiliary Surgery and Nutrition, 2019, 8, 569-571.	0.7	5
413	Liquid Biopsy for Hepatocellular Carcinoma. Current Hepatology Reports, 2019, 18, 390-399.	0.4	1
414	Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. BMC Cancer, 2019, 19, 1062.	1.1	19
415	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell, 2019, 36, 471-482.	7.7	280
416	Optimizing cancer care for hepatocellular carcinoma at a safetyâ€net hospital: The value of a multidisciplinary disease management team. Journal of Surgical Oncology, 2019, 120, 1365-1370.	0.8	19
417	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Current Oncology, 2019, 26, 665-681.	0.9	2
418	PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 2041-2054.	2.0	72
419	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies, 2019, 8, 51.	1.2	32
420	The Place of Novel Therapies in the American Association for the Study of Liver Diseases Guidelines for Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 51-55.	1.0	4
421	Costâ€effectiveness analysis of cabozantinib as secondâ€line therapy in advanced hepatocellular carcinoma. Liver International, 2019, 39, 2408-2416.	1.9	25
422	Emerging agents and regimens for hepatocellular carcinoma. Journal of Hematology and Oncology, 2019, 12, 110.	6.9	71
423	Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS ONE, 2019, 14, e0223678.	1.1	14
424	Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. Frontiers in Oncology, 2019, 9, 1157.	1.3	75
425	Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Medicine, 2019, 8, 6986-6994.	1.3	37
426	A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2019, 25, 6614-6622.	3.2	106
427	Early Therapeutic Vaccination Prediction of Hepatocellular Carcinoma via Imaging OX40-Mediated Tumor Infiltrating Lymphocytes. Molecular Pharmaceutics, 2019, 16, 4252-4259.	2.3	9
428	Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Lithuania), 2019, 55, 526.	0.8	147

#	Article	IF	Citations
429	Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. International Journal of Molecular Sciences, 2019, 20, 4154.	1.8	51
431	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Research, 2019, 79, 4326-4330.	0.4	99
432	Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. International Journal of Molecular Sciences, 2019, 20, 4307.	1.8	30
433	Checkpoint Inhibition and Infectious Diseases: A Good Thing?. Trends in Molecular Medicine, 2019, 25, 1080-1093.	3.5	37
434	PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2019, 4, 51-51.	1.5	16
435	The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019), Sapporo, Japan, August 29-31, 2019. Liver Cancer, 2019, 8, 1-204.	4.2	0
436	From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 396.	3.5	265
437	Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model. Frontiers in Oncology, 2019, 9, 864.	1.3	3
438	Is PD-1 blockade a potential therapy for HBV?. JHEP Reports, 2019, 1, 142-144.	2.6	10
439	The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma. Journal of Interventional Medicine, 2019, 2, 47-51.	0.2	3
440	New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 56-61.	1.0	23
441	Preoperative Radiomic Approach to Evaluate Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma Patients Using Contrast-Enhanced Computed Tomography. Annals of Surgical Oncology, 2019, 26, 4537-4547.	0.7	62
442	Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. International Immunopharmacology, 2019, 75, 105824.	1.7	79
443	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors, 2019, 6, 92-107.	0.3	22
444	Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers, 2019, 11, 1433.	1.7	13
445	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4705.	1.8	48
446	Cancer prevention and control: hepatocellular carcinoma. Ecancermedicalscience, 2019, 13, 949.	0.6	5
447	PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 505-510.	0.6	30

#	Article	IF	Citations
448	Treatment of inoperable hepatocellular carcinoma with immunotherapy. BMJ Case Reports, 2019, 12, e229744.	0.2	5
449	AFP-producing hepatoid adenocarcinoma (HAC) of peritoneum and omentum: a case report and literature review . OncoTargets and Therapy, 2019, Volume 12, 7649-7654.	1.0	18
450	Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 662-675.	8.2	87
451	Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. International Journal of Hyperthermia, 2019, 36, 1002-1010.	1.1	9
452	Adoptive cell transfer therapy for hepatocellular carcinoma. Frontiers of Medicine, 2019, 13, 3-11.	1.5	45
453	Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets. Seminars in Liver Disease, 2019, 39, 026-042.	1.8	257
454	Dual-targeted NIS polyplexesâ€"a theranostic strategy toward tumors with heterogeneous receptor expression. Gene Therapy, 2019, 26, 93-108.	2.3	22
455	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 599-608.	2.0	97
456	Genomic profiling of combined hepatocellularâ€cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. Journal of Pathology, 2019, 248, 164-178.	2.1	82
457	Hepatocellular Carcinoma: Etiology and Current and Future Drugs. Journal of Clinical and Experimental Hepatology, 2019, 9, 221-232.	0.4	167
459	An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice. Hepatology, 2019, 69, 2518-2532.	3.6	47
460	Systematic review with metaâ€analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Alimentary Pharmacology and Therapeutics, 2019, 49, 482-491.	1.9	40
461	Immune-related adverse events predict the therapeutic efficacy of antiâ€"PD-1 antibodies in cancer patients. European Journal of Cancer, 2019, 109, 21-27.	1.3	188
462	Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 1-11.	4.2	48
463	Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. European Radiology, 2019, 29, 4177-4187.	2.3	110
464	GITR ligation enhances functionality of tumorâ€infiltrating T cells in hepatocellular carcinoma. International Journal of Cancer, 2019, 145, 1111-1124.	2.3	42
465	Success of immune checkpoint blockade therapies â€" mechanisms and implications for hepatology. Zeitschrift Fur Gastroenterologie, 2019, 57, 74-86.	0.2	2
466	The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma. Molecular Therapy - Oncolytics, 2019, 14, 139-148.	2.0	17

#	Article	IF	Citations
467	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 615-621.	1.4	5
468	Tumour-associated macrophages in hepatocellular carcinoma: Pressing the metabolic switch to prevent T cell responses. Journal of Hepatology, 2019, 71, 243-245.	1.8	4
469	Immunohistochemistry-Enabled Precision Medicine. Cancer Treatment and Research, 2019, 178, 111-135.	0.2	5
470	Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 427-446.	4.2	89
471	Gammaâ€secretase complexâ€dependent intramembrane proteolysis of CD147 regulates the Notch1 signaling pathway in hepatocellular carcinoma. Journal of Pathology, 2019, 249, 255-267.	2.1	22
472	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Molecular Cancer Therapeutics, 2019, 18, 1506-1519.	1.9	16
473	Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepatic Oncology, 2019, 6, HEP11.	4.2	24
474	Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells, 2019, 8, 604.	1.8	12
475	Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut, 2019, 68, 2019-2031.	6.1	230
476	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. Annals of Oncology, 2019, 30, 1448-1459.	0.6	146
477	Checkpoint Inhibitors. Deutsches Ärzteblatt International, 2019, 116, 119-126.	0.6	83
478	Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers, 2019, 11, 841.	1.7	68
479	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. Modern Pathology, 2019, 32, 1646-1656.	2.9	16
480	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. Cancer Chemotherapy and Pharmacology, 2019, 84, 227-240.	1.1	50
481	Genomic landscape of lymphoepitheliomaâ€like hepatocellular carcinoma. Journal of Pathology, 2019, 249, 166-172.	2.1	26
482	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology, 2019, 71, 543-552.	1.8	180
483	FGF19â€“FGFR4 Signaling in Hepatocellular Carcinoma. Cells, 2019, 8, 536.	1.8	101
484	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancerâ€”A Phase 1 Study. JAMA Oncology, 2019, 5, 1332.	3.4	153

#	Article	IF	Citations
485	The evolving landscape of precision medicine in primary liver cancer. Hepatic Oncology, 2019, 6, HEP12.	4.2	7
486	Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. Journal of Hepatology, 2019, 71, 753-762.	1.8	81
487	Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 2019, 17, 661-674.	1.9	333
488	M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. British Journal of Cancer, 2019, 121, 22-33.	2.9	92
489	Significance of PDâ€'L1 clones and Câ€'MET expression in hepatocellular carcinoma. Oncology Letters, 2019, 17, 5487-5498.	0.8	9
491	Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?. , 2019, 7, 141.		14
492	Nivolumab in patients with advanced hepatocellular carcinoma and Childâ€Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer, 2019, 125, 3234-3241.	2.0	73
493	Radiotherapy for HCC: Ready for prime time?. JHEP Reports, 2019, 1, 131-137.	2.6	46
494	Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection. BJS Open, 2019, 3, 500-508.	0.7	40
495	Liquid Biopsy in Hepatocellular Carcinoma. , 2019, , 87-95.		0
496	Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. OncoImmunology, 2019, 8, 1615818.	2.1	34
497	Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€"PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	7.7	498
498	Immune checkpoint inhibitors in the treatment of virus-associated cancers. Journal of Hematology and Oncology, 2019, 12, 58.	6.9	43
499	Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Letters, 2019, 460, 1-9.	3.2	156
500	Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 546-553.	0.6	6
501	Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Digestive and Liver Disease, 2019, 51, 1067-1073.	0.4	25
502	Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS ONE, 2019, 14, e0217276.	1.1	34
503	Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Science China Life Sciences, 2019, 62, 1138-1143.	2.3	19

#	Article	IF	Citations
504	Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials. Frontiers in Oncology, 2019, 9, 301.	1.3	1
505	Systemic Treatment for Advanced Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 341-358.	4.2	82
506	Homeobox Genes and Hepatocellular Carcinoma. Cancers, 2019, 11, 621.	1.7	14
507	Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. British Journal of Cancer, 2019, 120, 1033-1036.	2.9	66
508	Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma. Medicine (United States), 2019, 98, e14823.	0.4	4
509	Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984346.	1.4	19
510	Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 71-84.	1.8	54
511	Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 248-260.	1.8	8
512	Immunotherapy in Older Adults: A Checkpoint to Palliation?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e110-e120.	1.8	11
513	Anticancer Effects of Emodin on HepG2 Cell: Evidence from Bioinformatic Analysis. BioMed Research International, 2019, 2019, 1-14.	0.9	23
514	Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma:Âa case report. Immunotherapy, 2019, 11, 651-656.	1.0	15
515	Pembrolizumab for the Treatment of Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 143-154.	4.2	25
516	Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal of Gastroenterology, 2019, 54, 538-545.	0.6	51
517	Assessment of tumor mutation burden calculation from gene panel sequencing data . OncoTargets and Therapy, 2019, Volume 12, 3401-3409.	1.0	38
518	Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. CardioVascular and Interventional Radiology, 2019, 42, 1262-1270.	0.9	2
519	Aberrant lipid metabolism as a therapeutic target in liver cancer. Expert Opinion on Therapeutic Targets, 2019, 23, 473-483.	1.5	104
520	Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clinical Pharmacokinetics, 2019, 58, 983-1014.	1.6	17
521	PRDM1 levels are associated with clinical diseases in chronic HBV infection and survival of patients with HBV-related hepatocellular carcinoma. International Immunopharmacology, 2019, 73, 156-162.	1.7	15

#	Article	IF	Citations
522	Patients Selection for Immunotherapy in Solid Tumors: Overcome the NaÃ¯ve Vision of a Single Biomarker. BioMed Research International, 2019, 2019, 1-15.	0.9	37
523	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
524	Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report. Tohoku Journal of Experimental Medicine, 2019, 247, 247-250.	0.5	4
525	Immunotherapy and the Interventional Oncologist: Challenges and Opportunitiesâ€"A Society of Interventional Oncology White Paper. Radiology, 2019, 292, 25-34.	3.6	57
526	Low CD8+ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44+/CD133+ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. Cancers, 2019, 11, 541.	1.7	77
527	A Psoriasiform Drug Eruption Secondary to Nivolumab for Hepatocellular Carcinoma: A Case Report. Hepatology, 2019, 70, 1477-1479.	3.6	5
528	Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Medicine, 2019, 11, 28.	3.6	107
529	Immunotherapy in hepatocellular carcinoma. Annals of Hepatology, 2019, 18, 291-297.	0.6	66
530	Proteomics promises a new era of precision cancer medicine. Signal Transduction and Targeted Therapy, 2019, 4, 13.	7.1	4
531	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	3.4	526
532	Pharmacological treatment of hepatocellular carcinoma with cavoatrial tumor thrombus â€" case series and literature review. Zeitschrift Fur Gastroenterologie, 2019, 57, 501-507.	0.2	6
533	Is Idarubicin the Future of TACE?. Radiology, 2019, 291, 809-810.	3.6	7
534	Clinical characteristics and outcomes of candidates for secondâ€line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatology Research, 2019, 49, 1054-1065.	1.8	40
535	Implications of Immunotherapy in Hepatobiliary Tumors. Visceral Medicine, 2019, 35, 18-26.	0.5	6
536	Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 373-378.	0.6	18
537	New treatment-induced adverse effects we need to learn as modern hepatologists. Hepatology International, 2019, 13, 391-394.	1.9	0
538	Role of immune checkpoint inhibitors in gastrointestinal cancer treatment. Memo - Magazine of European Medical Oncology, 2019, 12, 71-76.	0.3	2
539	Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 1745.	1.8	39

#	Article	IF	Citations
540	Tumor-Derived Î±-Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells. Cancer Immunology Research, 2019, 7, 1001-1012.	1.6	31
541	Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2019, 195, 1007-1017.	1.0	27
542	Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma . OncoTargets and Therapy, 2019, Volume 12, 2205-2214.	1.0	3
543	Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. Scientific Reports, 2019, 9, 6428.	1.6	21
544	From NASH to HCC: current concepts and future challenges. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 411-428.	8.2	872
545	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. Journal of Hematology and Oncology, 2019, 12, 42.	6.9	58
546	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Advances in Cancer Research, 2019, 143, 63-144.	1.9	52
547	Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut, 2019, 68, 1653-1666.	6.1	246
548	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470.	1.3	28
549	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research, 2019, 7, 805-812.	1.6	22
550	<scp>MYC</scp> in Germinal Centerâ€derived lymphomas: Mechanisms and therapeutic opportunities. Immunological Reviews, 2019, 288, 178-197.	2.8	42
551	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human Vaccines and Immunotherapeutics, 2019, 15, 1111-1122.	1.4	297
552	Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 53-55.	0.7	3
553	Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases and Sciences, 2019, 64, 1016-1029.	1.1	25
554	Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. Visceral Medicine, 2019, 35, 28-37.	0.5	7
555	Genomic correlates of response to immune checkpoint blockade. Nature Medicine, 2019, 25, 389-402.	15.2	346
556	Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?. Digestive Diseases and Sciences, 2019, 64, 918-927.	1.1	26
557	Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer. Digestive Diseases and Sciences, 2019, 64, 976-984.	1.1	2

#	Article	IF	Citations
558	Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models. Theranostics, 2019, 9, 1426-1452.	4.6	53
559	IDO and intraâ€tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma. Journal of Clinical Laboratory Analysis, 2019, 33, e22872.	0.9	16
560	Immunological and clinical implications of immune checkpoint blockade in human cancer. Archives of Pharmacal Research, 2019, 42, 567-581.	2.7	17
561	Progression after Immunotherapy for Fibrolamellar Carcinoma. Visceral Medicine, 2019, 35, 39-42.	0.5	19
562	Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. Oncologist, 2019, 24, S11-S20.	1.9	2
563	Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. European Journal of Cancer, 2019, 111, 38-49.	1.3	89
564	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist, 2019, 24, S3-S10.	1.9	108
565	OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection. Journal of Hepatology, 2019, 70, 1103-1113.	1.8	57
566	Immunotherapy: Current Status and Future Perspectives. Digestive Diseases and Sciences, 2019, 64, 1030-1040.	1.1	24
567	EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology, 2019, 70, 1222-1261.	1.8	629
568	Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology, 2019, 156, 1862-1876.e9.	0.6	92
570	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Annals of Oncology, 2019, 30, 884-896.	0.6	78
571	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterology, 2019, 10, 364-371.	0.9	65
572	Treatment Strategies for Hepatocellular Carcinoma â€“ a Multidisciplinary Approach. International Journal of Molecular Sciences, 2019, 20, 1465.	1.8	158
573	An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment. Journal of Materials Chemistry B, 2019, 7, 3088-3099.	2.9	11
574	A Dualâ€Bioresponsive Drugâ€Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade. Advanced Materials, 2019, 31, e1806957.	11.1	145
575	What Comes First: Treatment of Viral Hepatitis or Liver Cancer?. Digestive Diseases and Sciences, 2019, 64, 1041-1049.	1.1	12
576	The gut microbiome, antitumor immunity, and liver cancer. Hepatobiliary Surgery and Nutrition, 2019, 8, 67-68.	0.7	12

#	Article	IF	Citations
577	Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report. Journal of Ultrasound, 2019, 22, 363-370.	0.7	4
578	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Hormone and Metabolic Research, 2019, 51, 145-156.	0.7	234
579	Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?. Investigational New Drugs, 2019, 37, 1274-1288.	1.2	13
580	Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World Journal of Gastroenterology, 2019, 25, 789-807.	1.4	135
581	Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. Liver Cancer, 2019, 8, 326-340.	4.2	30
582	Role of CXCR6 in Antitumor Immune Surveillance. Gastroenterology, 2019, 156, 1565-1568.	0.6	1
583	RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncology, 2019, 15, 1811-1822.	1.1	99
584	Controversies in the management of hepatocellular carcinoma. JHEP Reports, 2019, 1, 17-29.	2.6	45
585	Hepatocellular Carcinoma. New England Journal of Medicine, 2019, 380, 1450-1462.	13.9	2,966
586	Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver International, 2019, 39, 1468-1477.	1.9	86
587	Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancers, 2019, 11, 509.	1.7	37
588	Programmed cell death proteinâ€1 (<scp>PD</scp>â€1)â€targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre realâ€world cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1323-1333.	1.9	106
589	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	3.5	170
590	Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. Hepatology, 2019, 70, 1437-1442.	3.6	104
591	CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4+ T-Cellâ€"Dependent Control of Senescence. Gastroenterology, 2019, 156, 1877-1889.e4.	0.6	83
592	MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology, 2019, 156, 1849-1861.e13.	0.6	131
593	Has PD-1 MET Its Match in Hepatocellular Carcinoma?. Gastroenterology, 2019, 156, 1563-1565.	0.6	1
594	Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9. Seminars in Liver Disease, 2019, 39, 261-274.	1.8	21

#	Article	IF	Citations
595	First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. BMC Cancer, 2019, 19, 279.	1.1	53
596	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Molecular Cancer, 2019, 18, 60.	7.9	361
597	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology, 2019, 70, 1262-1277.	1.8	150
598	Trial endpoints for systemic therapy in patients with hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 1060-1061.	1.8	1
599	A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1984-1991.	1.4	7
600	Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. Frontiers in Microbiology, 2019, 10, 475.	1.5	11
601	Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes, 2019, 10, 260.	1.0	21
602	Immunological Agents Used in Cancer Treatment. Eurasian Journal of Medicine, 2019, 51, 90-94.	0.2	32
603	Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. British Journal of Cancer, 2019, 120, 896-902.	2.9	42
604	Assisting anti-PD-1 antibody treatment with a liposomal system capable of recruiting immune cells. Nanoscale, 2019, 11, 7996-8011.	2.8	7
605	The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. Cell Death Discovery, 2019, 5, 86.	2.0	41
606	Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer. Visceral Medicine, 2019, 35, 3-10.	0.5	11
607	Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future. Clinical Liver Disease, 2019, 13, 13-19.	1.0	29
608	Systemic treatment of advanced hepatocellular cancer: new hope on the horizon. Expert Review of Anticancer Therapy, 2019, 19, 343-353.	1.1	16
609	Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a Dish. Stem Cells International, 2019, 2019, 1-8.	1.2	10
610	Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience. Cancer Medicine, 2019, 8, 1442-1446.	1.3	6
611	The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. Targeted Oncology, 2019, 14, 115-123.	1.7	19
613	Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 31-39.	1.8	55

#	Article	IF	Citations
614	Immunotherapeutic advances in gastrointestinal malignancies. Npj Precision Oncology, 2019, 3, 4.	2.3	16
615	Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 3304-3316.	3.2	109
616	Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 2019, 9, 19.	1.3	34
617	Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. OncoImmunology, 2019, 8, e1571388.	2.1	96
618	Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surgical Oncology, 2019, 28, 228-235.	0.8	23
619	Combined locoregional-immunotherapy for liver cancer. Journal of Hepatology, 2019, 70, 999-1007.	1.8	146
620	Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma . Cancer Management and Research, 2019, Volume 11, 981-996.	0.9	3
621	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416.	3.6	66
622	Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. Current Opinion in Oncology, 2019, 31, 54-64.	1.1	66
623	Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visceral Medicine, 2019, 35, 43-46.	0.5	6
624	Î³Î´ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways. International Immunopharmacology, 2019, 70, 167-173.	1.7	17
627	Emerging Role of the Pathologist in Precision Medicine for HCC. Digestive Diseases and Sciences, 2019, 64, 928-933.	1.1	5
628	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 421-432.	1.4	45
629	DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology, 2019, 156, 890-903.	0.6	48
630	Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiotherapy and Oncology, 2019, 131, 135-144.	0.3	118
631	Supplementary Sorafenib Therapies for Hepatocellular Carcinomaâ€"A Systematic Review and Meta-Analysis. Journal of Clinical Gastroenterology, 2019, 53, 486-494.	1.1	6
633	Predicting Tumor Mutational Burden from Liver Cancer Pathological Images Using Convolutional Neural Network. , 2019, , .		12
634	Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 2055-2066.	2.0	94

#	Article	IF	Citations
635	Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2019, 28, 717-729.	0.6	9
636	Systemic Therapy for Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 695-715.	0.6	9
637	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. , 2019, 7, 306.		642
638	Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomedical Journal, 2019, 42, 299-306.	1.4	62
639	Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. The Cochrane Library, 0, , .	1.5	0
640	STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. Cancers, 2019, 11, 1646.	1.7	79
641	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2019, 629, xxi-xl.	0.4	1
642	Advances in the Ablative Management of Hepatocellular Carcinoma. Advances in Clinical Radiology, 2019, 1, 215-225.	0.1	1
643	Reliability of PD-L1 assays using small tissue samples compared with surgical specimens. Medicine (United States), 2019, 98, e14972.	0.4	15
644	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988900.	1.4	44
645	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353.		91
646	PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. , 2019, 7, 331.		213
647	Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. , 2019, 7, 333.		129
648	The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma. Current Hepatology Reports, 2019, 18, 371-382.	0.4	0
649	Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. , 2019, 7, 322.		122
650	Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. International Journal of Biological Sciences, 2019, 15, 2654-2663.	2.6	18
651	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1696-1707.	7.7	157
652	Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Transplantation, 2019, 103, 2136-2143.	0.5	7

#	Article	IF	Citations
653	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2019, 25, 5961-5971.	3.2	118
654	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer, 2019, 8, 413-426.	4.2	40
655	Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology and Hepatology, 2019, 31, 1250-1255.	0.8	20
656	Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988900.	1.4	6
657	Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance. Medicine (United States), 2019, 98, e15755.	0.4	6
658	Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis. Medicine (United States), 2019, 98, e17832.	0.4	37
659	Can Mycophenolic Acid-based Immunosuppression Benefit Liver Transplant Patients With HCC?. Transplantation, 2019, 103, 873-874.	0.5	0
660	A Phase 2 Study of Galunisertib (TGF-Î²1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 2019, 10, e00056.	1.3	151
661	Second-line Treatments of Advanced Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2019, 53, 251-261.	1.1	19
662	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926.	1.7	27
663	The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. Journal of Oncology, 2019, 2019, 1-22.	0.6	10
664	Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. Cell Death and Disease, 2019, 10, 934.	2.7	98
665	Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date . OncoTargets and Therapy, 2019, Volume 12, 10335-10342.	1.0	19
666	Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models. Anti-Cancer Drugs, 2019, 30, 909-916.	0.7	12
667	Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Clinical and Translational Gastroenterology, 2019, 10, e00058.	1.3	38
668	Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells. Anti-Cancer Drugs, 2019, 30, 209-217.	0.7	16
669	TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. European Radiology, 2019, 29, 1285-1292.	2.3	22
670	The roles ofPDâ€1/PDâ€L1 and its signalling pathway in gastrointestinal tract cancers. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 3-10.	0.9	12

#	Article	IF	Citations
671	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer, 2019, 8, 281-294.	4.2	31
672	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 203-217.	4.2	48
673	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer, 2019, 8, 41-65.	4.2	38
674	A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 80-89.	3.2	62
675	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
676	Tremelimumab in Combination With Microwave Ablation in Patients With RefractoryÂBiliary Tract Cancer. Hepatology, 2019, 69, 2048-2060.	3.6	77
677	Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 2019, 156, 477-491.e1.	0.6	1,133
678	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 2019, 156, 492-509.	0.6	145
679	Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology, 2019, 69, 943-958.	3.6	48
680	Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology, 2019, 156, 325-337.	0.6	140
681	Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology, 2019, 156, 510-524.	0.6	179
682	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute, 2019, 111, 118-128.	3.0	49
683	Immunological cure of HBV infection. Hepatology International, 2019, 13, 113-124.	1.9	38
684	Goals and targets for personalized therapy for HCC. Hepatology International, 2019, 13, 125-137.	1.9	358
685	Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?. Drugs and Aging, 2019, 36, 1-11.	1.3	10
686	RIP Kinases in Liver Cell Death, Inflammation and Cancer. Trends in Molecular Medicine, 2019, 25, 47-63.	3.5	68
687	Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?. Cell Metabolism, 2019, 29, 18-26.	7.2	169
688	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. European Journal of Cancer, 2019, 106, 106-114.	1.3	41

#	Article	IF	Citations
689	Ramucirumab and its use in the treatment of hepatocellular carcinoma. Future Oncology, 2019, 15, 979-988.	1.1	8
690	Therapeutic advances for patients with intermediate hepatocellular carcinoma. Journal of Cellular Physiology, 2019, 234, 12116-12121.	2.0	30
691	Liver damage related to immune checkpoint inhibitors. Hepatology International, 2019, 13, 248-252.	1.9	36
692	Management of immune-related adverse events resulting from immune checkpoint blockade. Expert Review of Anticancer Therapy, 2019, 19, 209-222.	1.1	20
693	Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy. Journal of Comparative Effectiveness Research, 2019, 8, 81-90.	0.6	7
694	Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma. Cellular Immunology, 2019, 336, 66-74.	1.4	54
695	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. Future Oncology, 2019, 15, 563-565.	1.1	2
696	Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. Immunotherapy, 2019, 11, 167-175.	1.0	33
697	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. Journal of Cancer Research and Clinical Oncology, 2019, 145, 429-443.	1.2	13
698	Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. Current Treatment Options in Oncology, 2019, 20, 3.	1.3	26
699	Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. Journal of Cellular Physiology, 2019, 234, 12122-12132.	2.0	47
700	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 16.	3.5	27
701	Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clinical Cancer Research, 2019, 25, 515-523.	3.2	354
702	Medical oncologists must get more involved in systemic treatment. Annals of Oncology, 2019, 30, 6-8.	0.6	2
703	Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Hepatology, 2019, 69, 2258-2270.	3.6	64
704	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	3.2	390
705	Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. Journal of Cancer Research and Clinical Oncology, 2019, 145, 253-259.	1.2	44
706	Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clinical and Translational Oncology, 2019, 21, 702-712.	1.2	38

#	Article	IF	Citations
707	New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transplantation, 2019, 25, 311-322.	1.3	21
708	Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. Leukemia and Lymphoma, 2019, 60, 1204-1213.	0.6	4
709	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. , 2019, , 335-344.		1
710	Predictive Biomarkers and Targeted Therapies in Hepatic, Pancreatic, and Biliary Cancers. , 2019, , 437-444.		0
711	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Investigational New Drugs, 2019, 37, 567-572.	1.2	44
712	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunology, Immunotherapy, 2019, 68, 379-393.	2.0	100
713	Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. British Journal of Cancer, 2019, 120, 196-206.	2.9	27
714	Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2019, 42, 230-238.	0.9	13
715	Hepatocellular Carcinoma with Orbital Metastasis: a Unique Multidisciplinary Case Report. Journal of Gastrointestinal Cancer, 2019, 50, 978-982.	0.6	2
716	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
717	Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 303-312.	1.2	46
718	The Role of Angiogenesis in Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 912-920.	3.2	345
719	Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut, 2020, 69, 365-379.	6.1	117
720	Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy. Journal of Gastrointestinal Cancer, 2020, 51, 217-226.	0.6	10
721	Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. Journal of the Formosan Medical Association, 2020, 119, 1731-1741.	0.8	60
722	Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 195-218.	2.3	35
723	Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2020, 31, 25-34.	0.2	72
724	2019 Update of Indian National Association for Study of the LiverÂConsensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. Journal of Clinical and Experimental Hepatology, 2020, 10, 43-80.	0.4	47

#	Article	IF	Citations
725	Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics, 2020, 38, 5-24.	1.7	13
727	Dual Programmed Death Receptorâ€1 and Vascular Endothelial Growth Factor Receptorâ€2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology, 2020, 71, 1247-1261.	3.6	247
728	Immune checkpoints in the tumor microenvironment. Seminars in Cancer Biology, 2020, 65, 1-12.	4.3	146
729	4â€1BB Delineates Distinct Activation Status of Exhausted Tumorâ€infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, 2020, 71, 955-971.	3.6	70
730	The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. Journal of Hepatology, 2020, 72, 167-182.	1.8	116
731	REFLECTâ€”a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. Journal of Gastroenterology, 2020, 55, 113-122.	2.3	123
732	State-of-the-art in radiomics of hepatocellular carcinoma: a review of basic principles, applications, and limitations. Abdominal Radiology, 2020, 45, 342-353.	1.0	43
733	Liver and Bile Duct Cancer. , 2020, , 1314-1341.e11.		8
734	The promise of adoptive cellular immunotherapies in hepatocellular carcinoma. OncoImmunology, 2020, 9, 1673129.	2.1	26
735	Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?. Translational Gastroenterology and Hepatology, 2020, 5, 8-8.	1.5	18
736	Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Gastroenterology, 2020, 158, 664-678.e24.	0.6	55
737	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. Journal of Cancer, 2020, 11, 41-50.	1.2	3
738	Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. Journal of Geriatric Oncology, 2020, 11, 557-565.	0.5	5
739	Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. Journal of Hepatology, 2020, 72, 725-735.	1.8	71
740	Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. American Journal of Transplantation, 2020, 20, 879-883.	2.6	80
741	When food regimes become hegemonic: Agrarian India through a Gramscian lens. Journal of Agrarian Change, 2020, 20, 188-206.	0.8	8
742	Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 489-497.	1.8	38
743	Safe use of nivolumab in a patient with renal cell carcinoma and hepatitis B. Journal of Oncology Pharmacy Practice, 2020, 26, 1022-1024.	0.5	4

#	Article	IF	Citations
744	Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization. Oncogene, 2020, 39, 1429-1444.	2.6	52
745	Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma. Molecular Cancer Therapeutics, 2020, 19, 384-396.	1.9	18
746	Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment. Oncologist, 2020, 25, 105-111.	1.9	28
747	A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator. Journal of Biological Chemistry, 2020, 295, 1474-1488.	1.6	9
748	Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Review of Anticancer Therapy, 2020, 20, 63-74.	1.1	14
749	Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. Pathology International, 2020, 70, 140-154.	0.6	7
750	XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Antiâ€“PD-1 Efficacy. Cancer Immunology Research, 2020, 8, 81-93.	1.6	34
751	Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Hepatology, 2020, 72, 965-981.	3.6	159
752	Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. Frontiers of Medicine, 2020, 14, 273-283.	1.5	9
753	Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. Cancer Letters, 2020, 473, 25-32.	3.2	40
754	Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 896-908.	1.8	124
755	Immune checkpoint inhibitors and endocrine side effects, a narrative review. Postgraduate Medicine, 2020, 132, 206-214.	0.9	12
756	Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with Î±-fetoprotein concentrations of at least 400â€‰ng/ml. Journal of Medical Economics, 2020, 23, 347-352.	1.0	12
757	Immune Therapy for Liver Cancers. Cancers, 2020, 12, 77.	1.7	49
758	Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study. Anti-Cancer Drugs, 2020, 31, 190-195.	0.7	22
759	Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment. Acta Radiologica, 2020, 61, 983-991.	0.5	9
760	Harnessing big â€˜omicsâ€™ data and AI for drug discovery in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 238-251.	8.2	90
761	Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. Seminars in Liver Disease, 2020, 40, 131-142.	1.8	3

#	Article	IF	Citations
762	Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opinion on Drug Discovery, 2020, 15, 243-258.	2.5	15
763	Incorporating patientâ€reported outcomes in doseâ€finding clinical trials. Statistics in Medicine, 2020, 39, 310-325.	0.8	6
764	Immunotherapy for hepatocellular carcinoma. Cancer Letters, 2020, 470, 8-17.	3.2	169
765	Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma. Gut, 2020, 69, 1904-1906.	6.1	24
766	Correlation of molecular and morphologic effects of thermoembolization in a swine model using mass spectrometry imaging. Journal of Mass Spectrometry, 2020, 55, e4477.	0.7	1
767	Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatology International, 2020, 14, 80-95.	1.9	15
768	Toward a Better Understanding of Hepatocellular Carcinoma Immune Infiltrates. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 341-342.	2.3	2
769	Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2020, 51, 78-89.	1.9	71
770	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	1.9	10
771	Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treatment Reviews, 2020, 82, 101946.	3.4	104
772	Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma: Where does it come from?. Surgery Today, 2020, 50, 569-576.	0.7	3
773	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2020, 38, 193-202.	0.8	1,255
774	The chances of hepatic resection curing hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 711-717.	1.8	41
775	Identification of an HLAâ€A*24:02â€restricted Î±â€fetoprotein signal peptideâ€derived antigen and its specific Tâ€cell receptor for Tâ€cell immunotherapy. Immunology, 2020, 159, 384-392.	2.0	17
776	The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy. Cells, 2020, 9, 26.	1.8	29
777	Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Frontiers in Immunology, 2020, 11, 568759.	2.2	79
778	Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers, 2020, 12, 2859.	1.7	92
779	Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. Oncologist, 2020, 25, e1921-e1929.	1.9	5

#	Article	IF	Citations
780	Downstaging to Liver Transplant. Clinics in Liver Disease, 2020, 24, 665-679.	1.0	0
781	Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study. Oncologist, 2020, 25, e1532-e1540.	1.9	13
782	The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188451.	3.3	36
783	The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2020, 132, 110797.	2.5	35
785	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 755-769.	1.0	9
786	Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2020, 7, 567950.	1.6	13
787	Therapy of Primary Liver Cancer. Innovation(China), 2020, 1, 100032.	5.2	46
788	Icaritinâ€induced immunomodulatory efficacy in advanced hepatitis B virusâ€related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. Cancer Science, 2020, 111, 4218-4231.	1.7	40
789	Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2020, 19, 153303382094748.	0.8	3
790	Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers, 2020, 12, 2730.	1.7	24
791	Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus co-infection. Current Opinion in HIV and AIDS, 2020, 15, 193-199.	1.5	4
792	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	1.7	12
793	Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. Drug Metabolism and Disposition, 2020, 48, 1257-1263.	1.7	16
794	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943.		23
795	Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. Frontiers in Oncology, 2020, 10, 563249.	1.3	18
796	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers, 2020, 12, 3025.	1.7	55
797	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621.	2.5	8
798	Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 701-717.	1.0	11

#	Article	IF	Citations
799	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. IScience, 2020, 23, 101580.	1.9	22
800	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer, 2020, 9, 596-612.	4.2	10
801	Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines, 2020, 8, 616.	2.1	47
802	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. JAMA Oncology, 2020, 6, e204930.	3.4	124
803	MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma. Scientific Reports, 2020, 10, 17862.	1.6	20
804	Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 788-791.	0.6	1
805	Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma. Current Medical Research and Opinion, 2020, 36, 1813-1823.	0.9	0
806	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
807	Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry, 2020, 63, 11484-11497.	2.9	24
808	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. Vaccines, 2020, 8, 578.	2.1	16
809	Immuno-oncology for Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 739-753.	1.0	8
810	Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. International Journal of Molecular Sciences, 2020, 21, 7378.	1.8	62
811	Gastric necrosis after nivolumab therapy in a patient with advanced hepatocellular carcinoma. Digestive and Liver Disease, 2020, 53, 1506-1507.	0.4	1
812	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Reports, 2020, 2, 100170.	2.6	86
813	Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. Journal of Vascular and Interventional Radiology, 2020, 31, 1729-1738.e1.	0.2	27
814	Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. Acta Pharmaceutica Sinica B, 2020, 10, 2171-2182.	5.7	32
815	Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 1632.	1.3	5
816	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. JAMA Oncology, 2020, 6, e204564.	3.4	746

#	Article	IF	Citations
817	Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?. Clinical Liver Disease, 2020, 16, 96-100.	1.0	0
818	Immunotherapy for advanced hepatocellular carcinoma, where are we?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188441.	3.3	52
819	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2020, 73, 1460-1469.	1.8	254
820	Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience. Scandinavian Journal of Gastroenterology, 2020, 55, 1057-1062.	0.6	15
821	Stem cell factor produced by tumor cells expands myeloid-derived suppressor cells in mice. Scientific Reports, 2020, 10, 11257.	1.6	14
822	Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy. Liver Cancer, 2020, 9, 326-337.	4.2	11
823	Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers, 2020, 12, 1914.	1.7	72
824	Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clinical Gastroenterology and Hepatology, 2021, 19, 1520-1530.	2.4	23
825	Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3620-e3627.	1.8	24
826	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862.	1.7	47
827	Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs, 2020, 80, 1203-1210.	4.9	21
828	Immunotherapy in Gastrointestinal Cancers. Visceral Medicine, 2020, 36, 231-237.	0.5	7
829	Analysis of singleâ€cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma. Clinical and Translational Medicine, 2020, 10, e133.	1.7	17
830	Novel systemic therapy for hepatocellular carcinoma. Hepatology International, 2020, 14, 638-651.	1.9	15
831	Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma. Frontiers in Molecular Biosciences, 2020, 7, 602328.	1.6	30
832	Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Frontiers in Oncology, 2020, 10, 600233.	1.3	10
833	A prognostic risk model based on immuneâ€related genes predicts overall survival of patients with hepatocellular carcinoma. Health Science Reports, 2020, 3, e202.	0.6	2
834	Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection. Cancers, 2020, 12, 3383.	1.7	11

#	Article	IF	Citations
835	Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 11725-11740.	1.0	25
836	Enteritis secundaria a nivolumab, una causa creciente de diarrea. GastroenterologÃa Y HepatologÃa, 2020, 43, 620-621.	0.2	1
837	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87
838	Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Molecular Therapy - Nucleic Acids, 2020, 22, 937-947.	2.3	155
839	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. Journal of Clinical Medicine, 2020, 9, 3817.	1.0	27
840	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058.	1.3	5
841	A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1253-1253.	0.7	3
842	Hepatocellular carcinoma: old friends and new tricks. Experimental and Molecular Medicine, 2020, 52, 1898-1907.	3.2	154
843	Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient . OncoTargets and Therapy, 2020, Volume 13, 12477-12487.	1.0	9
844	Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 289-299.	1.8	25
845	Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. Frontiers in Oncology, 2020, 10, 580241.	1.3	31
846	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers, 2020, 12, 3285.	1.7	85
847	Animal Models: A Useful Tool to Unveil Metabolic Changes in Hepatocellular Carcinoma. Cancers, 2020, 12, 3318.	1.7	3
848	Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma. Cell and Bioscience, 2020, 10, 127.	2.1	51
849	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345.	0.8	350
850	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. Cancers, 2020, 12, 3397.	1.7	17
851	Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatology International, 2020, 14, 947-957.	1.9	46
852	Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis. Journal of Translational Medicine, 2020, 18, 306.	1.8	88

#	Article	IF	Citations
853	The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1017-1024.	1.4	14
854	2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery and Nutrition, 2020, 9, 452-463.	0.7	267
855	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors â€“ A territoryâ€wide cohort study. Cancer Medicine, 2020, 9, 7052-7061.	1.3	14
856	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. Journal of Autoimmunity, 2020, 114, 102514.	3.0	37
857	Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. New England Journal of Medicine, 2020, 383, 693-695.	13.9	16
858	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Frontiers in Cell and Developmental Biology, 2020, 8, 672.	1.8	205
859	Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient. ACG Case Reports Journal, 2020, 7, e00416.	0.2	17
860	Effectiveness and Safety of Nivolumab in Childâ€“Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. Cancers, 2020, 12, 1968.	1.7	40
861	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatmentâ€”Current Progress, Strategy, and Future Perspective. Frontiers in Immunology, 2020, 11, 1508.	2.2	60
862	Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 5232.	1.8	7
863	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093761.	1.4	78
864	A new clinical prognostic nomogram for liver cancer based on immune score. PLoS ONE, 2020, 15, e0236622.	1.1	7
865	Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Frontiers in Immunology, 2020, 11, 2039.	2.2	187
866	Hepatocellular Carcinoma: Special Issue Highlights. Cancers, 2020, 12, 2026.	1.7	0
867	Image-Guided Interventions in Oncology. , 2020, , .		1
868	Metabolic implication of tigecycline as an efficacious secondâ€line treatment for sorafenibâ€resistant hepatocellular carcinoma. FASEB Journal, 2020, 34, 11860-11882.	0.2	13
869	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. Cancers, 2020, 12, 2132.	1.7	18
870	MST4 inhibits human hepatocellular carcinoma cell proliferation and induces cell cycle arrest via suppression of PI3K/AKT pathway. Journal of Cancer, 2020, 11, 5106-5117.	1.2	16

#	Article	IF	Citations
871	Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients. Journal of Cancer, 2020, 11, 5440-5448.	1.2	14
872	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 2020, 38, 2960-2970.	0.8	723
873	Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. Vaccines, 2020, 8, 447.	2.1	19
874	Targeting the immune milieu in gastrointestinal cancers. Journal of Gastroenterology, 2020, 55, 909-926.	2.3	7
875	Efficacy and Safety of Banxia XieXin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients With Advanced Hepatocellular Carcinoma. Integrative Cancer Therapies, 2020, 19, 153473542094258.	0.8	8
876	Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 2020, 5, 146.	7.1	320
877	Different patterns of treatmentâ€related adverse events of programmed cell deathâ€1 and its ligandâ€1 inhibitors in different cancer types: A metaâ€analysis and systemic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e160-e178.	0.7	6
878	Letter: sequential or combinated systemic treatment for unresectable hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2020, 52, 915-916.	1.9	1
879	Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepatic Oncology, 2020, 7, HEP26.	4.2	2
880	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discovery, 2020, 10, 1842-1853.	7.7	179
881	Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma. Case Reports in Gastroenterology, 2020, 14, 367-372.	0.3	3
882	Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma. JCO Clinical Cancer Informatics, 2020, 4, 1002-1013.	1.0	29
883	Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Annals of Translational Medicine, 2020, 8, 1187-1187.	0.7	31
884	PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment. Frontiers in Immunology, 2020, 11, 589997.	2.2	45
885	Novel Therapies for Hepatocellular Carcinoma. Cancers, 2020, 12, 3049.	1.7	2
886	Carcinoma hepatocelular. Medicine, 2020, 13, 653-665.	0.0	4
887	New advances in the diagnosis and management of hepatocellular carcinoma. BMJ, The, 2020, 371, m3544.	3.0	210
888	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PDâ˜1/PD-L1 Checkpoint Blockade. Cancers, 2020, 12, 3048.	1.7	37

#	Article	IF	Citations
889	Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2020, 8, e001072.		45
890	Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in Immunology, 2020, 11, 1956.	2.2	143
891	Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 6302.	1.8	16
892	Realâ€world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e249-e261.	0.7	18
893	Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut, 2020, 69, 2025-2034.	6.1	77
894	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 6350-6361.	3.2	35
895	Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma. Cells, 2020, 9, 2002.	1.8	25
896	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
897	Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. Scientific Reports, 2020, 10, 14470.	1.6	11
898	Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. Liver Cancer, 2020, 9, 549-562.	4.2	14
899	Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nature Communications, 2020, 11, 4810.	5.8	95
900	Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation. Medicine (United States), 2020, 99, e22312.	0.4	5
901	Challenges of BCLC stage C hepatocellular carcinoma. Medicine (United States), 2020, 99, e21561.	0.4	2
902	Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. Cancer Prevention Research, 2020, 13, 911-922.	0.7	20
903	New Therapeutic Options for Advanced Hepatocellular Carcinoma. Cancer Control, 2020, 27, 107327482094597.	0.7	15
904	Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Medicine, 2020, 9, 7453-7459.	1.3	11
905	Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. Journal of Vascular and Interventional Radiology, 2020, 31, 1233-1241.	0.2	11
906	Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of antiâ€Lagâ€3 via reducing FGL1 expression. Cancer Medicine, 2020, 9, 7125-7136.	1.3	23

#	Article	IF	Citations
907	Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987.		70
908	Seven immuneâ€related genes prognostic power and correlation with tumorâ€infiltrating immune cells in hepatocellular carcinoma. Cancer Medicine, 2020, 9, 7440-7452.	1.3	24
909	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open, 2020, 5, e000714.	2.0	51
910	Is There a Role for Immunotherapy in Prostate Cancer?. Cells, 2020, 9, 2051.	1.8	65
911	Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 133-142.	1.8	29
915	Hepatocellular Carcinomaâ€"The Influence of Immunoanatomy and the Role of Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 6757.	1.8	9
916	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer, 2020, 28, 6145-6157.	1.0	14
917	Hepatocellular Carcinomaâ€"Circulating Tumor Cells Expressing PDâ€Ł1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors. Hepatology Communications, 2020, 4, 1527-1540.	2.0	60
918	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 2495.	1.7	12
919	FcÎ³RIIB engagement drives agonistic activity of Fc-engineered Î±OX40 antibody to stimulate human tumor-infiltrating T cells. , 2020, 8, e000816.		11
921	Bromoâ€and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma. Cancer Science, 2020, 111, 3503-3515.	1.7	17
922	LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1. Cancer Cell International, 2020, 20, 394.	1.8	53
923	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. Current HIV/AIDS Reports, 2020, 17, 547-556.	1.1	21
924	Ramucirumab and durvalumab for previously treated, advanced nonâ€"small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). European Journal of Cancer, 2020, 137, 272-284.	1.3	86
925	Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression. Cancers, 2020, 12, 2286.	1.7	4
926	Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. Journal of Clinical Medicine, 2020, 9, 2682.	1.0	4
927	Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. American Journal of Gastroenterology, 2020, 115, 1960-1969.	0.2	11
928	Enteritis secondary to nivolumab, a growing cause of diarrhoea. GastroenterologÃa Y HepatologÃa (English Edition), 2020, 43, 620-621.	0.0	1

#	Article	IF	Citations
929	Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study . OncoTargets and Therapy, 2020, Volume 13, 12683-12693.	1.0	26
930	Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancerâ€"Reply. JAMA Oncology, 2020, 6, 1981.	3.4	0
931	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. Journal of the Formosan Medical Association, 2020, 120, 1581-1590.	0.8	4
932	Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation. Clinical Medicine Insights: Oncology, 2020, 14, 117955492096877.	0.6	1
933	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers, 2020, 12, 3830.	1.7	47
934	Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions. Current Oncology, 2020, 27, 152-164.	0.9	14
935	The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis. Annals of Palliative Medicine, 2020, 9, 4081-4088.	0.5	5
936	Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Annals of Translational Medicine, 2020, 8, 1530-1530.	0.7	0
937	Molecularly targeted photothermal ablation improves tumor specificity and immune modulation in a rat model of hepatocellular carcinoma. Communications Biology, 2020, 3, 783.	2.0	13
938	Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. OncoImmunology, 2020, 9, 1846926.	2.1	74
939	Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Research, 2020, 4, 191-198.	0.5	8
940	Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Communications, 2020, 40, 681-693.	3.7	40
941	Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. Cell Discovery, 2020, 6, 90.	3.1	84
942	Protein tyrosine phosphatase receptor type D (PTPRD)â€"mediated signaling pathways for the potential treatment of hepatocellular carcinoma: a narrative review. Annals of Translational Medicine, 2020, 8, 1192-1192.	0.7	17
943	Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 337-345.	1.8	6
944	Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy. Vaccines, 2020, 8, 735.	2.1	18
945	TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 575776.	1.1	15
946	Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Briefings in Bioinformatics, 2021, 22, .	3.2	16

#	Article	IF	Citations
947	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology, 2020, 11, 598877.	2.2	133
948	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
949	Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 8165.	1.8	147
950	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discovery, 2020, 10, 1808-1825.	7.7	388
951	Strategies and Advances in Tumor Immunotherapy. Materials Science Forum, 2020, 1009, 15-22.	0.3	0
952	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. BioDrugs, 2020, 34, 749-762.	2.2	5
953	Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer, 2020, 9, 663-681.	4.2	27
954	Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 629-639.	4.2	20
955	Expression of Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (PNCK) in Hepatocellular Carcinoma. Cancer Genomics and Proteomics, 2020, 17, 747-755.	1.0	15
956	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Frontiers in Immunology, 2020, 11, 568931.	2.2	100
957	Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 338-357.	4.2	96
958	Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. Supportive Care in Cancer, 2020, 28, 5569-5579.	1.0	15
959	New systemic agents for hepatocellular carcinoma: an update 2020. Current Opinion in Gastroenterology, 2020, 36, 177-183.	1.0	17
960	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-Î±, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clinical Cancer Research, 2020, 26, 3936-3946.	3.2	86
961	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates, 2020, 51, 100702.	6.5	53
962	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers, 2020, 12, 1221.	1.7	46
963	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer, 2020, 9, 245-260.	4.2	172
964	Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Molecular Cancer, 2020, 19, 92.	7.9	147

#	Article	IF	Citations
965	Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with antiâ€“PDâ€1 therapy. Cancer Medicine, 2020, 9, 4962-4970.	1.3	78
966	The effect of tumor location on long-term results of microwave ablation for early-stage hepatocellular carcinoma. Abdominal Radiology, 2020, 45, 3923-3933.	1.0	9
967	A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology, 2020, 20, 651-668.	10.6	2,160
968	Navigating the new landscape of secondâ€line treatment in advanced hepatocellular carcinoma. Liver International, 2020, 40, 1800-1811.	1.9	33
969	Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma. Cancers, 2020, 12, 1243.	1.7	11
970	Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clinical Cancer Research, 2020, 26, 3979-3989.	3.2	184
971	Scientifically based combination therapies with immunoâ€oncology checkpoint inhibitors. British Journal of Clinical Pharmacology, 2020, 86, 1711-1725.	1.1	6
972	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	18.1	684
973	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. British Journal of Cancer, 2020, 123, 92-100.	2.9	10
974	Safety of nivolumab in combination with prior or concurrent radiation therapy in hepatocellular carcinoma. Journal of Radiation Oncology, 2020, 9, 45-52.	0.7	2
975	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. Journal of Hematology and Oncology, 2020, 13, 47.	6.9	84
976	NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+T cell responses capable of curing multi-focal cancer. , 2020, 8, e000464.		20
977	Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. Theranostics, 2020, 10, 6530-6543.	4.6	31
978	Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncology, The, 2020, 21, 808-820.	5.1	371
979	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 2020, 382, 1894-1905.	13.9	3,828
980	Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Review of Clinical Pharmacology, 2020, 13, 623-629.	1.3	8
981	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
982	Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. Experimental Hematology and Oncology, 2020, 9, 10.	2.0	48

#	Article	IF	Citations
983	Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines, 2020, 8, 247.	2.1	9
984	A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 4511-4520.	3.2	56
985	ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. , 2020, 8, e000340.		124
986	Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-Î¹B signaling. BMC Cancer, 2020, 20, 386.	1.1	13
987	Antiâ€“PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infectionâ€“Related Advanced Hepatocellular Carcinoma: A Literature Review. Frontiers in Immunology, 2020, 11, 1037.	2.2	55
988	Ultra-stable Biomembrane Force Probe for Accurately Determining Slow Dissociation Kinetics of PD-1 Blockade Antibodies on Single Living Cells. Nano Letters, 2020, 20, 5133-5140.	4.5	19
989	Histology-agnostic drug development â€" considering issues beyond the tissue. Nature Reviews Clinical Oncology, 2020, 17, 555-568.	12.5	60
990	Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-14.	0.5	14
991	The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas. Clinical Cancer Research, 2020, 26, 4947-4957.	3.2	24
992	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers, 2020, 12, 1502.	1.7	145
993	Resolution of a hepatoduodenal fistula after nivolumab treatment in a patient with hepatocellular carcinoma: challenges in immunotherapy. Acta Clinica Belgica, 2022, 77, 108-112.	0.5	4
994	Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092203.	1.4	42
995	Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology International, 2020, 14, 765-775.	1.9	37
996	Is the era of sorafenib over? A review of the literature. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092760.	1.4	45
997	Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncology, 2020, 16, 1525-1536.	1.1	50
998	Nonsurgical Management of Advanced Hepatocellular Carcinoma: A Clinical Practice Guideline. Current Oncology, 2020, 27, 106-114.	0.9	7
999	PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2020, 39, 99.	3.5	51
1000	Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells, 2020, 9, 1370.	1.8	256

#	Article	IF	Citations
1001	Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology. Frontiers in Oncology, 2020, 10, 1105.	1.3	21
1002	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clinical Cancer Research, 2020, 26, 4201-4205.	3.2	30
1003	Finding the hot spot: identifying immune sensitive gastrointestinal tumors. Translational Gastroenterology and Hepatology, 2020, 5, 48-48.	1.5	6
1004	Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expression, 2020, 20, 53-65.	0.5	65
1005	The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. Clinical and Translational Medicine, 2020, 10, 45-56.	1.7	22
1006	Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre. Lung Cancer, 2020, 146, 145-153.	0.9	14
1007	Cancer and SARS-CoV-2 Infection: Diagnostic and Therapeutic Challenges. Cancers, 2020, 12, 1581.	1.7	28
1008	GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma. Acta Biomaterialia, 2020, 113, 512-521.	4.1	30
1009	Infectious Complications of Immune Checkpoint Inhibitors. Infectious Disease Clinics of North America, 2020, 34, 235-243.	1.9	7
1010	HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacological Research, 2020, 159, 104992.	3.1	57
1011	Advances in immunotherapy for colorectal cancer: a review. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482091752.	1.4	139
1012	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. MedComm, 2020, 1, 47-68.	3.1	93
1013	Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2020, 76, 1345-1354.	0.8	16
1014	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. Current Oncology Reports, 2020, 22, 70.	1.8	11
1015	Cautious Optimismâ€"The Current Role of Immunotherapy in Gastrointestinal Cancers. Current Oncology, 2020, 27, 59-68.	0.9	4
1016	Nivolumab and anti-HCV activity, a case report. Acta Clinica Belgica, 2020, 76, 1-5.	0.5	3
1017	The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. Journal of Oncology, 2020, 2020, 1-15.	0.6	33
1018	Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies. Hepatobiliary Surgery and Nutrition, 2020, 9, 348-349.	0.7	1

#	Article	IF	Citations
1019	â€˜The same old storyâ€™: thoughts on authorized doses of anticancer drugs. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090541.	1.4	5
1020	Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. Hepatobiliary Surgery and Nutrition, 2020, 9, 13-24.	0.7	11
1021	Immune-based therapies for hepatocellular carcinoma. Oncogene, 2020, 39, 3620-3637.	2.6	154
1022	Dishevelled 1-Regulated Superpotent Cancer Stem Cells Mediate Wnt Heterogeneity and Tumor Progression in Hepatocellular Carcinoma. Stem Cell Reports, 2020, 14, 462-477.	2.3	18
1023	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 635, xix-xxxviii.	0.4	0
1024	Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors. Anticancer Research, 2020, 40, 1219-1227.	0.5	26
1025	Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes and Diseases, 2020, 7, 359-369.	1.5	40
1026	Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. Translational Gastroenterology and Hepatology, 2020, 5, 21-21.	1.5	2
1027	Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection. Frontiers in Immunology, 2020, 11, 401.	2.2	39
1028	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 636, xvii-xxxvi.	0.4	0
1029	Impact of Next-Generation Sequencing on Outcomes in Hepatocellular Carcinoma: How Precise Are We Really? . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 33-37.	1.8	14
1030	Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes and Diseases, 2020, 7, 320-327.	1.5	10
1031	The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 174-185.	1.8	13
1032	Systemic therapy in advanced-stage hepatocellular carcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 212-217.	0.3	1
1033	Recent Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 775.	1.7	70
1034	Nivolumab for the treatment of hepatocellular carcinoma. Expert Opinion on Biological Therapy, 2020, 20, 687-693.	1.4	30
1035	Establishment of a Prognostic Model Using Immune-Related Genes in Patients With Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 55.	1.1	14
1036	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology, 2020, 15, 914-947.	0.5	119

#	Article	IF	Citations
1037	New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. Cells, 2020, 9, 688.	1.8	58
1038	Management of hepatitis B in the era of checkpoint inhibition. , 2020, 8, e000276.		2
1039	Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	5
1040	The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2020, 8, 55.	1.8	97
1041	Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle. Hepatobiliary Surgery and Nutrition, 2020, 9, 86-88.	0.7	1
1042	Regorafenib Versus Nivolumab After Sorafenib Failure: Realâ€World Data in Patients With Hepatocellular Carcinoma. Hepatology Communications, 2020, 4, 1073-1086.	2.0	28
1043	Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Current Oncology Reports, 2020, 22, 76.	1.8	7
1044	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. OncoImmunology, 2020, 9, 1761229.	2.1	22
1045	Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 91-99.	1.8	7
1046	ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. Frontiers in Oncology, 2020, 10, 971.	1.3	10
1047	Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection. Frontiers in Oncology, 2020, 10, 1043.	1.3	29
1048	On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. , 2020, 8, e001145.		48
1049	Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors . Cancer Management and Research, 2020, Volume 12, 4585-4593.	0.9	37
1050	Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360, 2020, 1, 130-140.	0.9	62
1051	The research trend in ADC for the treatment of liver cancer. AIP Conference Proceedings, 2020, , .	0.3	0
1052	Article Commentary: Cancer Immunotherapy for the General Surgeon. American Surgeon, 2020, 86, 284-292.	0.4	0
1053	Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?. Radiology, 2020, 296, 575-583.	3.6	19
1054	Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093518.	1.4	6

#	Article	IF	Citations
1055	Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093248.	1.4	10
1056	Increased both PDâ€“L1 and PDâ€“L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis. Scientific Reports, 2020, 10, 10377.	1.6	26
1057	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 4427.	1.8	67
1058	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Annals of Hepatology, 2020, 19, 546-569.	0.6	11
1059	Balancing Cancer Immunotherapy Efficacy and Toxicity. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2898-2906.	2.0	28
1060	Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers, 2020, 12, 1663.	1.7	112
1061	Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers, 2020, 12, 1668.	1.7	54
1062	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepatic Oncology, 2020, 7, HEP20.	4.2	30
1063	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. Cancers, 2020, 12, 1826.	1.7	46
1064	Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188391.	3.3	96
1065	Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma. Pathology and Oncology Research, 2020, 26, 2587-2595.	0.9	4
1066	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. Seminars in Cancer Biology, 2022, 79, 44-57.	4.3	104
1067	Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World . OncoTargets and Therapy, 2020, Volume 13, 143-149.	1.0	15
1068	PDâ€1 inhibitors for nonâ€small cell lung cancer patients with special issues: Realâ€world evidence. Cancer Medicine, 2020, 9, 2352-2362.	1.3	29
1069	The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepatic Oncology, 2020, 7, HEP17.	4.2	46
1070	A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. British Journal of Cancer, 2020, 122, 963-970.	2.9	17
1071	DC-CIK as a widely applicable cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 601-607.	1.4	28
1072	Severe terminal ileitis induced by single-agent nivolumab administered every four weeks. Journal of Oncology Pharmacy Practice, 2020, 26, 1516-1519.	0.5	4

#	Article	IF	Citations
1073	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Oncologist, 2020, 25, 669-679.	1.9	30
1074	Strategies to eliminate HBV infection: an update. Future Virology, 2020, 15, 35-51.	0.9	7
1075	An Epitope on EGFR Loading Catastrophic Internalization Serve as a Novel Oncotarget for Hepatocellular Carcinoma Therapy. Cancers, 2020, 12, 456.	1.7	0
1076	Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 571-580.	5.1	373
1077	Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. Lancet Oncology, The, 2020, 21, 479-481.	5.1	29
1078	Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression. Oncologist, 2020, 25, 470-474.	1.9	26
1079	The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 11-17.	1.8	64
1080	Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. Health Science Reports, 2020, 3, e147.	0.6	4
1081	Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C. Clinical and Experimental Medicine, 2020, 20, 219-230.	1.9	7
1082	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transplantation, 2020, 26, 823-831.	1.3	25
1083	A signature of 33 immuneâ€related gene pairs predicts clinical outcome in hepatocellular carcinoma. Cancer Medicine, 2020, 9, 2868-2878.	1.3	47
1084	USP9X promotes the progression of hepatocellular carcinoma by regulating beta-catenin. Irish Journal of Medical Science, 2020, 189, 865-871.	0.8	8
1085	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOSâ€“ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Annals of Oncology, 2020, 31, 334-351.	0.6	138
1086	Recognition and management of the gastrointestinal and hepatic immuneâ€related adverse events. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 95-102.	0.7	6
1087	Optimizing curative management of hepatocellular carcinoma. Liver International, 2020, 40, 109-115.	1.9	19
1088	Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. Cancer Immunology, Immunotherapy, 2020, 69, 983-988.	2.0	11
1089	Adoptive T-cell therapy for HBV-associated HCC and HBV infection. Antiviral Research, 2020, 176, 104748.	1.9	31
1090	Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer, 2020, 20, 135.	1.1	32

#	Article	IF	Citations
1091	Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma. Cancer Letters, 2020, 476, 120-128.	3.2	17
1092	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. European Radiology, 2020, 30, 3759-3769.	2.3	97
1093	Normalization Cancer Immunotherapy for Melanoma. Journal of Investigative Dermatology, 2020, 140, 1134-1142.	0.3	13
1094	Current status of immunotherapy in gastrointestinal malignancies. Zeitschrift Fur Gastroenterologie, 2020, 58, 542-555.	0.2	5
1096	Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation. Hepatology, 2020, 72, 1987-1999.	3.6	78
1097	Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. Journal of Gastroenterology, 2020, 55, 653-661.	2.3	38
1098	Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. Clinical Imaging, 2020, 63, 35-49.	0.8	3
1099	Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine, 2020, 53, 102659.	2.7	48
1100	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer, 2020, 145, 181-185.	0.9	36
1101	Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers. Annual Review of Immunology, 2020, 38, 649-671.	9.5	31
1102	Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. Journal of Translational Medicine, 2020, 18, 67.	1.8	70
1103	Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold. Biomaterials, 2020, 239, 119859.	5.7	82
1104	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	1.8	310
1105	Advances in resection and transplantation for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 262-276.	1.8	107
1106	Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules, 2020, 10, 117.	1.8	39
1107	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 631, xxiii-xlii.	0.4	1
1108	Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review. Pharmaceuticals, 2020, 13, 8.	1.7	187
1109	Hepatocellular Carcinomaâ€"How to Determine Therapeutic Options. Hepatology Communications, 2020, 4, 342-354.	2.0	14

#	Article	IF	Citations
1110	Advances in molecular classification and precision oncology in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 215-229.	1.8	311
1111	mRECIST for HCC: Performance and novel refinements. Journal of Hepatology, 2020, 72, 288-306.	1.8	292
1112	Novel patient-derived preclinical models of liver cancer. Journal of Hepatology, 2020, 72, 239-249.	1.8	41
1113	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 320-341.	1.8	165
1114	Milestones in the pathogenesis and management of primary liver cancer. Journal of Hepatology, 2020, 72, 209-214.	1.8	39
1115	Molecular therapies for HCC: Looking outside the box. Journal of Hepatology, 2020, 72, 342-352.	1.8	250
1116	Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophysics Reports, 2020, 6, 19-32.	0.2	1
1117	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. Cancers, 2020, 12, 182.	1.7	74
1118	Metabolismâ€associated molecular classification of hepatocellular carcinoma. Molecular Oncology, 2020, 14, 896-913.	2.1	143
1119	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 632, xxiii-xlii.	0.4	0
1120	Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer. Medicine (United States), 2020, 99, e19013.	0.4	64
1121	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology, 2020, 15, 115-126.	1.7	15
1122	Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. Journal of Experimental and Clinical Cancer Research, 2020, 39, 29.	3.5	45
1123	Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. Liver Cancer, 2020, 9, 426-439.	4.2	26
1124	Emerging biomarkers in HCC patients: Current status. International Journal of Surgery, 2020, 82, 70-76.	1.1	36
1125	Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers, 2020, 12, 1089.	1.7	119
1126	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology, 2020, 16, 975-989.	1.1	136
1127	COVID-19: the use of immunotherapy in metastatic lung cancer. Immunotherapy, 2020, 12, 545-548.	1.0	20

#	Article	IF	Citations
1128	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncology, 2020, 6, 888.	3.4	293
1129	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 2020, 12, 738.	1.7	826
1130	A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy. Cancers, 2020, 12, 745.	1.7	20
1131	Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma. Cancers, 2020, 12, 872.	1.7	6
1132	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist, 2020, 25, e1280-e1285.	1.9	14
1133	Immunotherapy in hepatocellular carcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 218-222.	0.3	1
1134	Liver stem cells. , 2020, , 723-736.		1
1135	The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. Cancer Treatment Reviews, 2020, 86, 102011.	3.4	31
1136	Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients. Lung Cancer, 2020, 144, 1-9.	0.9	10
1137	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. British Journal of Cancer, 2020, 122, 1630-1637.	2.9	472
1138	Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Gastroenterology, 2020, 159, 609-623.	0.6	100
1139	EpCAM-high liver cancer stem cells resist natural killer cellâ€“mediated cytotoxicity by upregulating CEACAM1. , 2020, 8, e000301.		62
1140	PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
1141	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Frontiers in Immunology, 2020, 11, 508.	2.2	58
1142	Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 5276-5286.	3.2	13
1143	Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. Clinical Liver Disease, 2020, 15, 53-58.	1.0	23
1144	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	1.6	47
1145	Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 187-196.	1.8	26

#	Article	IF	Citations
1146	Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study. CardioVascular and Interventional Radiology, 2020, 43, 1175-1181.	0.9	12
1147	Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 230-230.	0.7	15
1148	Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach. Advanced Biology, 2020, 4, e2000030.	3.0	7
1149	Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Communications, 2020, 40, 135-153.	3.7	339
1150	Prognostic and predicted significance of Ubqln2 in patients with hepatocellular carcinoma. Cancer Medicine, 2020, 9, 4083-4094.	1.3	4
1151	Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index. Cancer Medicine, 2020, 9, 4290-4298.	1.3	74
1152	Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 845-854.	0.7	2
1153	Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. , 2020, 8, e000394.		39
1154	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29.	6.9	146
1155	A review of glioblastoma immunotherapy. Journal of Neuro-Oncology, 2021, 151, 41-53.	1.4	159
1156	Evolution of Systemic Therapy for Hepatocellular Carcinoma. Hepatology, 2021, 73, 150-157.	3.6	70
1157	Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. Visceral Medicine, 2021, 37, 87-93.	0.5	6
1158	Peroxisome proliferatorâ€activated receptor activity correlates with poor survival in patients resected for hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 327-335.	1.4	6
1159	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	3.6	235
1160	Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. Hepatology Research, 2021, 51, 5-18.	1.8	29
1161	Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma. Cancer Gene Therapy, 2021, 28, 89-97.	2.2	16
1162	Hepatocellular carcinoma, novel therapies on the horizon. Chinese Clinical Oncology, 2021, 10, 12-12.	0.4	12
1163	Advanced papillary thyroid carcinoma responding to nivolumab. Journal of Oncology Pharmacy Practice, 2021, 27, 453-456.	0.5	6

#	Article	IF	Citations
1164	Liver Cancer Immunity. Hepatology, 2021, 73, 86-103.	3.6	52
1165	Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. Journal of Gastrointestinal Surgery, 2021, 25, 421-427.	0.9	94
1166	Biomarkers for Hepatobiliary Cancers. Hepatology, 2021, 73, 115-127.	3.6	104
1167	FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. Clinical Cancer Research, 2021, 27, 1836-1841.	3.2	102
1168	PDâ€L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced nonâ€small cell lung cancer?. Journal of Gene Medicine, 2021, 23, e3294.	1.4	14
1169	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 350-359.	1.8	122
1170	Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut, 2021, 70, 204-214.	6.1	150
1171	Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology, 2021, 73, 27-37.	3.6	23
1172	Targeting Tumorâ€Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. Hepatology, 2021, 73, 821-832.	3.6	25
1173	Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 417-429.	2.0	43
1174	Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology, 2021, 73, 104-114.	3.6	54
1175	Transcriptome Profiling Identifies TIGIT as a Marker of Tâ€Cell Exhaustion in Liver Cancer. Hepatology, 2021, 73, 1399-1418.	3.6	61
1176	Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 893-907.	2.0	72
1177	rAj-Tspin, a novel recombinant peptide from Apostichopus japonicus, suppresses the proliferation, migration, and invasion of BEL-7402 cells via a mechanism associated with the ITGB1-FAK-AKT pathway. Investigational New Drugs, 2021, 39, 377-385.	1.2	7
1178	Hepatitis B reactivation and immune check point inhibitors. Digestive and Liver Disease, 2021, 53, 452-455.	0.4	15
1179	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Modern Pathology, 2021, 34, 823-833.	2.9	6
1180	Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clinical Cancer Research, 2021, 27, 1003-1011.	3.2	334
1181	The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. JAMA Oncology, 2021, 7, 113.	3.4	213

#	Article	IF	Citations
1182	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene, 2021, 40, 140-151.	2.6	77
1183	Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma. Cancer Reports, 2021, 4, e1294.	0.6	3
1184	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clinical Cancer Research, 2021, 27, 713-718.	3.2	27
1185	Therapeutic implications of immuneâ€profiling and <scp>EGFR</scp> expression in salivary gland carcinoma. Head and Neck, 2021, 43, 768-777.	0.9	14
1186	Ribociclib enhances infigratinibâ€induced cancer cell differentiation and delays resistance in FGFRâ€driven hepatocellular carcinoma. Liver International, 2021, 41, 608-620.	1.9	11
1187	Hepatitis C virus associated hepatocellular carcinoma. Advances in Cancer Research, 2021, 149, 103-142.	1.9	18
1188	Systemic treatment of HCC in special populations. Journal of Hepatology, 2021, 74, 931-943.	1.8	72
1189	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. Journal of Hepatology, 2021, 74, 700-715.	1.8	60
1190	Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 62-75.	1.4	7
1191	Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunology, Immunotherapy, 2021, 70, 1593-1603.	2.0	32
1192	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Critical Reviews in Oncology/Hematology, 2021, 157, 103167.	2.0	30
1193	Hepatocellular carcinoma: Clinicopathologic associations amidst marked phenotypic heterogeneity. Pathology Research and Practice, 2021, 217, 153290.	1.0	2
1194	Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes. Methods, 2021, 188, 61-72.	1.9	16
1195	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cellular and Molecular Immunology, 2021, 18, 112-127.	4.8	159
1196	Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 423-433.	1.2	1
1197	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International, 2021, 41, 598-607.	1.9	13
1198	Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. American Journal of Health-System Pharmacy, 2021, 78, 187-202.	0.5	9
1199	Healthâ€related qualityâ€ofâ€life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTEâ€240. Cancer, 2021, 127, 865-874.	2.0	20

#	Article	IF	Citations
1200	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2021, 120, 1051-1060.	0.8	72
1201	Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma. Bioorganic and Medicinal Chemistry, 2021, 29, 115862.	1.4	6
1202	Milestones in the treatment of hepatocellular carcinoma: A systematic review.. Critical Reviews in Oncology/Hematology, 2021, 157, 103179.	2.0	14
1203	A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2021, 20, 389-397.	1.9	7
1204	The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist, 2021, 26, e1036-e1049.	1.9	30
1205	Downâ€regulation of EOMES drives Tâ€cell exhaustion via abolishing EOMESâ€mediated repression of inhibitory receptors of T cells in liver cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 161-169.	1.6	10
1206	Transarterial chemoembolisation enhances programmed deathâ€1 and programmed deathâ€ligand 1 expression in hepatocellular carcinoma. Histopathology, 2021, 79, 36-46.	1.6	49
1207	Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell, 2021, 184, 404-421.e16.	13.5	399
1208	CMTM6 Stabilizes PDâ€L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. Hepatology Communications, 2021, 5, 334-348.	2.0	24
1209	Aggressive surgical approach in patients with adrenal-only metastases from hepatocellular carcinoma enables higher survival rates than standard systemic therapy. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 28-33.	0.6	5
1210	Qualification of tumour mutational burden by targeted nextâ€generation sequencing as a biomarker in hepatocellular carcinoma. Liver International, 2021, 41, 192-203.	1.9	32
1211	Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. European Radiology, 2021, 31, 2737-2746.	2.3	8
1212	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virusâ€related diseases. Liver International, 2021, 41, 133-149.	1.9	3
1213	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. Molecular Imaging and Biology, 2021, 23, 70-83.	1.3	1
1214	Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Antiâ€“Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. Liver Transplantation, 2021, 27, 444-449.	1.3	24
1215	Recurrence of hepatocellular carcinoma following liver transplantation. Expert Review of Gastroenterology and Hepatology, 2021, 15, 91-102.	1.4	21
1216	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cellular and Molecular Life Sciences, 2021, 78, 867-887.	2.4	9
1217	A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. Journal of Cellular Physiology, 2021, 236, 2572-2591.	2.0	26

#	Article	IF	Citations
1218	Gut microbiota: impacts on gastrointestinal cancer immunotherapy. Gut Microbes, 2021, 13, 1-21.	4.3	33
1219	Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101. Theranostics, 2021, 11, 5955-5969.	4.6	23
1220	TIGIT and PD1 Co-blockade Restores exÂvivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 443-464.	2.3	43
1221	Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. Cancer Immunology, Immunotherapy, 2021, 70, 1929-1937.	2.0	19
1222	Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma. Oncology & Hematology Review, 2021, 16, 90.	0.2	0
1223	Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals, 2021, 14, 36.	1.7	30
1224	Epidemiology, mutational landscape and staging of hepatocellular carcinoma. Chinese Clinical Oncology, 2021, 10, 2-2.	0.4	9
1225	Cryoglobulinemia unmasked by nivolumab in a patient with hepatitis C-induced hepatocellular carcinoma: A case report and literature review. International Journal of Critical Illness and Injury Science, 2021, 11, 95.	0.2	1
1226	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treatment and Research Communications, 2021, 27, 100328.	0.7	70
1227	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer, 2021, 10, 360-369.	4.2	25
1228	Therapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1988-1996.	1.4	18
1229	Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study. Oncology, 2021, 99, 641-651.	0.9	9
1230	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. American Journal of Gastroenterology, 2021, 116, 1274-1283.	0.2	37
1231	Tumors of the Liver. , 2021, , 1367-1380.		0
1232	HepatozellulÃres Karzinom. , 2021, , 447-454.		0
1233	Research trends in pharmacological modulation of tumorâ€associated macrophages. Clinical and Translational Medicine, 2021, 11, e288.	1.7	52
1234	Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	1.4	10
1235	Cancer Immunology. , 2021, , .		0

#	Article	IF	Citations
1236	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110109.	1.4	15
1237	The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma. Journal of Cancer, 2021, 12, 1284-1294.	1.2	51
1238	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Annals of Surgical Oncology, 2021, 28, 1499-1510.	0.7	3
1239	Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. EClinicalMedicine, 2021, 31, 100673.	3.2	23
1240	Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e2033761.	2.8	27
1241	Promising response to immunotherapy in metastatic nasopharyngeal carcinoma associated with hepatitis C virus â€“ a case report. ORL Ro, 2021, 2, 30.	0.0	0
1242	Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Advances in Cancer Research, 2021, 152, 329-381.	1.9	3
1243	Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nature Communications, 2021, 12, 227.	5.8	76
1244	Systemic therapy of liver cancer. Advances in Cancer Research, 2021, 149, 257-294.	1.9	44
1245	Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110169.	1.4	74
1246	Radiotherapy for Hepatocellular Carcinoma. , 2021, , 189-200.		0
1247	Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma. International Journal of Medical Sciences, 2021, 18, 2030-2041.	1.1	7
1248	Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patterns. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 364-378.	0.7	11
1249	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110311.	1.4	19
1250	Quantitative Approaches to Therapeutic Decision Making in Hepatocellular Carcinoma. JCO Oncology Practice, 2021, 17, OP.20.00846.	1.4	0
1251	Immunotherapy in hepatocellular cancer. Advances in Cancer Research, 2021, 149, 295-320.	1.9	0
1252	Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 574778.	1.3	4
1253	Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Frontiers in Immunology, 2020, 11, 613946.	2.2	40

#	Article	IF	Citations
1254	Multiplexed Imaging for Immune Profiling on Human FFPE Material. Methods in Molecular Biology, 2021, 2350, 125-144.	0.4	0
1255	Genome-wide CRISPR-Cas9 knockout library screening identified PTPMT1 in cardiolipin synthesis is crucial to survival in hypoxia in liver cancer. Cell Reports, 2021, 34, 108676.	2.9	30
1256	Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clinical and Molecular Hepatology, 2021, 27, 144-156.	4.5	19
1257	Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Translational Gastroenterology and Hepatology, 2021, 6, 11-11.	1.5	20
1258	Namodenoson in Advanced Hepatocellular Carcinoma and Childâ€“Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. Cancers, 2021, 13, 187.	1.7	25
1259	Regulation of PD-L1 expression in the tumor microenvironment. Journal of Hematology and Oncology, 2021, 14, 10.	6.9	281
1260	Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapyversuslenvatinib alone for advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110027.	1.4	91
1261	Pan-Cancer Molecular Characterization of m6A Regulators and Immunogenomic Perspective on the Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 618374.	1.3	28
1262	Perspectives of Radiotherapy in Immuno-oncology Era. , 2021, , 325-337.		0
1263	Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. Journal of Immunotherapy, 2021, 44, 132-139.	1.2	19
1264	Fundamentals of Digestive Cancers Immunology, Especially Gastric and Hepatocellular CarcinomasFondamentaux de lâ€™immunologie des Cancers Digestifs (Gastriques et HÃ©patocellulaires). Oncologie, 2021, 23, 47-59.	0.2	5
1265	Immunotherapy in Immunosuppressed Patients. , 2021, , 429-440.		0
1266	Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients. Frontiers in Oncology, 2020, 10, 581051.	1.3	8
1267	Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian Journal of Hepato-gastroenterology, 2021, 11, 32-40.	0.1	10
1268	Prognostic Impact of PD-1 on Tumor-Infiltrating Lymphocytes in 433 Resected Esophageal Cancers. Annals of Thoracic Surgery, 2021, , .	0.7	8
1269	Advanced drug delivery systems in liver cancer. , 2021, , 217-223.		1
1270	Molecular Carcinogenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma. , 2021, , 123-141.		0
1271	Image-Guided Intratumoral Delivery of Immunotherapeutics in Gastrointestinal Malignancies. Digestive Disease Interventions, 2021, 05, 022-031.	0.3	4

#	Article	IF	Citations
1272	Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110381.	0.8	2
1273	The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. Cancers, 2021, 13, 238.	1.7	14
1274	Paraspeckle Promotes Hepatocellular Carcinoma Immune Escape by Sequestering IFNGR1 mRNA. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 465-487.	2.3	5
1275	LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma. Journal of Cancer, 2021, 12, 217-223.	1.2	30
1276	Spatially-resolved proteomics and transcriptomics: An emerging digital spatial profiling approach for tumor microenvironment. Visualized Cancer Medicine, 2021, 2, 1.	0.5	9
1277	Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions. Immunotherapy, 2021, 13, 113-123.	1.0	2
1278	Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Scientific Reports, 2021, 11, 3731.	1.6	7
1279	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology, 2021, 53, 141-156.	0.3	126
1280	Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. JCO Oncology Practice, 2021, 17, e266-e277.	1.4	12
1281	Hepatocellular carcinoma in non-alcoholic fatty liver diseaseâ€”a review of an emerging challenge facing clinicians. Hepatobiliary Surgery and Nutrition, 2021, 10, 59-75.	0.7	34
1282	The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma. Targeted Oncology, 2021, 16, 153-163.	1.7	5
1283	Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 75.	7.1	323
1284	Clinical outcomes and influencing factors of PDâ€'1/PDâ€'L1 in hepatocellular carcinoma (Review). Oncology Letters, 2021, 21, 279.	0.8	36
1285	Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report. Journal of International Medical Research, 2021, 49, 030006052199440.	0.4	1
1286	Immunotherapy for hepatocellular carcinoma: The challenge of biomarker studies. Journal of the Chinese Medical Association, 2021, 84, 121-122.	0.6	2
1287	Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. Current Hepatology Reports, 2021, 20, 23-33.	0.4	10
1288	The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. International Journal of Molecular Sciences, 2021, 22, 1931.	1.8	31
1289	HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness. Cancer Research, 2021, 81, 2015-2028.	0.4	60

#	Article	IF	Citations
1290	Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers, 2021, 13, 584.	1.7	6
1291	Immunomodulation by Inflammation during Liver and Gastrointestinal Tumorigenesis and Aging. International Journal of Molecular Sciences, 2021, 22, 2238.	1.8	13
1292	Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 2559-2576.	2.0	40
1293	PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury. Journal of Clinical Investigation, 2021, 131, .	3.9	51
1294	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. European Journal of Radiology, 2021, 135, 109484.	1.2	20
1295	Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. , 2021, 9, e001945.		74
1296	Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Science Translational Medicine, 2021, 13, .	5.8	36
1297	Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. Frontiers in Oncology, 2020, 10, 610513.	1.3	17
1298	First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2021, 13, 931.	1.7	26
1299	â€œComplimenting the Complementâ€: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 627701.	1.3	22
1300	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers, 2021, 13, 651.	1.7	7
1301	Understanding relevant immune mechanisms in gastrointestinal oncology. Journal of Oncology Pharmacy Practice, 2021, 27, 107815522199286.	0.5	0
1302	Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Frontiers in Oncology, 2020, 10, 605057.	1.3	4
1303	Antiâ€Programmed deathâ€1 therapy in advanced hepatocellular carcinoma: A realâ€world experience. Clinical Case Reports (discontinued), 2021, 9, 2162-2167.	0.2	2
1304	Cellular heterogeneity and plasticity in liver cancer. Seminars in Cancer Biology, 2022, 82, 134-149.	4.3	58
1305	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 72.	7.1	191
1306	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 144-150.	0.6	8
1307	Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. Journal of Experimental and Clinical Cancer Research, 2021, 40, 73.	3.5	24

#	Article	IF	Citations
1308	The Roles of circRNAs in Liver Cancer Immunity. Frontiers in Oncology, 2020, 10, 598464.	1.3	13
1309	Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation. Npj Precision Oncology, 2021, 5, 27.	2.3	11
1310	Emerging Role of Immune Therapy in HCC. Digestive Disease Interventions, 2021, 05, 277-282.	0.3	0
1311	Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nature Communications, 2021, 12, 1455.	5.8	96
1312	Narrative review of hepatocellular carcinoma: from molecular bases to therapeutic approach. Digestive Medicine Research, 0, 4, 15-15.	0.2	1
1313	Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Frontiers in Oncology, 2021, 11, 650481.	1.3	23
1314	Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer. Frontiers in Immunology, 2021, 12, 630773.	2.2	22
1315	Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?. Radiology, 2021, 298, 680-692.	3.6	23
1316	A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	43
1317	Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 652172.	2.2	21
1318	Clinical recommendations for perioperative immunotherapyâ€induced adverse events in patients with nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 1469-1488.	0.8	7
1319	A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma. Aging, 2021, 13, 8563-8587.	1.4	8
1320	Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma. Cancers, 2021, 13, 1607.	1.7	19
1321	Three-Dimensional Macroporous Sponge for the Culture of Hepatocellular Carcinoma Patient-Derived Xenograft Organoids. SLAS Technology, 2021, 26, 249-254.	1.0	3
1322	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101590.	0.7	17
1323	Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration. Frontiers in Molecular Biosciences, 2021, 8, 602227.	1.6	3
1324	Development and validation of a robust immune-related risk signature for hepatocellular carcinoma. Medicine (United States), 2021, 100, e24683.	0.4	7
1325	Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Frontiers in Immunology, 2021, 12, 655697.	2.2	126

#	Article	IF	Citations
1326	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomarker Research, 2021, 9, 19.	2.8	43
1327	The Evolving Immunotherapy LandscapeÂand the Epidemiology, Diagnosis, and Management ofÂCardiotoxicity. JACC: CardioOncology, 2021, 3, 35-47.	1.7	80
1328	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	13.7	649
1329	Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncology, 2021, 17, 755-757.	1.1	60
1330	Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	5
1331	Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC). Current Treatment Options in Gastroenterology, 2021, 19, 351-368.	0.3	6
1332	Outcome of Immune Checkpoint Inhibitor and Molecular Target Agent Combination for Advanced Hepatocellular Carcinoma: Beyond Sorafenib Era. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 77, 145-147.	0.2	0
1333	Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Frontiers in Oncology, 2021, 11, 589680.	1.3	23
1334	CD8+ T Cell Responses during HCV Infection and HCC. Journal of Clinical Medicine, 2021, 10, 991.	1.0	22
1335	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers, 2021, 13, 1413.	1.7	13
1336	Programmed cell deathâ€ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2601-2609.	1.4	5
1337	Intratumoral Hypoxia and Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors. Physiology, 2021, 36, 73-83.	1.6	29
1338	Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 652007.	2.2	7
1339	Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry. Journal of Liver Cancer, 2021, 21, 58-70.	0.3	18
1340	Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery, 2021, 11, 1353-1367.	7.7	197
1341	Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. BMC Cancer, 2021, 21, 331.	1.1	1
1342	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664.		11
1343	The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 626984.	1.3	12

#	Article	IF	Citations
1344	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. Minerva Gastroenterology, 2021, 67, .	0.3	7
1345	Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection. Oncologist, 2021, 26, e827-e830.	1.9	9
1346	Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports. Journal of Medical Case Reports, 2021, 15, 132.	0.4	7
1347	Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. Expert Review of Gastroenterology and Hepatology, 2021, 15, 589-598.	1.4	17
1348	Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiotherapy and Oncology, 2021, 156, 120-126.	0.3	19
1349	Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. Journal of Gastroenterology, 2021, 56, 456-469.	2.3	11
1350	4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice. Scientific Reports, 2021, 11, 6310.	1.6	13
1351	PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer, 2021, 21, 301.	1.1	42
1352	A metabolism-related gene signature for predicting the prognosis and therapeutic responses in patients with hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 500-500.	0.7	17
1353	How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals, 2021, 14, 233.	1.7	9
1354	Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	5
1355	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 177-191.	1.8	9
1356	Therapeutic applications of the cancer immunoediting hypothesis. Seminars in Cancer Biology, 2022, 78, 63-77.	4.3	29
1357	Immune Checkpoint Inhibitors in the Treatment of Cancer. Current Clinical Pharmacology, 2022, 17, 103-113.	0.2	18
1358	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Frontiers in Oncology, 2021, 11, 617335.	1.3	49
1359	Nivolumab for the treatment of esophageal cancer. Expert Opinion on Biological Therapy, 2021, 21, 1-7.	1.4	9
1360	The Epigenetic Regulation of Microenvironment in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 653037.	1.3	7
1361	Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. Aging, 2021, 13, 11257-11280.	1.4	11

#	Article	IF	Citations
1362	Predictive Factors for the Effectiveness of Repeated Lines of Transarterial Chemoembolization in the Treatment of Localized Hepatocellular Carcinoma. Journal of Oncology Diagnostic Radiology and Radiotherapy, 2021, 4, 42-52.	0.1	0
1363	Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer, 2021, 125, 190-199.	2.9	26
1364	Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2Î±/ATF4/CHOP axis in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 127.	3.5	23
1365	Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Frontiers in Molecular Biosciences, 2021, 8, 635243.	1.6	22
1366	Nomogram development and validation to predict hepatocellular carcinoma tumor behavior by preoperative gadoxetic acid-enhanced MRI. European Radiology, 2021, 31, 8615-8627.	2.3	21
1367	The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study. Frontiers in Oncology, 2021, 11, 646979.	1.3	23
1368	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 562315.	1.3	38
1369	Checkpoint Inhibitor-Induced Colitisâ€"A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. Pharmaceuticals, 2021, 14, 367.	1.7	13
1370	Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers, 2021, 13, 1729.	1.7	14
1371	Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers, 2021, 13, 2164.	1.7	14
1372	Identification of Biomarkers Related to Immune Cell Infiltration in Hepatocellular Carcinoma Using Gene Co-Expression Network. Pathology and Oncology Research, 2021, 27, 601693.	0.9	2
1373	Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy, 2021, 13, 371-385.	1.0	16
1374	Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?. Hepatobiliary Surgery and Nutrition, 2021, 10, 180-192.	0.7	47
1375	Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. Liver Cancer, 2021, 10, 249-259.	4.2	49
1376	Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer, 2021, 10, 296-308.	4.2	63
1377	Frontiers of therapy for hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 3648-3659.	1.0	16
1378	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. Immunotherapy, 2021, 13, 509-525.	1.0	3
1379	Advances in immunotherapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 525-543.	8.2	609

#	Article	IF	Citations
1380	Î²-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy. Cancers, 2021, 13, 1830.	1.7	16
1381	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Frontiers in Immunology, 2021, 12, 643310.	2.2	27
1382	Repeated transarterial chemoembolization with epirubicinâ€'loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. Molecular and Clinical Oncology, 2021, 14, 119.	0.4	1
1383	Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunology, Immunotherapy, 2021, 70, 3207-3216.	2.0	21
1384	Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. Liver Cancer, 2021, 10, 407-418.	4.2	17
1385	Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplantation Reviews, 2021, 35, 100606.	1.2	6
1386	The Current Landscape of Clinical Trials for Systemic Treatment of HCC. Cancers, 2021, 13, 1962.	1.7	40
1387	NAFLD-Associated HCC: Progress and Opportunities. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 223-239.	1.8	33
1388	Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance. Current Medicinal Chemistry, 2021, 28, 1126-1142.	1.2	19
1389	Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. Frontiers in Immunology, 2021, 12, 642958.	2.2	12
1390	Therapies for hepatocellularÂcarcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. Abdominal Radiology, 2021, 46, 3540-3548.	1.0	3
1391	AB4 inhibits Notch signaling and promotes cancer cell apoptosis in liver cancer. Oncology Reports, 2021, 45, .	1.2	1
1392	Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. Annals of Translational Medicine, 2021, 9, 652-652.	0.7	22
1393	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2021, 10, 275-284.	4.2	29
1394	The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Current Opinion in Oncology, 2021, 33, 386-394.	1.1	13
1395	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine, 2021, 13, .	5.8	59
1396	Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers, 2021, 13, 1922.	1.7	29
1397	Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist, 2021, 26, e1216-e1225.	1.9	26

#	Article	IF	Citations
1398	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Metaâ€Analysis. Frontiers in Oncology, 2021, 11, 650292.	1.3	22
1399	The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kongâ€"A Territory-Wide Cohort Study. Cancers, 2021, 13, 2002.	1.7	8
1400	Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers, 2021, 13, 1949.	1.7	31
1401	Combined Inhibition of TGF-Î²1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. Journal of Clinical Medicine, 2021, 10, 1889.	1.0	25
1402	Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Panminerva Medica, 2021, , .	0.2	2
1403	The Future of Clinical Trial Design in Oncology. Cancer Discovery, 2021, 11, 822-837.	7.7	32
1404	Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 4710.	1.8	22
1405	TYRO3 induces antiâ€"PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. Journal of Clinical Investigation, 2021, 131, .	3.9	135
1406	Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. Current Medicinal Chemistry, 2021, 28, 3107-3146.	1.2	9
1407	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers, 2021, 13, 2677.	1.7	6
1408	Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Drug Design, Development and Therapy, 2021, Volume 15, 1873-1882.	2.0	20
1409	Hyperthermia and Tumor Immunity. Cancers, 2021, 13, 2507.	1.7	24
1410	The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers, 2021, 13, 2621.	1.7	15
1411	Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. Scientific Reports, 2021, 11, 10264.	1.6	0
1412	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Journal of Experimental and Clinical Cancer Research, 2021, 40, 172.	3.5	104
1413	Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. Frontiers in Oncology, 2021, 11, 559161.	1.3	34
1414	Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?. Cancers, 2021, 13, 2708.	1.7	19
1415	Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells, 2021, 10, 1332.	1.8	24

#	Article	IF	Citations
1416	Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Frontiers in Oncology, 2021, 11, 683341.	1.3	13
1417	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer, 2021, 125, 200-208.	2.9	22
1418	Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer, 2021, 21, 569.	1.1	17
1419	Kinetics of the neutrophilâ€lymphocyte ratio during PDâ€1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver International, 2021, 41, 2189-2199.	1.9	26
1420	The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines, 2021, 9, 532.	2.1	65
1421	Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy. Cancers, 2021, 13, 2543.	1.7	4
1422	Recent Advances in Hepatitis B Treatment. Pharmaceuticals, 2021, 14, 417.	1.7	27
1423	Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. International Immunopharmacology, 2021, 94, 107467.	1.7	18
1424	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated Î± â€fetoprotein: Outcomes by treatmentâ€emergent ascites. Hepatology Research, 2021, 51, 715-721.	1.8	5
1425	Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1. Aging, 2021, 13, 20094-20115.	1.4	16
1426	Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission. Journal of Pain and Symptom Management, 2021, 61, 940-947.e3.	0.6	10
1427	Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma. Journal of Biomedical Nanotechnology, 2021, 17, 771-792.	0.5	1
1428	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 477-492.	1.8	15
1429	Immuneâ€related adverse events predict responses to <scp>PD</scp>â€1 blockade immunotherapy in hepatocellular carcinoma. International Journal of Cancer, 2021, 149, 959-966.	2.3	15
1430	Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 387-401.	1.8	62
1431	High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma. Scientific Reports, 2021, 11, 11078.	1.6	8
1433	Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma. Hepatology, 2021, 73, 2591-2593.	3.6	13
1434	Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs. Anticancer Research, 2021, 41, 2569-2573.	0.5	2

#	Article	IF	Citations
1435	Imaging of treatment response during systemic therapy for hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 3625-3633.	1.0	5
1436	Tâ€cell mediated responses against alphaâ€foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patientsâ€™ survival. Liver Cancer International, 2021, 2, 7-14.	0.2	0
1437	The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552.	2.2	20
1438	Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 2434-2457.	1.4	18
1439	Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open, 2021, 5, 705-711.	0.7	2
1440	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. International Journal of Molecular Sciences, 2021, 22, 5801.	1.8	182
1441	Systemic Therapy for Hepatocellular Carcinoma. Clinical Liver Disease, 2021, 17, 337-340.	1.0	5
1442	Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 686621.	1.3	28
1443	Immunotherapy Management in Special Cancer Patient Populations. JCO Oncology Practice, 2021, 17, 240-245.	1.4	8
1444	The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers, 2021, 13, 2651.	1.7	18
1445	MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis. Cellular Oncology (Dordrecht), 2021, 44, 821-834.	2.1	34
1446	Immunotherapy for GI Cancers. Advances in Oncology, 2021, 1, 283-295.	0.1	0
1447	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. Seminars in Liver Disease, 2021, 41, 136-141.	1.8	10
1448	PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma. Translational Cancer Research, 2021, 10, 2305-2317.	0.4	3
1449	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 650486.	2.2	26
1450	Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 683240.	1.6	14
1451	Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Review of Anticancer Therapy, 2021, 21, 621-628.	1.1	11
1452	Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 25-38.	2.0	15

#	Article	IF	Citations
1453	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. Expert Opinion on Biological Therapy, 2021, 21, 1623-1634.	1.4	10
1454	Hepatocellular Carcinoma in Sub-Saharan Africa. JCO Global Oncology, 2021, 7, 756-766.	0.8	25
1455	Gastrointestinal cancer treatment with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 342-348.	0.1	0
1456	Cellular based treatment modalities for unresectable hepatocellular carcinoma. World Journal of Clinical Oncology, 2021, 12, 290-308.	0.9	4
1457	The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma. Scientific Reports, 2021, 11, 10728.	1.6	3
1458	Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 507-512.	1.8	8
1459	Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 346-359.	4.2	70
1460	The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101664.	0.7	9
1461	The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers, 2021, 13, 2608.	1.7	34
1462	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 2021, 10, 181-223.	4.2	307
1463	Effect of dermatological consultation on survival in patients with checkpoint inhibitorâ€associated cutaneous toxicity. British Journal of Dermatology, 2021, 185, 627-635.	1.4	12
1464	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. International Journal of Molecular Sciences, 2021, 22, 5123.	1.8	61
1465	A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. Liver Cancer, 2021, 10, 500-509.	4.2	9
1466	The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 529-543.	1.8	11
1467	Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. Expert Opinion on Investigational Drugs, 2021, 30, 827-835.	1.9	3
1468	Exploring liver cancer biology through functional genetic screens. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 690-704.	8.2	31
1469	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs and Aging, 2021, 38, 579-591.	1.3	5
1470	Editorial: Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 698515.	1.3	0

#	Article	IF	Citations
1471	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver International, 2021, 41, 2759-2767.	1.9	5
1472	3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness. Cell Death Discovery, 2021, 7, 173.	2.0	10
1473	Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. Journal of Gastrointestinal Oncology, 2021, 12, 1117-1131.	0.6	7
1474	WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. Nature Communications, 2021, 12, 3500.	5.8	28
1475	Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discovery Today, 2021, 26, 1539-1546.	3.2	18
1476	Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy, 2021, 13, 637-644.	1.0	63
1477	Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokineticsÂand future treatment strategies. Future Oncology, 2021, 17, 2243-2256.	1.1	36
1478	Response to crizotinib in a patient with METâ€•amplified hepatocellular carcinoma. Hepatology Research, 2021, 51, 1164-1169.	1.8	4
1479	Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells. Current Oncology, 2021, 28, 2150-2172.	0.9	9
1480	The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants. Advances in Therapy, 2021, 38, 3900-3910.	1.3	7
1481	Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?. World Journal of Gastroenterology, 2021, 27, 3429-3439.	1.4	4
1482	Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2021, 10, 2662.	1.0	13
1483	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Frontiers in Oncology, 2021, 11, 641428.	1.3	32
1484	Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. Clinical and Experimental Medicine, 2022, 22, 65-74.	1.9	41
1485	Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer. Bioscience Reports, 2021, 41, .	1.1	12
1486	<scp>FDA</scp> Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. Oncologist, 2021, 26, 797-806.	1.9	61
1487	Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAgâ€Negative Chronic Hepatitis B. Hepatology Communications, 2021, 5, 1632-1648.	2.0	20
1488	An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Frontiers in Pharmacology, 2021, 12, 707930.	1.6	12

#	Article	IF	Citations
1489	Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologistâ€™s Role. Cancers, 2021, 13, 2871.	1.7	17
1490	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 587-598.	1.8	1
1491	SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death and Disease, 2021, 12, 570.	2.7	20
1493	Portal hypertension and hepatocellular carcinoma: Des liaisons dangereusesâ€¦. Liver International, 2021, 41, 1734-1743.	1.9	31
1494	Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody. Annals of Surgical Oncology, 2022, 29, 30-32.	0.7	2
1495	Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. Clinical Gastroenterology and Hepatology, 2022, 20, 898-907.	2.4	29
1496	Characterization of response to atezolizumabÂ+ÂbevacizumabÂ versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. Cancer Medicine, 2021, 10, 5437-5447.	1.3	29
1497	Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. Npj Precision Oncology, 2021, 5, 52.	2.3	24
1498	Realâ€world evidence in hepatocellular carcinoma. Liver International, 2021, 41, 61-67.	1.9	6
1499	SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection. Journal of Clinical Investigation, 2021, 131, .	3.9	23
1500	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584.	0.6	91
1501	YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports, 2021, 11, 13482.	1.6	13
1502	The TGF-Î² Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers, 2021, 13, 3248.	1.7	37
1503	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Annals of Allergy, Asthma and Immunology, 2021, 126, 630-638.	0.5	23
1504	Nivolumab exposureâ€“response analysis for adjuvant treatment of melanoma supporting a change in posology. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 748-759.	1.3	3
1505	Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody. Cancer Immunology, Immunotherapy, 2022, 71, 353-363.	2.0	15
1506	Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors. Hepatology, 2021, 74, 2264-2276.	3.6	39
1507	Identification of CD8+ T Cell-Related Genes: Correlations with Immune Phenotypes and Outcomes of Liver Cancer. Journal of Immunology Research, 2021, 2021, 1-17.	0.9	8

#	Article	IF	Citations
1508	Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Seminars in Liver Disease, 2021, 41, 263-276.	1.8	14
1509	USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. Journal of Experimental and Clinical Cancer Research, 2021, 40, 201.	3.5	27
1510	Erk phosphorylation reduces the thymoquinone toxicity in human hepatocarcinoma. Environmental Toxicology, 2021, 36, 1990-1998.	2.1	7
1511	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. Acta Biochimica Et Biophysica Sinica, 2021, 53, 961-978.	0.9	4
1512	Prospects and Challenges for T Cell-Based Therapies of HCC. Cells, 2021, 10, 1651.	1.8	13
1513	Paeoniflorin Affects Hepatocellular Carcinoma Progression by Inhibiting Wnt/Î²-Catenin Pathway through Downregulation of 5-HT1D. Current Pharmaceutical Biotechnology, 2021, 22, 1246-1253.	0.9	10
1514	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. Expert Opinion on Investigational Drugs, 2022, 31, 371-378.	1.9	65
1515	Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World Journal of Gastroenterology, 2021, 27, 2994-3009.	1.4	103
1516	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cellâ€“Mediated Antitumor Immunity Through PDâ€L1. Hepatology Communications, 2022, 6, 178-193.	2.0	16
1517	Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncology Practice, 2022, 18, 35-41.	1.4	12
1518	Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World Journal of Gastroenterology, 2021, 27, 4104-4142.	1.4	15
1519	Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. Cancer Cell International, 2021, 21, 371.	1.8	18
1520	Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 598-613.	0.4	19
1521	Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World Journal of Clinical Cases, 2021, 9, 5754-5768.	0.3	9
1522	Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World Journal of Clinical Cases, 2021, 9, 5988-5998.	0.3	2
1523	Emerging Regulatory Mechanisms Involved in Liver Cancer Stem Cell Properties in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 691410.	1.8	13
1524	Immunotherapy use outside clinical trial populations: never say never?. Annals of Oncology, 2021, 32, 866-880.	0.6	22
1525	Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treatment Reviews, 2021, 98, 102221.	3.4	43

#	Article	IF	Citations
1526	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Journal of Clinical Medicine, 2021, 10, 3201.	1.0	13
1527	Systemic therapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology, 2021, 51, 1363-1371.	0.6	3
1528	Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). Frontiers in Oncology, 2021, 11, 684867.	1.3	35
1529	How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers, 2021, 13, 3536.	1.7	4
1530	Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma. Cancer Cell International, 2021, 21, 342.	1.8	27
1531	Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells, 2021, 10, 1715.	1.8	130
1532	Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2021, , 1.	1.1	2
1533	Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. Vaccines, 2021, 9, 807.	2.1	2
1534	DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 676922.	2.2	15
1535	Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection. BMC Cancer, 2021, 21, 817.	1.1	2
1536	Emerging data on nivolumab for esophageal squamous cell carcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 845-854.	1.4	1
1537	Capitalizing on Success of Systemic Therapy to Improve Outcomes of Intermediate-Stage HCC. JCO Oncology Practice, 2021, , OP.21.00451.	1.4	0
1538	Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointestinal Tumors, 2021, 8, 145-152.	0.3	6
1539	Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. Gut, 2022, 71, 1176-1191.	6.1	52
1540	Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma. Cancers, 2021, 13, 3771.	1.7	7
1541	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. Journal of Inflammation Research, 2021, Volume 14, 3077-3088.	1.6	5
1542	Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. International Journal of Molecular Sciences, 2021, 22, 7800.	1.8	26
1543	The immunological and metabolic landscape in primary and metastatic liver cancer. Nature Reviews Cancer, 2021, 21, 541-557.	12.8	212

#	Article	IF	Citations
1544	Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 511-520.	0.6	29
1545	The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1195-1210.	1.2	8
1546	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Frontiers in Pharmacology, 2021, 12, 714483.	1.6	9
1547	Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma â€“ 2020 Guangzhou Recommendations. Frontiers in Oncology, 2021, 11, 621834.	1.3	4
1548	Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. Lung Cancer Management, 2021, 10, LMT51.	1.5	10
1549	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 741-757.	1.8	29
1550	Efficacy and biomarker exploration of camrelizumab combined with apatinib in the treatment of advanced primary liver cancer: a retrospective study. Anti-Cancer Drugs, 2021, 32, 1093-1098.	0.7	4
1551	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nature Cancer, 2021, 2, 891-903.	5.7	147
1552	Evolution of systemic treatment for advanced hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2021, 37, 643-653.	0.8	11
1553	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 1244-1256.	0.9	4
1554	The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells, 2021, 10, 1909.	1.8	6
1555	The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC. Frontiers in Immunology, 2021, 12, 638763.	2.2	23
1556	Radioembolization for Hepatocellular Carcinoma. Digestive Disease Interventions, 2021, 05, 268-276.	0.3	0
1557	Advances of Targeted Therapy for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 719896.	1.3	23
1558	Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2â€“3 study. Lancet Oncology, The, 2021, 22, 977-990.	5.1	459
1559	Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	4
1560	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. Journal of Hepatology, 2021, 75, 177-189.	1.8	29
1561	TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Frontiers in Immunology, 2021, 12, 699895.	2.2	102

#	Article	IF	Citations
1562	Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer, 2021, 21, 775.	1.1	28
1563	Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?. Expert Opinion on Investigational Drugs, 2021, , 1-3.	1.9	1
1564	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822.	1.8	17
1565	Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World Journal of Stem Cells, 2021, 13, 795-824.	1.3	7
1566	Tspan5 promotes epithelialâ€“mesenchymal transition and tumour metastasis of hepatocellular carcinoma by activating Notch signalling. Molecular Oncology, 2021, 15, 3184-3202.	2.1	16
1567	Inhibitors of immune checkpointsâ€”PD-1, PD-L1, CTLA-4â€”new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer and Metastasis Reviews, 2021, 40, 949-982.	2.7	72
1568	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist, 2021, 26, e1786-e1799.	1.9	52
1569	Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as firstâ€line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer, 2021, 127, 3782-3793.	2.0	82
1570	Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. , 2021, 9, e003132.		17
1571	Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer. Nanophotonics, 2021, 10, 3295-3302.	2.9	8
1572	MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models. International Journal of Molecular Sciences, 2021, 22, 9168.	1.8	10
1573	Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma. Molecular Immunology, 2021, 136, 82-97.	1.0	10
1574	Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review. International Immunopharmacology, 2021, 97, 107703.	1.7	1
1575	Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade. Translational Oncology, 2021, 14, 101116.	1.7	8
1576	Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3517-3534.	1.2	5
1577	Deciphering the Dynamic Complexities of the Liver Microenvironment â€” Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI). AAPS Journal, 2021, 23, 99.	2.2	1
1578	Autophagy controls programmed deathâ€ligandÂ1 expression on cancer cells (Review). Biomedical Reports, 2021, 15, 84.	0.9	12
1579	Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma. Cancer Medicine, 2021, 10, 6374-6383.	1.3	19

#	Article	IF	Citations
1580	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers, 2021, 13, 4334.	1.7	20
1581	Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Antiâ€"Programmed Cell Deathâ€1 in HCC. Hepatology, 2021, 74, 2544-2560.	3.6	144
1582	The State of Immunotherapy in Hepatobiliary Cancers. Cells, 2021, 10, 2096.	1.8	18
1583	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 887-897.	1.8	17
1584	Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation. Cancer Letters, 2021, 513, 14-25.	3.2	22
1585	Multifunctional Nanocarriersâ€Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. Advanced NanoBiomed Research, 2021, 1, 2100010.	1.7	5
1586	Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals, 2021, 14, 763.	1.7	30
1587	First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1245-1251.	1.4	75
1588	N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes. Journal of Gastrointestinal Oncology, 2021, 12, 1860-1872.	0.6	6
1589	Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2115-2125.	1.2	55
1590	Treatment of Advanced Hepatocellular Carcinoma. , 0, , .		0
1591	Using cell-free DNA for HCC surveillance and prognosis. JHEP Reports, 2021, 3, 100304.	2.6	27
1592	Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 606-614.	4.2	30
1593	Comprehensive Analyses of the Infiltrating Immune Cell Landscape and Its Clinical Significance in Hepatocellular Carcinoma. International Journal of General Medicine, 2021, Volume 14, 4695-4704.	0.8	7
1594	Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. Clinical Drug Investigation, 2021, 41, 795-808.	1.1	4
1595	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. Digestive and Liver Disease, 2021, 53, 1011-1019.	0.4	7
1596	Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers, 2021, 13, 4387.	1.7	15
1597	Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomarker Research, 2021, 9, 64.	2.8	13

#	Article	IF	Citations
1598	Changes in Wnt and TGF-Î² Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7. Frontiers in Cell and Developmental Biology, 2021, 9, 639779.	1.8	27
1599	Complete Response in Metastatic Hepatocellular Carcinoma with Cardiac and Lung Involvement via Multimodality Treatment. Medicina (Lithuania), 2021, 57, 849.	0.8	1
1600	Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. JHEP Reports, 2021, 3, 100318.	2.6	5
1601	Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. Frontiers in Oncology, 2021, 11, 650394.	1.3	16
1602	Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World Journal of Gastrointestinal Oncology, 2021, 13, 772-798.	0.8	11
1603	Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. Journal of Clinical and Translational Hepatology, 2022, 10, 147-158.	0.7	21
1604	Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hepatology International, 2021, 15, 1278-1287.	1.9	16
1605	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Reports, 2021, 3, 100305.	2.6	83
1606	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, singleâ€arm, phase 2 study. Cancer, 2021, 127, 4585-4593.	2.0	7
1607	Siglecâ€15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44. FEBS Letters, 2021, 595, 2290-2302.	1.3	16
1608	Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights. Journal of Cellular and Molecular Medicine, 2021, 25, 8602-8614.	1.6	15
1609	Recent update on comprehensive therapy for advanced hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 845-855.	0.8	10
1610	RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance. Medical Science Monitor, 2021, 27, e930994.	0.5	4
1611	Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	4
1612	Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 615-628.	4.2	31
1613	Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody. Frontiers in Immunology, 2021, 12, 712351.	2.2	5
1614	Combined DNA Methylation and Transcriptomic Assessments to Determine a Prognostic Model for PD-1-Negative Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 708819.	1.8	4
1615	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 927-939.	1.1	9

#	Article	IF	Citations
1616	Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1749.	3.3	15
1617	Viral Infection and Lung Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 577514.	1.3	1
1618	Immune checkpoint inhibitor-related hepatotoxicity: A review. World Journal of Gastroenterology, 2021, 27, 5376-5391.	1.4	52
1619	Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers, 2021, 13, 4343.	1.7	8
1620	Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 710207.	1.8	14
1621	Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy. Journal of Inflammation Research, 2021, Volume 14, 3879-3890.	1.6	21
1622	Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. British Journal of Cancer, 2021, , .	2.9	12
1623	Application of Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 699060.	1.3	8
1624	Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepatic Oncology, 2022, 9, HEP41.	4.2	2
1625	Immunotherapy in Hepatocellular Carcinoma. Current Treatment Options in Oncology, 2021, 22, 87.	1.3	25
1626	PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. Expert Opinion on Investigational Drugs, 2022, 31, 415-423.	1.9	78
1627	Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. Pharmaceutics, 2021, 13, 1387.	2.0	18
1628	A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1129-1145.	1.8	5
1629	Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. Frontiers in Immunology, 2021, 12, 720748.	2.2	5
1631	Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets. Cancer Research, 2021, 81, 5765-5776.	0.4	9
1632	Medical therapy of HCC. Journal of Hepatology, 2022, 76, 208-210.	1.8	11
1633	Prognosis after liver transplantation in patients treated with anti- PD-1 immunotherapy for advanced hepatocellular carcinoma: case series. Annals of Palliative Medicine, 2021, 10, 9354-9361.	0.5	10
1634	The Impact of Histologic Liver Inflammation on Oncology and the Prognosis of Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 893-902.	0.7	9

#	Article	IF	Citations
1635	Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma â€“ The Changing Tides. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1089-1115.	1.8	28
1636	Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 1132-1143.	0.8	2
1637	An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously. Journal of Hepatology, 2021, , .	1.8	3
1638	Unraveling the Multifaceted Nature of CD8 T Cell Exhaustion Provides the Molecular Basis for Therapeutic T Cell Reconstitution in Chronic Hepatitis B and C. Cells, 2021, 10, 2563.	1.8	12
1639	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers, 2021, 13, 4882.	1.7	15
1640	Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 739975.	1.1	7
1641	Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1195-1207.	1.8	19
1642	Identification and validation of a novel immune-related signature associated with macrophages and CD8 T cell infiltration predicting overall survival for hepatocellular carcinoma. BMC Medical Genomics, 2021, 14, 232.	0.7	2
1643	Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunology, Immunotherapy, 2022, 71, 1063-1074.	2.0	26
1644	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
1645	GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. , 2021, 9, e002787.		47
1646	Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1147-1158.	1.8	8
1647	Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages. BMC Cancer, 2021, 21, 1007.	1.1	6
1648	Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment. Medicine (United States), 2021, 100, e27013.	0.4	4
1649	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002â€“2020). Gastroenterology, 2021, 161, 879-898.	0.6	123
1650	The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 744951.	1.3	9
1651	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. Cancers, 2021, 13, 4719.	1.7	7
1652	Prospects for the Global Elimination of Hepatitis B. Annual Review of Virology, 2021, 8, 437-458.	3.0	26

#	Article	IF	Citations
1653	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844.	1.3	12
1654	Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Seminars in Liver Disease, 2022, 42, 087-103.	1.8	10
1655	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. Cancers, 2021, 13, 4797.	1.7	12
1656	Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2021, 21, 1147-1164.	1.5	17
1657	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. Journal of Hepatology, 2022, 76, 446-457.	1.8	121
1658	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. Journal of Hepatology, 2021, 75, 600-609.	1.8	127
1659	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
1660	Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes. Endocrine Practice, 2021, 27, 886-893.	1.1	9
1661	Paradigm shift in the treatment options of hepatocellular carcinoma. Liver International, 2022, 42, 2067-2079.	1.9	19
1662	Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. Cancer Cell International, 2021, 21, 503.	1.8	14
1663	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Digestive and Liver Disease, 2021, , .	0.4	2
1664	Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opinion on Therapeutic Targets, 2021, 25, 645-658.	1.5	5
1665	Does immune checkpoint inhibitor exhibit limited efficacy against nonâ€viral hepatocellular carcinoma?: A review of clinical trials. Hepatology Research, 2022, 52, 67-74.	1.8	9
1666	Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2021, 14, 1700-1705.	0.4	1
1667	Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review. Journal of International Medical Research, 2021, 49, 030006052110445.	0.4	2
1668	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	0.8	257
1669	Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. Frontiers in Immunology, 2021, 12, 733530.	2.2	23
1670	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. Translational Oncology, 2021, 14, 101153.	1.7	5

#	Article	IF	Citations
1671	Horizons of development of immunotherapy for malignant liver tumors. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 81-89.	0.1	0
1672	Systemic Therapy in Hepatocellular Carcinoma. , 0, , .		0
1673	Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors. Journal of the National Cancer Institute, 2022, 114, 808-818.	3.0	13
1674	Epigenetic mechanisms of liver tumor resistance to immunotherapy. World Journal of Hepatology, 2021, 13, 979-1002.	0.8	5
1675	Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery, 2021, 13, 953-966.	0.8	4
1676	Identification, Verification and Pathway Enrichment Analysis of Prognosis-Related Immune Genes in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 695001.	1.3	3
1677	The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Frontiers in Oncology, 2021, 11, 635731.	1.3	26
1678	Advances in immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Liver Cancer, 2021, 21, 139-145.	0.3	3
1679	Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment. Journal of Liver Cancer, 2021, 21, 124-138.	0.3	2
1680	HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines, 2021, 9, 1345.	1.4	22
1681	Systemic treatment of hepatocellular carcinoma: An EASL position paper. Journal of Hepatology, 2021, 75, 960-974.	1.8	217
1682	Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. Journal of Hepatology, 2021, 75, 879-887.	1.8	12
1683	Optimization of immunotherapy for patients with hepatobiliary cancer. Hepatobiliary Surgery and Nutrition, 2021, 10, 717-719.	0.7	2
1684	PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer. International Immunopharmacology, 2021, 99, 107929.	1.7	16
1685	Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surgery and Nutrition, 2021, 10, 661-671.	0.7	46
1686	The upward trend in the immunotherapy utilization for hepatobiliary cancers. Hepatobiliary Surgery and Nutrition, 2021, 10, 692-695.	0.7	8
1687	The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. International Journal of General Medicine, 2021, Volume 14, 6343-6358.	0.8	4
1688	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. International Immunopharmacology, 2021, 100, 108128.	1.7	13

#	Article	IF	Citations
1689	Controversies in the Management of Hepatitis B. Clinics in Liver Disease, 2021, 25, 785-803.	1.0	4
1690	Preferentially released miR-122 from cyclodextrin-based star copolymer nanoparticle enhances hepatoma chemotherapy by apoptosis induction and cytotoxics efflux inhibition. Bioactive Materials, 2021, 6, 3744-3755.	8.6	18
1691	Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis. International Immunopharmacology, 2021, 100, 108135.	1.7	3
1692	Combinatorial therapy in tumor microenvironment: Where do we stand?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188585.	3.3	48
1693	Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study. Journal of Ethnopharmacology, 2021, 281, 114539.	2.0	18
1694	Research Progress on Anti-Tumor Immune Mechanism of CD8+T Cells in HBV-Related Hepatocellular Carcinoma. Advances in Clinical Medicine, 2021, 11, 2347-2354.	0.0	0
1695	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. Chinese Clinical Oncology, 2021, 10, 11-11.	0.4	8
1696	The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma. International Journal of Biological Sciences, 2021, 17, 3059-3079.	2.6	24
1697	Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Frontiers in Molecular Biosciences, 2020, 7, 609322.	1.6	48
1698	The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Scientific Reports, 2021, 11, 2415.	1.6	26
1699	Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. Journal of Comparative Effectiveness Research, 2021, 10, 343-352.	0.6	13
1700	A Phase II Trial of Y90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular Carcinomaâ€“ CA 209-678. SSRN Electronic Journal, 0, , .	0.4	0
1701	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. Expert Opinion on Emerging Drugs, 2021, 26, 39-52.	1.0	9
1702	Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nature Communications, 2021, 12, 440.	5.8	175
1703	Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma. , 2021, , 333-364.		0
1704	Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics, 2021, 11, 3489-3501.	4.6	35
1705	PD-L2 based immune signature confers poor prognosis in HNSCC. OncoImmunology, 2021, 10, 1947569.	2.1	21
1706	Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. Liver Cancer, 2021, 10, 380-393.	4.2	51

#	Article	IF	Citations
1707	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers, 2021, 13, 271.	1.7	39
1708	Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer, 2021, 10, 137-150.	4.2	21
1709	BRD7 inhibits tumor progression by positively regulating the p53 pathway in hepatocellular carcinoma. Journal of Cancer, 2021, 12, 1507-1519.	1.2	8
1710	Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma. Computational and Structural Biotechnology Journal, 2021, 19, 2775-2789.	1.9	22
1711	Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers, 2021, 13, 192.	1.7	27
1712	Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers. Hepatoma Research, 2021, 2021, .	0.6	14
1713	Adjuvant Stereotactic Body Radiotherapy After Marginal Resection for Hepatocellular Carcinoma With Micro-Vascular Invasion: A Randomized Controlled Trial. SSRN Electronic Journal, 0, , .	0.4	0
1714	Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma. , 2021, , 277-283.		0
1715	Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis. Cancers, 2021, 13, 213.	1.7	6
1716	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals, 2021, 14, 43.	1.7	8
1717	Checkpoint Inhibitors and Hepatotoxicity. Biomedicines, 2021, 9, 101.	1.4	17
1718	Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean Journal of Radiology, 2021, 22, 1822-1833.	1.5	9
1719	Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. SSRN Electronic Journal, 0, , .	0.4	1
1720	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	18.1	2,757
1721	Immune Checkpoint Inhibitors in the Treatment of HCC. Frontiers in Oncology, 2020, 10, 601240.	1.3	77
1722	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer, 2021, 10, 451-460.	4.2	5
1723	Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Medicine, 2020, 9, 2106-2112.	1.3	28
1724	A Realâ€World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGETâ€HCC. Hepatology Communications, 2021, 5, 538-547.	2.0	6

#	Article	IF	Citations
1725	Molecular-Targeted Therapies in Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 225-238.	0.4	7
1726	Immune Therapies. Molecular and Translational Medicine, 2019, , 239-253.	0.4	1
1727	Immunotherapy in Gastrointestinal Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 93-106.	0.8	7
1728	Hepatitis B Virus Infection: Overview. Advances in Experimental Medicine and Biology, 2020, 1179, 1-16.	0.8	41
1729	Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117.	0.8	22
1730	Spatiotemporal Changes in Checkpoint Molecule Expression. Advances in Experimental Medicine and Biology, 2020, 1248, 167-200.	0.8	5
1731	Hepatitis B. Gastroenterology Clinics of North America, 2020, 49, 215-238.	1.0	36
1732	Neoadjuvant Use of Oncolytic Herpes Virus G47Î" Enhances the Antitumor Efficacy of Radiofrequency Ablation. Molecular Therapy - Oncolytics, 2020, 18, 535-545.	2.0	23
1733	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. British Journal of Cancer, 2018, 119, 80-88.	2.9	74
1734	Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. Bioscience Reports, 2020, 40, .	1.1	33
1735	Hepatic Stellate Cellâ€"Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis. Seminars in Liver Disease, 2020, 40, 307-320.	1.8	76
1736	The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. Acta OncolÃ³gica, 2020, 59, 940-943.	0.8	4
1737	TAM kinase inhibition and immune checkpoint blockadeâ€" a winning combination in cancer treatment?. Expert Opinion on Therapeutic Targets, 2021, 25, 141-151.	1.5	17
1738	Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma. OncoImmunology, 2018, 7, e1502129.	2.1	7
1739	Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. JNCI Cancer Spectrum, 2021, 5, pkaa100.	1.4	12
1740	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 74-81.	0.6	36
1741	PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. Annals of Surgery, 2019, 269, 471-478.	2.1	135
1742	Transplant Oncology in Primary and Metastatic Liver Tumors. Annals of Surgery, 2021, 273, 483-493.	2.1	33

#	Article	IF	Citations
1745	A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 19-27.	0.7	2
1746	Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. Liver International, 2020, 40, 2263-2271.	1.9	26
1747	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
1748	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 2020, 9, 682-720.	4.2	427
1749	Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer, 2020, 9, 640-662.	4.2	78
1750	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight, 2019, 4, .	2.3	345
1751	Augmentation of IFN-Î³+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight, 2019, 4, .	2.3	52
1752	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. Journal of Clinical Investigation, 2019, 129, 3324-3338.	3.9	209
1753	Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. Journal of Clinical Investigation, 2020, 130, 4679-4693.	3.9	42
1754	Hypoxia-inducible factors and innate immunity in liver cancer. Journal of Clinical Investigation, 2020, 130, 5052-5062.	3.9	85
1755	Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).. Journal of Clinical Oncology, 2020, 38, 549-549.	0.8	4
1756	An Individualized Immune Prognostic Index is a Superior Predictor of Survival of Hepatocellular Carcinoma. Medical Science Monitor, 2020, 26, e921786.	0.5	8
1757	Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Research, 2020, 9, 620.	0.8	41
1758	Immunotherapyâ€Induced Colitis: An Emerging Problem for the Hospitalist. Journal of Hospital Medicine, 2018, 13, 413-418.	0.7	25
1759	Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?. World Journal of Clinical Cases, 2019, 7, 1253-1261.	0.3	13
1760	EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma. PLoS ONE, 2020, 15, e0242191.	1.1	20
1761	Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2019, 7, 1-8.	0.7	41
1762	Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. Journal of Clinical and Translational Hepatology, 2020, 8, 168-176.	0.7	49

#	Article	IF	Citations
1763	Urgent need to define Pretreatment predictors of immune check point inhibitors related endocrinopathies: A case report and review of literature. Journal of Translational Internal Medicine, 2017, 5, 235-239.	1.0	1
1764	Tyrosine Kinase Inhibitors in the Treatment of Hepatocellular Carcinoma. , 0, , 127-139.		4
1765	BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arquivos De Gastroenterologia, 2020, 57, 1-20.	0.3	22
1766	Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma. Journal of Liver Cancer, 2019, 19, 1-11.	0.3	4
1767	Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. Journal of Liver Cancer, 2019, 19, 108-116.	0.3	5
1768	Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma. Journal of Liver Cancer, 2020, 20, 128-134.	0.3	6
1769	LncRNA CDKN2BAS predicts poor prognosis in patients with hepatocellular carcinoma and promotes metastasis via the miR-153-5p/ARHGAP18 signaling axis. Aging, 2018, 10, 3371-3381.	1.4	84
1770	The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis. Aging, 2020, 12, 204-223.	1.4	24
1771	New landscapes and horizons in hepatocellular carcinoma therapy. Aging, 2020, 12, 3053-3094.	1.4	37
1772	Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications. Aging, 2020, 12, 4970-4995.	1.4	11
1773	Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging, 2020, 12, 11466-11484.	1.4	27
1774	Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes. Aging, 2020, 12, 12187-12205.	1.4	13
1775	Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma. Aging, 2020, 12, 19641-19659.	1.4	4
1776	Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients. Aging, 2020, 12, 22906-22926.	1.4	15
1777	Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma. Aging, 2020, 12, 25172-25188.	1.4	5
1778	Molecular characteristics of hepatocellular carcinomas from different age groups. Oncotarget, 2017, 8, 101591-101598.	0.8	4
1779	Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma. Oncotarget, 2019, 10, 5194-5206.	0.8	16
1780	Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape. Hepatoma Research, 2019, 2019, .	0.6	2

#	Article	IF	Citations
1781	The multifaceted oncogene SND1 in cancer: focus on hepatocellular carcinoma. Hepatoma Research, 2018, 4, 32.	0.6	16
1782	Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Research, 2020, 2020, .	0.6	6
1783	Immune checkpoint inhibitor in liver cancerâ€"unique regional differences. Annals of Translational Medicine, 2020, 8, 1336-1336.	0.7	4
1784	Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure. Annals of Translational Medicine, 2020, 8, 1700-1700.	0.7	6
1785	Camrelizumabâ€"targeting a novel PD-1 epitope to treat hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1614-1614.	0.7	2
1786	Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 385-401.	1.8	8
1787	PHARMACOLOGICAL THERAPY OF HEPATOCELLULAR CANCER PRACTICAL ISSUES AND SOLUTIONS. Meditsinskiy Sovet, 2017, , 11-23.	0.1	2
1788	Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage. Internal Medicine, 2020, 59, 2245-2248.	0.3	6
1789	Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma. Current Medicinal Chemistry, 2020, 27, 4789-4805.	1.2	6
1790	Targeting PD-L1 Protein: Translation, Modification and Transport. Current Protein and Peptide Science, 2018, 20, 82-91.	0.7	20
1791	Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Current Drug Targets, 2019, 20, 1180-1202.	1.0	13
1792	Immunoterapia z uÅ¼yciem przeciwciaÅ, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. Acta Haematologica Polonica, 2018, 49, 207-227.	0.1	5
1793	A Case of Acute Exacerbation of Hepatitis B by Pembrolizumab for a Lung Adenocarcinoma Patient with Hepatitis B Surface Antigen. Japanese Journal of Lung Cancer, 2020, 60, 115-119.	0.0	2
1794	Successful endoscopic treatment of hepatoduodenal fistula formed during sorafenib treatment for hepatocellular carcinoma with duodenal invasion. Acta Hepatologica Japonica, 2019, 60, 91-98.	0.0	3
1795	2018 Korean Liver Cancer Associationâ€"National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2019, 20, 1042.	1.5	189
1796	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clinical and Molecular Hepatology, 2020, 26, 155-162.	4.5	44
1797	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. Clinical and Molecular Hepatology, 2020, 26, 328-339.	4.5	32
1798	Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma. Clinical and Molecular Hepatology, 2020, 26, 305-308.	4.5	5

#	Article	IF	Citations
1799	Targeting PIN1 as a Therapeutic Approach for Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2019, 7, 369.	1.8	14
1800	Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. Cancers, 2020, 12, 1274.	1.7	27
1801	Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers, 2020, 12, 1290.	1.7	20
1802	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers, 2020, 12, 1303.	1.7	6
1803	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers, 2021, 13, 90.	1.7	21
1804	Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 232.	1.8	6
1805	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals, 2021, 14, 3.	1.7	16
1806	Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals, 2021, 14, 28.	1.7	17
1807	Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond. Current Oncology, 2020, 27, 173-180.	0.9	5
1808	Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease. Current Oncology, 2020, 27, 165-172.	0.9	9
1809	Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World Journal of Gastroenterology, 2018, 24, 1839-1858.	1.4	30
1810	Biomarkers for hepatocellular carcinoma: Whatâ€™s new on the horizon?. World Journal of Gastroenterology, 2018, 24, 3974-3979.	1.4	34
1811	Liver transplantation for hepatocellular carcinoma: Where do we stand?. World Journal of Gastroenterology, 2019, 25, 2591-2602.	1.4	71
1812	Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World Journal of Gastroenterology, 2019, 25, 3136-3150.	1.4	51
1813	Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients?. World Journal of Gastroenterology, 2019, 25, 3563-3571.	1.4	10
1814	Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World Journal of Gastroenterology, 2019, 25, 3607-3618.	1.4	14
1815	Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. World Journal of Gastroenterology, 2019, 25, 3649-3663.	1.4	36
1816	Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 3704-3721.	1.4	107

#	Article	IF	Citations
1817	Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 3870-3896.	1.4	70
1818	Gastrointestinal cancer stem cells as targets for innovative immunotherapy. World Journal of Gastroenterology, 2020, 26, 1580-1593.	1.4	9
1819	Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World Journal of Gastroenterology, 2020, 26, 1888-1900.	1.4	20
1820	Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. World Journal of Gastroenterology, 2020, 26, 2040-2048.	1.4	13
1821	Gut microbiota mediated molecular events and therapy in liver diseases. World Journal of Gastroenterology, 2020, 26, 7603-7618.	1.4	20
1822	Targeting cancer stem cells in cholangiocarcinoma (Review). International Journal of Oncology, 2020, 57, 397-408.	1.4	15
1823	Implications of driver genes associated with a high tumor mutation burden identified using nextâ€generation sequencing on immunotherapy in hepatocellular carcinoma. Oncology Letters, 2020, 19, 2739-2748.	0.8	16
1824	Fat mass and obesity-associated protein promotes the tumorigenesis and development of liver cancer. Oncology Letters, 2020, 20, 1409-1417.	0.8	13
1825	Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review). Oncology Letters, 2020, 20, 45.	0.8	12
1826	Innate immune cells and their interaction with TÂcells in hepatocellular carcinoma (Review). Oncology Letters, 2020, 21, 57.	0.8	11
1827	Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncology Reviews, 2020, 14, 515.	0.8	5
1828	Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI). Journal of Cancer Research and Therapeutics, 2020, 16, 327-334.	0.3	12
1829	Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders. Journal of Immunotherapy and Precision Oncology, 2019, 2, 59-64.	0.6	8
1830	Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?. Immune Network, 2020, 20, e11.	1.6	42
1831	2018 Korean Liver Cancer Association and National Cancer Center for Clinical Practice Guidelines of Hepatocellular Carcinoma: What's Different from 2014?. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2019, 74, 101.	0.2	2
1832	Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: A case report. World Journal of Gastrointestinal Oncology, 2020, 12, 1209-1215.	0.8	19
1833	Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2020, 12, 663-676.	0.8	13
1834	Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World Journal of Hepatology, 2018, 10, 571-584.	0.8	22

#	Article	IF	Citations
1835	Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. World Journal of Hepatology, 2020, 12, 1211-1227.	0.8	12
1836	Immunotherapy for Chronic Hepatitis B Virus Infection. Gut and Liver, 2018, 12, 497-507.	1.4	76
1837	2018 Korean Liver Cancer Associationâ€"National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut and Liver, 2019, 13, 227-299.	1.4	255
1838	Novel molecular targets in hepatocellular carcinoma. World Journal of Clinical Oncology, 2020, 11, 589-605.	0.9	15
1839	Lenvatinib as first-line therapy for recurrentÂhepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?. World Journal of Transplantation, 2020, 10, 297-306.	0.6	8
1840	Systemic treatment of advanced or recurrent biliary tract cancer. BioScience Trends, 2020, 14, 328-341.	1.1	29
1841	Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 302-310.	2.3	214
1842	Role of Immunotherapy in Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 479-489.	2.3	295
1843	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 541-565.	2.3	477
1844	Second-line treatment options in hepatocellular carcinoma. Drugs in Context, 2019, 8, 1-13.	1.0	32
1845	Autophagy-related genes prognosis signature as potential predictive markers for immunotherapy in hepatocellular carcinoma. PeerJ, 2020, 8, e8383.	0.9	28
1846	Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases. Cureus, 2020, 12, e11150.	0.2	16
1847	Abscopal Resolution of a Hepatic Metastasis in a Patient with Metastatic Cholangiocarcinoma Following Radical Stereotactic Body Radiotherapy to a Synchronous Early Stage Non-small Cell Lung Cancer. Cureus, 2019, 11, e4082.	0.2	6
1848	GOLM1 Drives Colorectal Cancer Metastasis by Regulating Myeloid-derived Suppressor Cells. Journal of Cancer, 2021, 12, 7158-7166.	1.2	8
1849	The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. Advances in Clinical Medicine, 2021, 11, 4628-4634.	0.0	0
1850	Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. National Science Review, 2022, 9, nwab192.	4.6	15
1851	Infections virales chroniques (hÃ©patites, VIH) et impact sur le choix thÃ©rapeutique. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S272-2S279.	0.0	0
1852	Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Frontiers in Immunology, 2021, 12, 765101.	2.2	63

#	Article	IF	Citations
1853	Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes. Frontiers in Cell and Developmental Biology, 2021, 9, 700553.	1.8	6
1854	Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy, 2021, 13, 1395-1405.	1.0	35
1855	â€œSweet deathâ€: Fructose as a metabolic toxin that targets the gut-liver axis. Cell Metabolism, 2021, 33, 2316-2328.	7.2	68
1856	ZnS@BSA Nanoclusters Potentiate Efficacy of Cancer Immunotherapy. Advanced Materials, 2021, 33, e2104037.	11.1	89
1857	Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis. Frontiers in Oncology, 2021, 11, 694409.	1.3	10
1858	Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World Journal of Gastrointestinal Oncology, 2021, 13, 1397-1411.	0.8	9
1859	Role of N6-Methyladenosine (m6A) Methylation Regulators in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 755206.	1.3	16
1860	MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells. Gastroenterology, 2022, 162, 575-589.	0.6	38
1861	Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers, 2021, 13, 5295.	1.7	9
1862	Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer. Genome Medicine, 2021, 13, 166.	3.6	19
1863	High Expression Levels of SLC38A1 Are Correlated with Poor Prognosis and Defective Immune Infiltration in Hepatocellular Carcinoma. Journal of Oncology, 2021, 2021, 1-15.	0.6	13
1864	Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Frontiers in Oncology, 2021, 11, 737767.	1.3	15
1865	Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 333-350.	4.5	22
1866	The Immunology of Hepatocellular Carcinoma. Vaccines, 2021, 9, 1184.	2.1	41
1867	Radioembolization in the Setting of Systemic Therapies. Seminars in Interventional Radiology, 2021, 38, 472-478.	0.3	1
1868	COVID and Lung Cancer. Current Oncology Reports, 2021, 23, 134.	1.8	21
1869	Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. Frontiers in Oncology, 2021, 11, 756672.	1.3	12
1870	Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review. Digestive Diseases, 2022, 40, 565-580.	0.8	4

#	Article	IF	Citations
1871	MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy. Academic Radiology, 2022, 29, 819-829.	1.3	8
1872	UHRF1 Could Be a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma. International Journal of General Medicine, 2021, Volume 14, 6769-6776.	0.8	1
1873	Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opinion on Drug Safety, 2021, , 1-10.	1.0	1
1874	The ITA.LI.CA Consortium: how multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence.. Annals of Hepatology, 2021, , 100564.	0.6	1
1875	Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib. OncoTargets and Therapy, 2021, Volume 14, 5019-5026.	1.0	4
1876	The management of post-transplantation recurrence of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 1-16.	4.5	27
1877	Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 1025-1035.	3.7	56
1878	Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharmaceutica Sinica B, 2021, 11, 3727-3739.	5.7	34
1879	Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 9-21.	4.2	29
1880	Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1233-1240.	1.8	71
1881	Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. BMC Cancer, 2021, 21, 1126.	1.1	29
1882	Immunotherapy after liver transplantation: Where are we now?. World Journal of Gastrointestinal Surgery, 2021, 13, 1267-1278.	0.8	20
1883	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International, 0, , .	0.2	3
1884	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. Cancers, 2021, 13, 5134.	1.7	8
1885	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Frontiers in Oncology, 2021, 11, 737497.	1.3	22
1886	A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. Annual Review of Medicine, 2022, 73, 231-250.	5.0	11
1887	Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Frontiers in Immunology, 2021, 12, 754961.	2.2	16
1888	Immunotherapy after liver transplantation: Where are we now?. World Journal of Gastrointestinal Surgery, 2021, 13, 1266-1277.	0.8	0

#	Article	IF	Citations
1889	Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 387-394.	1.4	10
1890	Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Scientific Reports, 2021, 11, 19711.	1.6	9
1891	Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments. Hepatology, 2022, 75, 1139-1153.	3.6	34
1892	Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines, 2021, 9, 1524.	1.4	10
1893	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging, 2021, 13, 23416-23434.	1.4	17
1894	Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. JGH Open, 2021, 5, 1266-1274.	0.7	9
1895	Lobar Radioembolization for Intermediate and Advanced Hepatocellular Carcinoma: Retrospective and Prospective Data. Seminars in Interventional Radiology, 2021, 38, 412-418.	0.3	1
1896	Hepatocellular Carcinoma Immunotherapy. Annual Review of Medicine, 2022, 73, 267-278.	5.0	86
1897	Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma. PeerJ, 2021, 9, e12315.	0.9	16
1898	In vitro 3D liver tumor microenvironment models for immune cell therapy optimization. APL Bioengineering, 2021, 5, 041502.	3.3	2
1899	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. Cancer Treatment Reviews, 2021, 101, 102300.	3.4	8
1900	The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. International Immunopharmacology, 2021, 101, 108220.	1.7	6
1901	The progress of immune checkpoint therapy in primary liver cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188638.	3.3	29
1902	Clinical Profile and Results in Cancers Treated with Nivolumab: A Single Centre Study. Open Journal of Immunology, 2018, 08, 107-111.	0.5	0
1903	Medical Therapy Options for Advanced Disease in Hepatocellular Carcinoma. , 2018, , 91-97.		0
1904	Updates in the Systemic Treatment of Hepatocellular Carcinoma. Oncology & Hematology Review, 2018, 14, 76.	0.2	0
1906	Roles of theÂImmune System in theÂDevelopment and Progression of Hepatocellular Carcinoma. , 2019, , 23-37.		0
1907	Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers. , 2019, , 613-631.		0

#	Article	IF	Citations
1908	Stereotactic Body Radiation Therapy for Gastrointestinal Cancers. , 2019, , 277-288.		0
1909	Liver Cancer. , 2019, , 405-420.		0
1910	Advances in Research on Immunological Checkpoint Inhibitors in Immunotherapy of Liver Cancer. International Journal of Clinical Medicine, 2019, 10, 62-69.	0.1	0
1911	Leadership in immuno-oncology network 2 (LION:2) immunotherapy oncology - A present status. International Journal of Molecular and Immuno Oncology, 0, 4, 3-5.	0.0	0
1912	Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-analysis, 2019, 7, 80-95.	0.1	2
1913	Analysis of Existing Guidelines and Randomized, Controlled, Clinical Trials for Development of [Guideline of Clinical Trial on Herbal Medicinal Product for Liver Cancer]. The Journal of Internal Korean Medicine, 2019, 40, 89-116.	0.0	1
1914	A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy. Journal of Liver Cancer, 2019, 19, 74-78.	0.3	0
1915	Revolution in Cancer Immunotherapy and its Perspective. Yamaguchi Medical Journal, 2019, 68, 5-12.	0.1	0
1916	The future is now: beyond first line systemic therapy in hepatocellular carcinoma. Translational Cancer Research, 2019, 8, S261-S274.	0.4	5
1917	Progress in basic and clinical research of targeted drugs for primary hepatocellular carcinoma. World Chinese Journal of Digestology, 2019, 27, 450-458.	0.0	2
1918	Hot topics in hepatocellular carcinoma. Translational Cancer Research, 2019, 8, S216-S218.	0.4	0
1919	The Management of Hepatocellular Carcinoma. , 2020, , 237-271.		1
1920	An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era. Journal of Liver Cancer, 2019, 19, 117-127.	0.3	0
1922	Second-line treatment of hepatocellular carcinoma: from theory to practical issues. Meditsinskiy Sovet, 2019, , 30-36.	0.1	2
1924	Hepatobiliary Tumors: Immunopathology and Immunotherapy. , 2020, , 241-259.		0
1925	Systemic Therapy of Advanced Liver Cancer. , 2020, , 661-666.		0
1926	Protocol For An Adjuvant Alpha-Fetoprotein-Derived Peptide After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: Safety Study. JMIR Research Protocols, 2020, 9, e17082.	0.5	0
1927	Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms. Journal of Immunotherapy and Precision Oncology, 2020, 3, 3-15.	0.6	3

#	Article	IF	Citations
1929	Application of curved ablation in liver cancer with special morphology or location: Report of two cases. World Journal of Clinical Cases, 2020, 8, 1713-1720.	0.3	0
1930	The complexity of immune cell landscape in hepatocellular carcinomas with different risksâ€"reply letter. Annals of Translational Medicine, 2020, 8, 729-729.	0.7	0
1931	Systemic therapy of hepatocellular carcinoma: reality and prospects. Annals of HPB Surgery, 2020, 25, 27-38.	0.1	2
1933	Immunotherapy in hepatocellular carcinoma: Combination strategies. World Journal of Meta-analysis, 2020, 8, 190-209.	0.1	1
1934	Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States. Hepatobiliary Surgery and Nutrition, 2020, 9, 501-504.	0.7	0
1935	Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review. Current Cancer Drug Targets, 2020, 20, 720-727.	0.8	12
1937	Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. European Radiology, 2022, 32, 2437-2447.	2.3	9
1938	Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers, 2021, 13, 5448.	1.7	5
1939	CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 759565.	2.2	29
1940	Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics, 2021, 13, 1811.	2.0	8
1941	Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Clinical Journal of Gastroenterology, 2021, 14, 1718-1724.	0.4	16
1942	Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers, 2021, 13, 5475.	1.7	10
1943	Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma. Cancers, 2021, 13, 5495.	1.7	15
1944	Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	1.4	6
1945	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clinical Immunology, 2021, 232, 108873.	1.4	19
1946	Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice. Molecular Cancer Therapeutics, 2022, 21, 149-158.	1.9	5
1947	Integrated Analysis of FAM57A Expression and Its Potential Roles in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 719973.	1.3	2
1948	Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.. Journal of Hepatology, 2021, , .	1.8	3

#	Article	IF	Citations
1949	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. International Immunopharmacology, 2021, 101, 108322.	1.7	18
1950	Introduction on Cancer Immunology and Immunotherapy. , 2020, , 1-9.		0
1951	Prognostic Factors for Patients With a Large Number of Hepatocellular Carcinoma Nodules. Journal of Clinical Medicine Research, 2020, 12, 26-35.	0.6	1
1953	Tumors of the Liver. , 2020, , 1-14.		0
1954	Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Seminars in Interventional Radiology, 2020, 37, 456-465.	0.3	5
1955	Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?. Annals of Translational Medicine, 2020, 8, 1701-1701.	0.7	2
1956	Association of interleukin-6 gene polymorphisms with the risk of hepatocellular carcinoma. Medicine (United States), 2020, 99, e23659.	0.4	3
1957	Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. Case Reports in Oncological Medicine, 2020, 2020, 1-6.	0.2	4
1958	Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review. International Journal of Medical Students, 2020, 8, 273-280.	0.2	1
1959	Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences, 2021, , 129-159.	0.2	0
1960	Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?. Annals of Translational Medicine, 2020, 8, 1695-1695.	0.7	0
1961	Overexpression of NNT-AS1 Activates TGF-Î² Signaling to Decrease Tumor CD4 Lymphocyte Infiltration in Hepatocellular Carcinoma. BioMed Research International, 2020, 2020, 1-11.	0.9	18
1962	The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future. Annals of Translational Medicine, 2020, 8, 1617-1617.	0.7	2
1963	Current Immunotherapy in Gastrointestinal Malignancies a Review. Journal of Investigative Medicine, 2021, 69, 689-696.	0.7	13
1964	Cancer Treatment Modalities Systemic and Locoregional Approaches: Challenges and Opportunities of Multidisciplinary Approaches. , 2021, , 17-37.		1
1965	Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Current Drug Metabolism, 2020, 21, 866-884.	0.7	8
1966	Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. , 2020, 38, 89-91.		1
1967	Liver Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 227-241.	0.8	8

#	Article	IF	Citations
1969	Efficacy Considerations in Phase I Trials. , 2020, , 159-183.		0
1970	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi Journal of Gastroenterology, 2020, 26, 1.	0.5	13
1971	Therapeutic Vaccines for Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 113-158.	0.2	1
1972	Crosstalk of Molecular Signaling in Hepatocellular Carcinoma. , 2020, , 85-94.		1
1974	Immunotherapy in Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 15-29.	0.2	0
1975	Immunotherapy and Radiosurgery. , 2020, , 423-436.		0
1976	Hepatocellular Carcinoma: Western Experience. , 2020, , 81-118.		0
1977	A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. Euroasian Journal of Hepato-gastroenterology, 2021, 10, 56-63.	0.1	5
1978	Immunotherapeutics of Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 51-60.	0.2	0
1979	Successful stories of drug repurposing for cancer therapy in hepatocellular carcinoma. , 2020, , 213-229.		4
1980	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
1981	Sorafenib in the Treatment of Hepatocellular Carcinoma. Advances in Clinical Medicine, 2020, 10, 2241-2245.	0.0	0
1983	Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series. Hepatoma Research, 2020, 2020, .	0.6	1
1984	Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure. Journal of Liver Cancer, 2020, 20, 72-77.	0.3	1
1985	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A New Era in Treatment of Advanced Disease. Sohag Medical Journal (SMJ), 2020, 24, 20-26.	0.1	0
1986	Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines, 2021, 9, 1639.	1.4	84
1987	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. Journal of Histochemistry and Cytochemistry, 2022, 70, 53-81.	1.3	6
1988	Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma. Cancers, 2021, 13, 5586.	1.7	13

#	Article	IF	Citations
1989	Clinical implications of WNT/Î²-catenin signaling for hepatocellular carcinoma. Global Health & Medicine, 2020, 2, 269-272.	0.6	4
1990	Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. Digestive Disease Interventions, 2020, 04, 373-381.	0.3	0
1991	Combination Therapies with Ablation: Immunoablation. Digestive Disease Interventions, 2020, 04, 358-364.	0.3	0
1993	Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Current Gene Therapy, 2020, 20, 84-99.	0.9	11
1994	Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. American Journal of Cancer Research, 2017, 7, 2503-2514.	1.4	13
1995	Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. Journal of Nature and Science, 2018, 4, .	1.1	5
1996	Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor. American Journal of Cancer Research, 2018, 8, 1689-1696.	1.4	11
1997	Drugs in Development for Hepatocellular Carcinoma. Gastroenterology and Hepatology, 2018, 14, 542-544.	0.2	1
1998	DSE regulates the malignant characters of hepatocellular carcinoma cells by modulating CCL5/CCR1 axis. American Journal of Cancer Research, 2019, 9, 347-362.	1.4	9
1999	The Use of Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma. Gastroenterology and Hepatology, 2019, 15, 48-50.	0.2	1
2000	Current and Future Systemic Therapies for Hepatocellular Carcinoma. Gastroenterology and Hepatology, 2019, 15, 266-272.	0.2	9
2001	Factors impacting technical success rate of image-guided intra-arterial therapy in rat orthotopic liver tumor model. American Journal of Translational Research (discontinued), 2019, 11, 3761-3770.	0.0	7
2002	Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. American Journal of Cancer Research, 2019, 9, 1536-1545.	1.4	38
2003	Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma. American Journal of Cancer Research, 2019, 9, 2442-2455.	1.4	12
2004	Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors. American Journal of Cancer Research, 2020, 10, 1085-1102.	1.4	2
2005	Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 1522-1533.	1.4	4
2006	Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 1658-1667.	1.4	8
2007	Recent progress in treatment of hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 2993-3036.	1.4	55

#	Article	IF	Citations
2008	GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 3705-3720.	1.4	4
2009	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532.	0.7	0
2010	Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience. American Journal of Cancer Research, 2020, 10, 4547-4560.	1.4	3
2011	T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. American Journal of Cancer Research, 2020, 10, 4585-4606.	1.4	8
2013	Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 2319-2330.	1.4	3
2014	Cyclooxygenase-2 expressed hepatocellular carcinoma induces cytotoxic T lymphocytes exhaustion through M2 macrophage polarization. American Journal of Translational Research (discontinued), 2021, 13, 4360-4375.	0.0	5
2015	Irreversible electroporation enhances immunotherapeutic effect in the off-target tumor in a murine model of orthotopic HCC. American Journal of Cancer Research, 2021, 11, 3304-3319.	1.4	0
2016	Targeting the eicosanoid pathway in hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 2456-2476.	1.4	1
2017	Efficacy and toxicity of SBRT in advanced hepatocellular carcinoma with portal vein tumor thrombosis - a retrospective study. Reports of Practical Oncology and Radiotherapy, 2021, 26, 573-581.	0.3	1
2018	Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 1745-1745.	0.7	2
2019	Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation. Neoplasia, 2022, 24, 34-49.	2.3	0
2020	HepatozellulÃres Karzinom. , 2022, , 283-290.		0
2021	New Systemic Treatment Options for Hepatobiliary Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 633-635.	2.3	0
2022	Norcholic Acid Promotes Tumor Progression and Immune Escape by Regulating Farnesoid X Receptor in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 711448.	1.3	18
2023	The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 1185-1198.	1.8	35
2024	A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open, 2021, 7, .	0.4	3
2025	Long non-coding RNA HOMER3-AS1 drives hepatocellular carcinoma progression via modulating the behaviors of both tumor cells and macrophages. Cell Death and Disease, 2021, 12, 1103.	2.7	14
2026	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene. Journal of Personalized Medicine, 2021, 11, 1199.	1.1	4

#	Article	IF	Citations
2027	Glycosylated 4â€methylumbelliferone as a targeted therapy for hepatocellular carcinoma. Liver International, 2022, 42, 444-457.	1.9	3
2028	Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 783236.	2.2	66
2029	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 5665.	1.7	5
2030	Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2022, 28, 479-488.	3.2	16
2031	Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. Stem Cell Investigation, 2021, 8, 22-22.	1.3	1
2032	Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients. World Journal of Gastroenterology, 2021, 27, 7340-7349.	1.4	32
2033	Aldehyde dehydrogenase expression may be a prognostic biomarker and associated with liver cirrhosis in patients resected for hepatocellular carcinoma. Surgical Oncology, 2022, 40, 101677.	0.8	1
2034	Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. Immunotherapy, 2021, , .	1.0	0
2035	GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. Signal Transduction and Targeted Therapy, 2021, 6, 397.	7.1	58
2036	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research, 2022, 175, 105997.	3.1	43
2037	Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. , 2021, 9, e003195.		3
2038	Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. International Journal of Molecular Sciences, 2021, 22, 12947.	1.8	4
2039	Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. Nature Communications, 2021, 12, 6742.	5.8	45
2040	Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma. International Immunopharmacology, 2021, 101, 108340.	1.7	23
2041	Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study. Frontiers in Oncology, 2021, 11, 751159.	1.3	16
2042	Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 785185.	1.1	13
2043	Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2022, 19, 151-172.	12.5	643
2044	Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology, 2022, 75, 1257-1274.	3.6	26

#	Article	IF	Citations
2045	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers, 2021, 13, 5797.	1.7	13
2046	Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chinese Medical Journal, 2021, 134, 2911-2921.	0.9	21
2047	Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. International Immunopharmacology, 2021, 101, 108337.	1.7	3
2048	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open, 2021, 6, 100330.	2.0	25
2049	Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 361-369.	1.9	68
2050	The microbiome, gastrointestinal cancer, and immunotherapy. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 263-272.	1.4	9
2051	Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy. Translational Cancer Research, 2021, 11, 0-0.	0.4	5
2053	Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2021, 20, 153303382110638.	0.8	10
2054	A Status Quo Review of Immunotherapy for Advanced Hepatocellular Carcinoma. Advances in Clinical Medicine, 2021, 11, 5740-5746.	0.0	1
2055	Progress in the Treatment of Hepatocellular Carcinoma Complicated with Portal Vein Tumor Thrombus. Advances in Clinical Medicine, 2021, 11, 6018-6023.	0.0	0
2056	Immunotherapy in Gastrointestinal Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 259-272.	0.8	3
2057	HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma. American Journal of Clinical Pathology, 2022, 158, 62-69.	0.4	4
2058	A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review. Journal of Gastrointestinal Oncology, 2022, 13, 426-437.	0.6	7
2059	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. SSRN Electronic Journal, 0, , .	0.4	0
2060	Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1243-1255.	0.4	67
2061	Biomarkers for predicting the efficacy of immune checkpoint inhibitors. Journal of Cancer, 2022, 13, 481-495.	1.2	12
2062	Immunotherapy in older patients with hepatocellular carcinoma. European Journal of Cancer, 2022, 162, 76-98.	1.3	8
2063	Organoids as research models for hepatocellular carcinoma. Experimental Cell Research, 2022, 411, 112987.	1.2	7

#	Article	IF	Citations
2064	Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model. Journal of Surgical Research, 2022, 272, 37-50.	0.8	4
2065	Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients. European Journal of Gastroenterology and Hepatology, 2022, 34, 213-219.	0.8	10
2066	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532-1532.	0.7	2
2067	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
2068	An Observational Study of Exploratory Using Anti-PD-1 Antibody in the Treatment of Advanced Pancreatic Cancer. Advances in Clinical Medicine, 2021, 11, 6097-6105.	0.0	0
2069	Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma. BMC Cancer, 2021, 21, 1347.	1.1	3
2070	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 401-413.	1.9	9
2071	Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. Bioscience Reports, 2022, 42, .	1.1	13
2072	Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. OncoImmunology, 2022, 11, .	2.1	2
2073	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers, 2022, 14, 621.	1.7	34
2074	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncology, 2022, 18, 1423-1435.	1.1	14
2075	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Molecular Cancer, 2022, 21, 28.	7.9	393
2076	Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 208-218.	3.7	105
2077	Metabolism-Associated Gene Signatures for FDG Avidity on PET/CT and Prognostic Validation in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 845900.	1.3	3
2078	Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. , 2022, 10, e003133.		20
2079	Disrupted BRCA1â€PALB2 interaction induces tumor immunosuppression and Tâ€lymphocyte infiltration in HCC through cGASâ€STING pathway. Hepatology, 2023, 77, 33-47.	3.6	28
2080	The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. Frontiers in Immunology, 2021, 12, 802049.	2.2	6
2081	Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 257-273.	8.2	77

#	Article	IF	Citations
2082	Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Seminars in Cancer Biology, 2022, 86, 799-815.	4.3	28
2083	The Emerging Role of Tissue-Resident Memory CD8+ T Lymphocytes in Human Digestive Tract Cancers. Frontiers in Oncology, 2021, 11, 819505.	1.3	7
2084	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Medicine, 2022, 14, 1.	3.6	68
2085	Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World Journal of Gastrointestinal Oncology, 2022, 14, 163-180.	0.8	12
2086	Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. Frontiers in Immunology, 2021, 12, 798474.	2.2	10
2087	Hepatic Tumor Stiffness Measured by Shear Wave Elastography is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. SSRN Electronic Journal, 0, , .	0.4	0
2088	Recent advances in systemic therapy for hepatocellular carcinoma. Biomarker Research, 2022, 10, 3.	2.8	94
2089	ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 799566.	1.3	2
2090	Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Frontiers in Immunology, 2022, 13, 815575.	2.2	63
2091	Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients. Frontiers in Molecular Biosciences, 2021, 8, 800679.	1.6	2
2092	Is There an Impact of Locoregional Therapy on Immune Response Modulation in HCC?. Radiology, 2022, 303, 226-228.	3.6	2
2093	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 219-229.	3.7	79
2094	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. Frontiers in Pharmacology, 2021, 12, 786174.	1.6	8
2095	Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy. Frontiers in Immunology, 2022, 13, 781660.	2.2	21
2096	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90.	5.1	526
2097	Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to antiâ€“programmed cell death proteinâ€1 therapy. Hepatology, 2022, 76, 1602-1616.	3.6	18
2098	Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. Hepatology, 2022, 76, 630-645.	3.6	13
2099	Targets of immunotherapy for hepatocellular carcinoma: An update. World Journal of Hepatology, 2022, 14, 140-157.	0.8	7

#	Article	IF	Citations
2100	Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers, 2022, 14, 504.	1.7	14
2101	Potential therapeutic strategies to combat HCC. Current Molecular Pharmacology, 2022, 15, .	0.7	1
2102	The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma. Laboratory Investigation, 2022, 102, 613-620.	1.7	2
2104	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. Journal of Personalized Medicine, 2022, 12, 149.	1.1	14
2106	Influence of Helicobacter pylori infection on PDâ€1/PDâ€L1 blockade therapy needs more attention. Helicobacter, 2022, 27, e12878.	1.6	15
2107	Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. Future Oncology, 2022, , .	1.1	4
2108	Preclinical mouse models of hepatocellular carcinoma: An overview and update. Experimental Cell Research, 2022, 412, 113042.	1.2	4
2109	Immune modulating nanoparticles depleting tumor-associated macrophages to enhance immune checkpoint blockade therapy. Chemical Engineering Journal, 2022, 435, 134779.	6.6	9
2110	Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant. Hepatoma Research, 0, , .	0.6	3
2111	Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. Frontiers in Immunology, 2022, 13, 830292.	2.2	24
2112	T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 203-214.	2.3	1
2114	Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell International, 2022, 22, 73.	1.8	21
2115	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Digestive and Liver Disease, 2022, 54, 452-460.	0.4	38
2116	An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 2046-2058.	0.6	2
2117	Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma. Aging, 2022, 14, 1473-1491.	1.4	10
2118	Advances in understanding role of gut microbiota in immunotherapy for hepatocellular carcinoma. World Chinese Journal of Digestology, 2022, 30, 147-151.	0.0	0
2119	Recent insights into the use of immune checkpoint inhibitors in gastric cancer. Porto Biomedical Journal, 2022, 7, e162.	0.4	3
2120	Advances in new antivirals for chronic hepatitis B. Chinese Medical Journal, 2022, 135, 571-583.	0.9	4

#	Article	IF	Citations
2121	Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors. Meditsinskiy Sovet, 2021, , 84-93.	0.1	0
2122	Immunotherapies for hepatocellular carcinoma. Cancer Medicine, 2022, 11, 571-591.	1.3	29
2123	Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2022, 31, 337-346.	1.9	6
2124	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. Frontiers in Oncology, 2021, 11, 801379.	1.3	21
2125	New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. International Journal of Biological Sciences, 2022, 18, 2775-2794.	2.6	27
2126	Immunotherapy in GI Cancers: Hepatocellular Carcinoma: Perspective. , 2022, , 177-183.		0
2127	Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. Advances in Cancer Research, 2022, , 367-413.	1.9	6
2128	Hepatocellular carcinomaâ€"An updated review. , 2022, , 11-31.		0
2129	Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity. Cancer Control, 2022, 29, 107327482210781.	0.7	2
2130	Implications of genetic heterogeneity in hepatocellular cancer. Advances in Cancer Research, 2022, , 103-135.	1.9	5
2131	A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2022, 21, 153303382210751.	0.8	21
2132	HAMP Is a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
2133	Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210802.	1.4	43
2134	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350.	0.5	3
2135	A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response. Mathematical Biosciences and Engineering, 2022, 19, 4719-4736.	1.0	1
2136	Comparative genomics and molecular epidemiology on hepatitis virusâ€"induced hepatocellular carcinoma. , 2022, , 257-285.		1
2137	Long-term remission by nivolumab monotherapy for sorafenib-refractory hepatocellular carcinoma. Journal of Cancer Research and Practice, 2022, 9, 41.	0.2	1
2138	Role of transcription factors in hepatocellular carcinoma. , 2022, , 149-163.		0

#	Article	IF	Citations
2139	Down-regulation of TRPV6 Is Associated With Adverse Prognosis in Hepatocellular Carcinoma Treated With Curative Resection. Cancer Genomics and Proteomics, 2022, 19, 259-269.	1.0	1
2140	Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma. Cancer Control, 2022, 29, 107327482210768.	0.7	5
2141	High Expression of Ferritinophagy-Related RRM2 Gene in Relation to Unfavorable Outcome and Immune Cells Infiltration in Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
2142	FMO4 shapes immunoâ€metabolic reconfiguration in hepatocellular carcinoma. Clinical and Translational Medicine, 2022, 12, e740.	1.7	3
2143	A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. ELife, 2022, 11, .	2.8	47
2144	Î²-Catenin signaling in hepatocellular carcinoma. Journal of Clinical Investigation, 2022, 132, .	3.9	80
2145	Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo. Molecules, 2022, 27, 1482.	1.7	8
2146	PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA. Future Oncology, 2022, 18, 1691-1703.	1.1	4
2147	A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	0
2148	Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 824208.	1.3	28
2149	Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 842220.	1.8	8
2150	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
2151	The Bright and the Dark Side of TGF-Î² Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. Cancers, 2022, 14, 940.	1.7	16
2152	Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer. Nature Communications, 2022, 13, 954.	5.8	38
2153	Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma. Cancer Cell International, 2022, 22, 97.	1.8	7
2154	Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma. Annals of HPB Surgery, 2022, 27, 33-39.	0.1	0
2155	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 425-435.	1.9	3
2156	Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?. Seminars in Cancer Biology, 2022, 86, 1175-1185.	4.3	2

#	Article	IF	Citations
2157	Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Cancer Immunology, Immunotherapy, 2022, 71, 2371-2379.	2.0	4
2158	PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. International Journal of Molecular Sciences, 2022, 23, 2707.	1.8	9
2159	Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients. Clinical Cancer Research, 2022, 28, 3499-3508.	3.2	32
2160	Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 157-170.	1.8	23
2161	OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression. Cancer Immunology, Immunotherapy, 2022, 71, 2677-2689.	2.0	7
2162	Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 233-263.	1.8	27
2163	Lenvatinib plus pembrolizumab for systemic therapy-naÃ¯ve and -experienced unresectable hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 2631-2643.	2.0	23
2166	Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer, 2022, 22, 270.	1.1	23
2167	Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 814120.	1.3	3
2168	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers, 2022, 14, 1760.	1.7	20
2169	DePICting T cellâ€“APC crosstalk in cancer. Nature Cancer, 2022, 3, 265-267.	5.7	3
2170	Prognostic potential of the small GTPase Ran and its methylation in hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 248-256.	0.6	1
2171	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer, 2022, 164, 95-104.	1.3	0
2172	Immunotherapy and Transarterial therapy of <scp>HCC</scp>: What the interventional radiologist needs to know about the changing landscape of <scp>HCC</scp> treatment?. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 478-482.	0.9	10
2173	Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. Clinical Colorectal Cancer, 2022, 21, 236-243.	1.0	6
2174	ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma. Frontiers in Genetics, 2022, 13, 842351.	1.1	8
2175	Nanoliposome C6â€Ceramide in combination with antiâ€CTLA4 antibody improves antiâ€tumor immunity in hepatocellular cancer. FASEB Journal, 2022, 36, e22250.	0.2	10
2176	Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma. European Radiology, 2022, 32, 5156-5165.	2.3	4

#	Article	IF	Citations
2177	Effectiveness of TKI Inhibitors Combined With PD-1 in Patients With Postoperative Early Recurrence of HCC: A Real-World Study. Frontiers in Oncology, 2022, 12, 833884.	1.3	9
2178	Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. Journal of Hepatology, 2022, 77, 453-466.	1.8	50
2179	Immune-related lincRNA pairs predict prognosis and therapeutic response in hepatocellular carcinoma. Scientific Reports, 2022, 12, 4259.	1.6	1
2180	Comparative safety, efficacy and survival outcome of anti-PD-1 immunotherapy in colorectal cancer patients with vs without hepatitis B virus infection: a multicenter cohort study. Clinical and Translational Gastroenterology, 2022, Publish Ahead of Print, .	1.3	6
2181	Advances in artificial intelligence techniques drive the application of radiomics in the clinical research of hepatocellular carcinoma. , 2022, 1, 49-54.		1
2182	Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 2022, 40, 252-254.	7.7	9
2183	Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Cancers, 2022, 14, 1526.	1.7	7
2184	Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development. Expert Opinion on Investigational Drugs, 2022, 31, 483-494.	1.9	2
2186	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. Chemotherapy, 2023, 68, 1-15.	0.8	0
2187	Prognostic significance of <scp>albuminâ€“bilirubin</scp> score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 662-670.	0.9	5
2188	Oligometastatic Disease in the Liver: The Role of Interventional Oncology. British Journal of Radiology, 2022, 95, 20211350.	1.0	4
2189	N6-Methyladenine-Related Signature for Immune Microenvironment and Response to Immunotherapy in Hepatocellular Carcinoma. International Journal of General Medicine, 2022, Volume 15, 3525-3540.	0.8	5
2190	Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Frontiers in Oncology, 2022, 12, 821903.	1.3	2
2191	Phase IIÂclinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Future Oncology, 2022, 18, 2173-2191.	1.1	1
2192	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers, 2022, 14, 1747.	1.7	36
2193	The Treatment Landscape of Advanced Hepatocellular Carcinoma. Current Oncology Reports, 2022, 24, 917-927.	1.8	21
2194	LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 203-220.	1.8	8
2195	Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 265-272.	1.8	18

#	Article	IF	Citations
2196	Pyroptosis-Related Risk Signature Exhibits Distinct Prognostic, Immune, and Therapeutic Landscapes in Hepatocellular Carcinoma. Frontiers in Genetics, 2022, 13, 823443.	1.1	6
2197	Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. International Journal of Molecular Sciences, 2022, 23, 3207.	1.8	7
2198	The clinical and prognostic significance of CMTM6/PD-L1 in oncology. Clinical and Translational Oncology, 2022, 24, 1478-1491.	1.2	2
2199	Suppression of the transforming growth factor-Î² signaling pathway produces a synergistic effect of combination therapy with programmed death receptor 1 blockade and radiofrequency ablation against hepatic carcinoma in mice. Bioengineered, 2022, 13, 9046-9058.	1.4	2
2200	The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligandâ€1 in advanced hepatocellular carcinoma patients. Asia-Pacific Journal of Clinical Oncology, 2022, , .	0.7	3
2201	Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2449-2460.	3.2	39
2202	Apoptosis, Pyroptosis, and Ferroptosis Conspiringly Induce Immunosuppressive Hepatocellular Carcinoma Microenvironment and Î³Î´ T-Cell Imbalance. Frontiers in Immunology, 2022, 13, 845974.	2.2	15
2204	Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis. Frontiers in Oncology, 2022, 12, 807102.	1.3	18
2205	Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Computational and Structural Biotechnology Journal, 2022, 20, 1752-1763.	1.9	3
2206	Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma. Biomarkers in Medicine, 2022, 16, 435-448.	0.6	0
2207	The Immune Response: A New Frontier in Interventional Oncology. Radiology, 2022, 303, 229-230.	3.6	0
2208	Immunotherapy for hepatocellular carcinoma: a â€œCRAFITYâ€•approach to patient stratification. Hepatobiliary Surgery and Nutrition, 2022, 11, 327-329.	0.7	1
2209	Immune checkpoint inhibitors for hepatocellular carcinoma â€“ A game changer in treatment landscape. Journal of the Formosan Medical Association, 2022, 121, 1371-1383.	0.8	3
2210	Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress. International Journal of Molecular Sciences, 2022, 23, 3917.	1.8	5
2211	Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model. Experimental Hematology and Oncology, 2022, 11, 20.	2.0	6
2212	Blocking CD47 promotes antitumour immunity through CD103+ dendritic cellâ€“NK cell axis in murine hepatocellular carcinoma model. Journal of Hepatology, 2022, 77, 467-478.	1.8	47
2213	Circumsporozoite Protein of Plasmodium berghei- and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)-b-poly(benzyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.8	
2214	Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 406-416.e11.	2.3	31

#	Article	IF	Citations
2215	Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology, 2022, 75, 1604-1626.	3.6	97
2216	Targeting tumor associated macrophages in hepatocellular carcinoma. Biochemical Pharmacology, 2022, 199, 114990.	2.0	13
2217	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European Journal of Cancer, 2022, 167, 1-12.	1.3	43
2218	Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial. European Journal of Cancer, 2022, 166, 176-184.	1.3	26
2219	Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surgical Oncology, 2022, 42, 101748.	0.8	2
2220	Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy. Bioactive Materials, 2022, 16, 107-119.	8.6	24
2221	Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence. Engineering, 2022, 10, 57-64.	3.2	4
2222	Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?. Frontiers in Medicine, 2021, 8, 771887.	1.2	10
2223	Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma. Nature Communications, 2021, 12, 7142.	5.8	21
2224	Hepatitis B virus polymerase-specific T cell epitopes shift in a mouse model of chronic infection. Virology Journal, 2021, 18, 242.	1.4	2
2225	Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story. Journal of Gastrointestinal Cancer, 2021, 52, 1217-1222.	0.6	3
2226	Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors. Life, 2021, 11, 1400.	1.1	1
2227	Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life, 2021, 11, 1355.	1.1	8
2228	Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Immunology, 2021, 12, 794099.	2.2	34
2229	FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opinion on Investigational Drugs, 2022, 31, 393-400.	1.9	4
2230	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. Frontiers in Immunology, 2021, 12, 773168.	2.2	18
2231	Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdominal Radiology, 2022, 47, 969-980.	1.0	11
2232	Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Frontiers in Oncology, 2021, 11, 798832.	1.3	16

#	Article	IF	Citations
2233	First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Frontiers in Oncology, 2021, 11, 771045.	1.3	20
2234	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers, 2022, 14, 109.	1.7	21
2235	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. Frontiers in Oncology, 2021, 11, 803133.	1.3	83
2236	Response Evaluation and Survival Prediction Following PDâ€1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria. Frontiers in Oncology, 2021, 11, 764189.	1.3	12
2237	Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 6307.	1.7	17
2238	Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers, 2021, 13, 6337.	1.7	3
2239	A targetable LIFRâ^'NF-Î¹Bâ^'LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nature Communications, 2021, 12, 7333.	5.8	117
2240	Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e2136128.	2.8	29
2241	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528.	21.5	201
2242	Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients. Frontiers in Molecular Biosciences, 2021, 8, 781307.	1.6	10
2243	A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract. Medical Science Monitor, 2022, 28, e935348.	0.5	2
2244	Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies. Medicine (United States), 2021, 100, e28113.	0.4	5
2245	Second-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: analysis at a Hispanic-majority NCI-designated cancer center. Journal of Gastrointestinal Oncology, 2021, 12, 2943-2951.	0.6	3
2246	Construction and Validation of a Combined Ferroptosis and Hypoxia Prognostic Signature for Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 809672.	1.6	12
2247	Đembrolizumab as second line therapy for hepatocellular patient. Meditsinskiy Sovet, 2021, , 150-154.	0.1	0
2248	Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. Frontiers in Immunology, 2021, 12, 792781.	2.2	39
2249	Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma. Molecular Imaging, 2021, 2021, 1-8.	0.7	3
2250	Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral BÂcells as a potential immunotherapy target. Oncology Reports, 2021, 47, .	1.2	8

#	Article	IF	Citations
2251	Differentiation of malignant from non-malignant portal vein thrombosis in liver cirrhosis: the challenging dilemma. Egyptian Liver Journal, 2021, 11, .	0.3	3
2252	Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis. Medicine (United States), 2021, 100, e27987.	0.4	3
2253	Key Candidate Prognostic Biomarkers Correlated with Immune Infiltration in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1607-1622.	1.8	8
2254	Evaluation of response in patients with hepatocellular carcinoma treated with intratumoral dendritic cell vaccination using intravoxel incoherent motion (IVIM) MRI and histogram analysis. Acta Radiologica, 2023, 64, 32-41.	0.5	2
2255	Biological therapies in patients with liver disease: are they really lifesavers?. Expert Opinion on Biological Therapy, 2022, 22, 473-490.	1.4	0
2257	Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States. Cancer Medicine, 2022, 11, 602-617.	1.3	1
2259	Frontline therapy for advanced hepatocellular carcinoma: an update. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210861.	1.4	13
2260	A single-cell atlas of diffuse large B cell lymphoma. Cell Reports, 2022, 39, 110713.	2.9	33
2261	Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. Future Oncology, 2022, 18, 2269-2288.	1.1	12
2262	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology, 2022, 76, 1649-1659.	3.6	18
2263	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers, 2022, 14, 2056.	1.7	24
2264	Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 683-694.	1.8	45
2265	Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. Expert Review of Gastroenterology and Hepatology, 2022, 16, 333-339.	1.4	65
2266	Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 315-325.	1.8	5
2267	Novel approaches in search for biomarkers of cholangiocarcinoma. World Journal of Gastroenterology, 2022, 28, 1508-1525.	1.4	3
2268	Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers. Frontiers in Immunology, 2022, 13, 810539.	2.2	4
2269	lncRNA MIAT targets miRâ€411â€5p/STAT3/PDâ€L1 axis mediating hepatocellular carcinoma immune response. International Journal of Experimental Pathology, 2022, 103, 102-111.	0.6	15
2270	Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers, 2022, 14, 1901.	1.7	15

#	Article	IF	Citations
2271	Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer. European Journal of Medicinal Chemistry, 2022, 237, 114376.	2.6	3
2272	IFNÎ± Potentiates Antiâ€“PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer Discovery, 2022, 12, 1718-1741.	7.7	66
2273	Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma. Frontiers in Immunology, 2022, 13, 862527.	2.2	23
2274	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers, 2022, 14, 2018.	1.7	15
2275	Systemic Therapy in Metastatic Hepatocellular Carcinoma. Current Gastroenterology Reports, 2022, 24, 65-71.	1.1	4
2276	Efficacy and safety of <scp>PD</scp>â€‘1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. Cancer Medicine, 2022, 11, 3612-3622.	1.3	13
2277	Major postoperative complications are associated with early recurrence of hepatocellular carcinoma following hepatectomy. Langenbeck's Archives of Surgery, 2022, 407, 2373-2380.	0.8	2
2314	The combination of PD-1 blockade with interferon-Î± has a synergistic effect on hepatocellular carcinoma. , 2022, 19, 726-737.		28
2315	Improving the synergistic combination of programmed deathâ€‘1/programmed death ligandâ€‘1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 560-574.	0.9	3
2317	Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.. American Journal of Cancer Research, 2021, 11, 6173-6187.	1.4	0
2318	Updates on clinical trials for the management of hepatocellular carcinoma. , 2022, , 259-273.		0
2319	Immunotherapy for hepatocellular cancer: a review of current status. , 2022, , 245-258.		0
2320	Research Progress of Immune Checkpoint Inhibitors in the Treatment of Primary Liver Cancer. Advances in Clinical Medicine, 2022, 12, 3360-3366.	0.0	0
2321	Immune checkpoint inhibitors for hepatocellular carcinoma. , 2022, , 215-223.		0
2322	Therapeutic options for the management of hepatocellular carcinoma. , 2022, , 43-62.		0
2323	Application and Research Progress of Immunosuppressive Agent-Based Systemic System Therapy in Advanced Hepatocellular Carcinoma. Advances in Clinical Medicine, 2022, 12, 3079-3086.	0.0	0
2324	Precision medicine approaches for treating hepatocellular carcinoma. , 2022, , 287-299.		0
2325	OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment. Oncogene, 2022, , .	2.6	4

#	Article	IF	Citations
2326	Exploring hypoxic biology to improve radiotherapy outcomes. Expert Reviews in Molecular Medicine, 2022, 24, e21.	1.6	4
2327	Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Investigational New Drugs, 2022, 40, 789-797.	1.2	14
2328	Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. Journal of Liver Cancer, 2022, 22, 93-102.	0.3	6
2329	Hepatitis B Virus-Associated Hepatocellular Carcinoma. Viruses, 2022, 14, 986.	1.5	37
2330	Establishment and Analysis of a Combined Diagnostic Model of Liver Cancer with Random Forest and Artificial Neural Network. Mathematical Problems in Engineering, 2022, 2022, 1-17.	0.6	0
2331	Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Cancers, 2022, 14, 2357.	1.7	18
2332	Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 219, 533-546.	1.0	6
2333	Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges. Frontiers in Pharmacology, 2022, 13, .	1.6	10
2334	Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. Cancers, 2022, 14, 2381.	1.7	4
2335	Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. World Journal of Clinical Cases, 2022, 10, 3989-4019.	0.3	6
2336	Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. Journal of Personalized Medicine, 2022, 12, 738.	1.1	2
2337	Dysregulation of immune checkpoint proteins in hepatocellular carcinoma: Impact on metabolic reprogramming. Current Opinion in Pharmacology, 2022, 64, 102232.	1.7	1
2338	Rejuvenating hepatic tumor microenvironment immunity with a phosphatidylserine-targeting small molecule drug conjugate. Biomedicine and Pharmacotherapy, 2022, 151, 113084.	2.5	0
2339	The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. International Immunopharmacology, 2022, 109, 108842.	1.7	3
2340	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401.	5.7	126
2341	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatology Communications, 2022, 6, 1776-1785.	2.0	7
2343	Immune cell infiltration and immunotherapy in hepatocellular carcinoma. Mathematical Biosciences and Engineering, 2022, 19, 7178-7200.	1.0	2
2344	Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. Expert Review of Precision Medicine and Drug Development, 2022, 7, 50-57.	0.4	1

#	Article	IF	Citations
2345	Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. Frontiers in Pharmacology, 2022, 13, .	1.6	4
2346	Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021. Expert Opinion on Investigational Drugs, 2022, 31, 693-706.	1.9	2
2347	Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma. Frontiers in Immunology, 2022, 13, 868480.	2.2	14
2348	Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.. American Journal of Cancer Research, 2022, 12, 1899-1911.	1.4	0
2349	Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.. American Journal of Cancer Research, 2022, 12, 1606-1620.	1.4	0
2350	Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210979.	1.4	7
2351	Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210994.	1.4	1
2352	Molecular characteristics of novel immune subtypes of HCC based on lncRNAs related to immune disorders. Scientific Reports, 2022, 12, .	1.6	0
2353	Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/Î²â€catenin signal activation. Oncology Letters, 2022, 24, .	0.8	8
2359	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology, 2022, 3, 118-127.	1.2	20
2360	An exploratory clinical trial of apatinib combined with intensityâ€modulated radiation therapy for patients with unresectable hepatocellular carcinoma. Cancer Medicine, 0, , .	1.3	5
2361	Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. Frontiers in Immunology, 0, 13, .	2.2	7
2362	Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 263-274.	0.7	1
2363	Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. Frontiers in Oncology, 0, 12, .	1.3	22
2364	Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China. Advances in Therapy, 2022, 39, 3334-3346.	1.3	7
2365	Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Dermatology, 2022, 158, 933.	2.0	20
2366	Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Viruses, 2022, 14, 1128.	1.5	11
2367	Comprehensive Analyses of MELK-Associated ceRNA Networks Reveal a Potential Biomarker for Predicting Poor Prognosis and Immunotherapy Efficacy in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1

#	Article	IF	Citations
2368	Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. International Journal of Clinical Oncology, 0, , .	1.0	2
2369	Hepatocellular Carcinoma: Pick the Winnerâ€"Tyrosine Kinase Inhibitor Versus Immuno-oncology Agentâ€"Based Combinations. Journal of Clinical Oncology, 2022, 40, 2763-2773.	0.8	18
2370	Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. Korean Journal of Transplantation, 2022, 36, 82-98.	0.0	9
2371	Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opinion on Emerging Drugs, 2022, 27, 141-149.	1.0	4
2372	Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	1
2373	A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment. BMC Cancer, 2022, 22, .	1.1	0
2374	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	17
2376	Emerging Therapies for Hepatocellular Carcinoma (HCC). Cancers, 2022, 14, 2798.	1.7	87
2377	Hepatobiliary carcinomas. , 2023, , 358-365.		0
2380	Novel hypoxia features with appealing implications in discriminating the prognosis, immune escape and drug responses of 947 hepatocellular carcinoma patients. Translational Cancer Research, 2022, 11, 2097-2121.	0.4	3
2381	Complete response by patients with advanced hepatocellular carcinoma after combination immune/targeted therapy and transarterial chemoembolization: two case reports and literature review. Translational Cancer Research, 2021, .	0.4	1
2382	Interventional oncology update. European Journal of Radiology Open, 2022, 9, 100430.	0.7	2
2383	Immunotherapy in hepatocellular carcinoma. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	1
2385	Metabolomics and integrated network pharmacology analysis reveal SNKAF decoction suppresses cell proliferation and induced cell apoptisis in hepatocellularÂcarcinoma via PI3K/Akt/P53/FoxO signaling axis. Chinese Medicine, 2022, 17, .	1.6	7
2386	The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biology and Medicine, 2022, 19, 1-16.	1.4	18
2387	The LINC00261/MiR105-5p/SELL axis is involved in dysfunction of B cell and is associated with overall survival in hepatocellular carcinoma. PeerJ, 0, 10, e12588.	0.9	5
2388	Immunotherapy of advanced hepatocellular carcinoma: case report and literature review. Meditsinskiy Sovet, 2022, , 31-39.	0.1	2
2389	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205.		26

#	Article	IF	Citations
2390	Calreticulin nuclear translocalization alleviates CaM/CaMKII/CREB signaling pathway to enhance chemosensitivity in HDAC inhibitor-resistant hepatocellular carcinoma cells. Aging, 0, , .	1.4	2
2391	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatology International, 2022, 16, 1150-1160.	1.9	35
2392	Imaging for better responses to immunotherapy in hepatocellular carcinoma. Hepatology, 2023, 77, 6-9.	3.6	1
2393	Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2023, 478, 23-37.	1.4	7
2394	Novel Î³Î´ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma. BMC Cancer, 2022, 22, .	1.1	2
2395	Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event. World Journal of Gastrointestinal Oncology, 2022, 14, 1103-1114.	0.8	8
2397	Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-6.	0.5	0
2398	Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. Frontiers in Immunology, 0, 13, .	2.2	2
2399	Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Frontiers in Oncology, 0, 12, .	1.3	19
2400	Four-Pyroptosis Gene-Based Nomogram as a Novel Strategy for Predicting the Effect of Immunotherapy in Hepatocellular Carcinoma. BioMed Research International, 2022, 2022, 1-24.	0.9	2
2401	Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma. Meditsinskiy Sovet, 2022, , 157-162.	0.1	0
2403	The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF-ÎºB Signaling. Medicina (Lithuania), 2022, 58, 798.	0.8	3
2404	Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?. World Journal of Hepatology, 2022, 14, 1074-1086.	0.8	1
2405	Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. Frontiers in Oncology, 0, 12, .	1.3	15
2406	Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitorâ€“treated unresectable hepatocellular carcinoma. , 2022, 10, e004779.		47
2407	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World Journal of Clinical Oncology, 2022, 13, 448-472.	0.9	6
2408	MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. Cancers, 2022, 14, 2880.	1.7	7
2409	Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	18

#	Article	IF	Citations
2410	Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach. International Immunopharmacology, 2022, 109, 108889.	1.7	11
2411	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211132.	1.4	10
2412	Immunotherapy in cancer patients with chronic hepatitis C viral infection. Journal of Cancer Research and Therapeutics, 2022, .	0.3	0
2413	Identification and Validation of Necroptosis-Related LncRNA Signature in Hepatocellular Carcinoma for Prognosis Estimation and Microenvironment Status. Frontiers in Genetics, 0, 13, .	1.1	2
2414	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer, 2022, 3, 665-680.	5.7	18
2415	Prediction of Prognosis in Patients with Hepatocellular Carcinoma Based on Molecular Subtypes of Immune Genes. Gastroenterology Research and Practice, 2022, 2022, 1-14.	0.7	0
2416	TKIs beyond immunotherapy predict improved survival in advanced HCC. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
2417	Emerging insights on immunotherapy in liver cancer. Antioxidants and Redox Signaling, 0, , .	2.5	4
2418	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. Frontiers in Immunology, 0, 13, .	2.2	16
2420	Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 0, 9, .	1.6	12
2421	Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2023, 149, 969-978.	1.2	9
2422	Research Progress of DUB Enzyme in Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
2423	Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	4
2424	The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2022, , .	0.1	0
2425	Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 0, 9, .	1.6	6
2426	Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 571-581.	1.8	10
2427	Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. Cancers, 2022, 14, 3213.	1.7	10
2428	Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review. Frontiers in Oncology, 0, 12, .	1.3	2

#	Article	IF	Citations
2429	Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer, 2022, 11, 558-571.	4.2	6
2430	Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. Frontiers in Immunology, 0, 13, .	2.2	23
2431	Cold Atmospheric Plasma Conveys Selectivity Against Hepatocellular Carcinoma Cells via Triggering EGFR(Tyr1068)-Mediated Autophagy. Frontiers in Oncology, 0, 12, .	1.3	4
2432	Necroptosis-Related Genes Signatures Identified Molecular Subtypes and Underlying Mechanisms in Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
2433	Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. Molecular Therapy - Oncolytics, 2022, 26, 226-244.	2.0	4
2434	Identification of Ferroptosisâ€related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy. Cancer Medicine, 0, , .	1.3	5
2435	Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Frontiers in Oncology, 0, 12, .	1.3	10
2436	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
2437	Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. Journal of Big Data, 2022, 9, .	6.9	21
2438	Relationship between ATOH1 and tumor microenvironment in colon adenocarcinoma patients with different microsatellite instability status. Cancer Cell International, 2022, 22, .	1.8	3
2439	Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China. Frontiers in Oncology, 0, 12, .	1.3	5
2440	Bioinformatics Analysis for Constructing a Six-Immune-Related Long Noncoding RNA Signature as a Prognostic Model of Hepatocellular Carcinoma. BioMed Research International, 2022, 2022, 1-15.	0.9	0
2441	The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate. Frontiers in Medicine, 0, 9, .	1.2	3
2442	Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. The Lancet Gastroenterology and Hepatology, 2022, 7, 1049-1060.	3.7	3
2443	Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	5
2444	Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. BMC Infectious Diseases, 2022, 22, .	1.3	4
2445	Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review. Cancers, 2022, 14, 3373.	1.7	17
2446	Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response. International Immunopharmacology, 2022, 109, 108866.	1.7	8

#	Article	IF	Citations
2447	Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. Annals of Hepatology, 2022, 27, 100740.	0.6	1
2448	Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma. , 2023, , 109-132.		0
2449	Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma. Cancer Gene Therapy, 2022, 29, 1951-1960.	2.2	17
2450	Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition). Liver Cancer, 2022, 11, 511-526.	4.2	11
2451	Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. European Radiology, 2023, 33, 512-522.	2.3	15
2452	Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers in Pharmacology, 0, 13, .	1.6	8
2453	Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211132.	1.4	8
2454	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologistsâ€™ Perspectives. Middle East Journal of Digestive Diseases, 2022, 14, 244-253.	0.2	1
2455	The role of molecular pathology in the precision diagnosis and subclassification of hepatocellular carcinoma. Universa Medicina, 2022, 41, 194-206.	0.1	0
2456	Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma. Immunogenetics, 0, , .	1.2	1
2458	Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. Cytokine and Growth Factor Reviews, 2022, 67, 1-10.	3.2	4
2459	Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?. World Journal of Gastroenterology, 2022, 28, 3595-3607.	1.4	1
2460	Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma. Chinese Medicine, 2022, 17, .	1.6	10
2461	A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma. Cells, 2022, 11, 2302.	1.8	4
2462	Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. World Journal of Gastroenterology, 2022, 28, 3573-3585.	1.4	4
2463	The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the tumor microenvironment of patients with hepatocellular carcinoma. Annals of Translational Medicine, 2022, 10, 766-766.	0.7	4
2464	Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2022, 12, 139-150.	0.1	2
2465	Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis. Frontiers in Genetics, 0, 13, .	1.1	11

#	Article	IF	Citations
2466	Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. Biomedicines, 2022, 10, 1842.	1.4	5
2467	Monocarboxylate transporter upregulation in induced regulatory T cells promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma patients. Frontiers in Oncology, 0, 12, .	1.3	3
2468	Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	6
2469	Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel. Frontiers in Oncology, 0, 12, .	1.3	3
2470	Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2023, 72, 371-384.	2.0	7
2471	Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis. World Journal of Hepatology, 2022, 14, 1277-1290.	0.8	1
2472	The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. Frontiers in Immunology, 0, 13, .	2.2	15
2473	Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	14
2474	The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma. Journal of Clinical Medicine, 2022, 11, 4874.	1.0	5
2475	A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nature Communications, 2022, 13, .	5.8	89
2477	Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma. Nanomaterials, 2022, 12, 2832.	1.9	2
2478	CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	17
2479	Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor. Molecular Pharmaceutics, 0, , .	2.3	1
2480	Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	7
2481	Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. Cancers, 2022, 14, 3892.	1.7	1
2482	Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab. Liver Cancer, 2023, 12, 44-56.	4.2	1
2483	Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. , 2022, 10, e004006.		14
2484	Blockade of Tâ€cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBVâ€related HCC in mice. Hepatology, 2023, 77, 965-981.	3.6	12

#	Article	IF	Citations
2485	Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma. Journal of Immunology Research, 2022, 2022, 1-27.	0.9	1
2487	The prognostic significance of inflammation-immunity-nutrition score on postoperative survival and recurrence in hepatocellular carcinoma patients. Frontiers in Oncology, 0, 12, .	1.3	1
2488	Biomarkers for response to immunotherapy in hepatobiliary malignancies. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 413-419.	0.6	12
2489	Comprehensive analysis of the cancer driver genes constructs a seven-gene signature for prediction of survival and tumor immunity in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	2
2490	A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review. Cancer Cell International, 2022, 22, .	1.8	3
2491	Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study. Anticancer Research, 2022, 42, 4461-4470.	0.5	0
2492	Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma. Clinical and Experimental Medicine, 2023, 23, 579-590.	1.9	6
2493	Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. Journal of Hepatocellular Carcinoma, 0, Volume 9, 823-837.	1.8	8
2494	Tumor associated macrophages-derived exosomes facilitate hepatocellular carcinoma malignance by transferring lncMMPA to tumor cells and activating glycolysis pathway. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	40
2495	Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Scientific Reports, 2022, 12, .	1.6	6
2496	Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Medicinal Chemistry, 0, , .	1.1	1
2497	Metabolism-Related Gene Pairs to Predict the Clinical Outcome and Molecular Characteristics of Early Hepatocellular Carcinoma. Cancers, 2022, 14, 3957.	1.7	2
2498	Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. Cancers, 2022, 14, 3971.	1.7	5
2499	Prognostic and Immunological Significance of FUNDC1 in Hepatocellular Carcinoma: A Study on TCGA Mining. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-15.	0.7	3
2500	Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. Journal of Hepatocellular Carcinoma, 0, Volume 9, 855-867.	1.8	5
2501	Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. Frontiers in Immunology, 0, 13, .	2.2	6
2502	Construction of a prognostic model related to copper dependence in breast cancer by single-cell sequencing analysis. Frontiers in Genetics, 0, 13, .	1.1	1
2503	Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy. Radiation Medicine and Protection, 2022, , .	0.4	1

#	Article	IF	Citations
2504	Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 420-429.	0.6	9
2505	Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. BMC Cancer, 2022, 22, .	1.1	1
2506	The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology, 2023, 77, 1773-1796.	3.6	101
2507	Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatology International, 2022, 16, 1199-1207.	1.9	17
2508	Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment. , 0, , .		0
2509	An anti-CTLA-4 heavy chainâ€“only antibody with enhanced T _{reg} depletion shows excellent preclinical efficacy and safety profile. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	13
2510	Immunotherapy for hepatocellular carcinoma. Clinical and Experimental Medicine, 2023, 23, 569-577.	1.9	8
2511	Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. European Journal of Cancer, 2022, 174, 68-77.	1.3	45
2512	Atezolizumab plus bevacizumab versus nivolumab as firstâ€line treatment for advanced or unresectable hepatocellular carcinoma: A costâ€effectiveness analysis. Cancer, 2022, 128, 3995-4003.	2.0	9
2513	Nutrition deprivation affects the cytotoxic effect of CD8 T cells in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2022, 14, 1887-1891.	0.8	3
2514	Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma. Biochemical Genetics, 0, , .	0.8	0
2515	Delivery of human natural killer cell-derived exosomes for liver cancer therapy: an in vivo study in subcutaneous and orthotopic animal models. Drug Delivery, 2022, 29, 2897-2911.	2.5	23
2516	Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. Frontiers in Oncology, 0, 12, .	1.3	13
2517	Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis. Frontiers in Oncology, 0, 12, .	1.3	7
2518	Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1011-1027.	1.8	3
2519	Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology, 2023, 164, 72-88.e18.	0.6	48
2520	Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biology, 2022, 56, 102463.	3.9	60
2521	Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma. International Immunopharmacology, 2022, 112, 109223.	1.7	7

#	Article	IF	Citations
2522	Systemic Treatments and Related Side Effects in Liver Tumors. , 2022, , 259-270.		0
2523	Immune checkpoint inhibitor therapy for hepatocellular carcinoma. Annals of Gastroenterology, 2022, , .	0.4	0
2524	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. SSRN Electronic Journal, 0, , .	0.4	0
2525	Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. Cancer Control, 2022, 29, 107327482211112.	0.7	17
2526	Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities. Hepatoma Research, 0, 8, 32.	0.6	0
2527	Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. , 2022, , 761-776.		0
2528	Effect ofHelicobacter pylorion immunotherapy is gaining more attention. Helicobacter, 2022, 27, .	1.6	6
2530	Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development. Journal of Cancer Research and Clinical Oncology, 2023, 149, 4047-4061.	1.2	2
2531	National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clinical Gastroenterology and Hepatology, 2023, 21, 1581-1589.	2.4	5
2532	Antitumor Effect of Zinc Acetate in Hepatocellular Carcinoma Cell Lines via the Induction of Apoptosis. Journal of Nutritional Science and Vitaminology, 2022, 68, 303-311.	0.2	1
2533	Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	2
2534	Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. Cancers, 2022, 14, 4201.	1.7	1
2535	PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib. Frontiers in Oncology, 0, 12, .	1.3	2
2536	Nutrition deprivation affects the cytotoxic effect of CD8 T cells in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2022, 14, 1886-1890.	0.8	0
2537	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Frontiers in Oncology, 0, 12, .	1.3	5
2539	Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. PLoS ONE, 2022, 17, e0274451.	1.1	1
2540	A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	1
2541	Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China. Frontiers in Genetics, 0, 13, .	1.1	4

#	Article	IF	Citations
2542	Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. Discover Oncology, 2022, 13, .	0.8	6
2543	Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Frontiers in Oncology, 0, 12, .	1.3	9
2544	Role of genetic testing in hepatic, pancreatic, and biliary cancers. Surgical Oncology, 2022, 44, 101844.	0.8	7
2545	A retrospective study of PD-L1 immunohistochemistry for hepatocellular carcinoma. , 2022, 1, 187-193.		1
2546	Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	8
2547	The Role of Immunotherapy in Pancreatic Cancer. Current Oncology, 2022, 29, 6864-6892.	0.9	18
2549	Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. , 2022, 10, e005128.		4
2550	Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study. Frontiers in Oncology, 0, 12, .	1.3	8
2551	A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. Current Oncology, 2022, 29, 6445-6462.	0.9	6
2552	Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open, 2022, 6, .	0.7	20
2553	Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy. Frontiers in Medicine, 0, 9, .	1.2	5
2554	Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. World Journal of Gastroenterology, 2022, 28, 4929-4942.	1.4	5
2555	Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Frontiers in Oncology, 0, 12, .	1.3	6
2556	Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review. Frontiers in Oncology, 0, 12, .	1.3	2
2557	PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. Biomolecules, 2022, 12, 1226.	1.8	4
2558	Immunotherapy and Hepatocellular Cancer: Where Are We Now?. Cancers, 2022, 14, 4523.	1.7	7
2559	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Frontiers in Immunology, 0, 13, .	2.2	83
2560	Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma. Frontiers in Medicine, 0, 9, .	1.2	5

#	Article	IF	Citations
2561	Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2023, 115, 202-213.	0.4	25
2563	Neoantigens and their clinical applications in human gastrointestinal cancers. World Journal of Surgical Oncology, 2022, 20, .	0.8	1
2564	Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	11
2565	Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
2566	Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting Î²-catenin mutation in patients with hepatocellular carcinoma: A retrospective study. Frontiers in Oncology, 0, 12, .	1.3	2
2567	Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Frontiers in Immunology, 0, 13, .	2.2	8
2568	The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study. Frontiers in Oncology, 0, 12, .	1.3	2
2569	A <scp>CD8</scp> ⁺ T cellâ€related genes prognostic model for hepatocellular carcinoma patients. Scandinavian Journal of Immunology, 0, , .	1.3	1
2570	HCV and tumor-initiating stem-like cells. Frontiers in Physiology, 0, 13, .	1.3	1
2571	Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers, 2022, 14, 4616.	1.7	18
2572	Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 11363.	1.8	6
2573	A novel signature of combing cuproptosis- with ferroptosis-related genes for prediction of prognosis, immunologic therapy responses and drug sensitivity in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	9
2574	Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer. Frontiers in Genetics, 0, 13, .	1.1	1
2575	Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma. Journal of Biological Chemistry, 2022, 298, 102442.	1.6	2
2577	Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	9
2578	Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice. OncoTargets and Therapy, 0, Volume 15, 1079-1094.	1.0	4
2579	Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions. JCO Global Oncology, 2022, , .	0.8	4
2580	Integrative pan-cancer landscape of MMS22L and its potential role in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	0

#	Article	IF	Citations
2581	Application of genomic selection and experimental techniques to predict cell death and immunotherapeutic efficacy of ferroptosis-related CXCL2 in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
2582	Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy. ACS Biomaterials Science and Engineering, 2022, 8, 4819-4826.	2.6	2
2583	Enhancement of dendritic cellÂimmunotherapy by recalling antigens for hepatocellular carcinoma in mice. Immunotherapy, 2022, 14, 1225-1236.	1.0	1
2584	Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. Liver Cancer, 2023, 12, 72-84.	4.2	16
2585	Research Progress of Systematic Therapy for Advanced Primary Liver Cancer. Advances in Clinical Medicine, 2022, 12, 9622-9627.	0.0	0
2586	Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression. Technology in Cancer Research and Treatment, 2022, 21, 153303382211313.	0.8	6
2587	Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Advances, 2022, 12, 31068-31082.	1.7	8
2588	Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis. Technology in Cancer Research and Treatment, 2022, 21, 153303382211336.	0.8	4
2589	First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review. Current Oncology, 2022, 29, 7305-7326.	0.9	2
2590	Hepatocellular Carcinoma Medical Therapy. Updates in Surgery Series, 2023, , 173-179.	0.0	0
2591	Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. World Journal of Hepatology, 0, 14, 1862-1874.	0.8	5
2592	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1109-1125.	1.8	11
2593	Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Pharmaceutics, 2022, 14, 2263.	2.0	3
2594	Immunotherapy and Hepatocellular Carcinoma. , 0, , .		0
2595	Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go. Frontiers in Oncology, 0, 12, .	1.3	3
2596	Single-cell transcriptomics reveals the role of Macrophage-NaÃ¯ve CD4â€‰+â€‰T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma. Journal of Translational Medicine, 2022, 20, .	1.8	9
2597	Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 14809-14831.	2.9	5
2598	Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Immunotherapy, 2022, 14, 1341-1351.	1.0	9

#	Article	IF	Citations
2599	Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment. Journal of Personalized Medicine, 2022, 12, 1726.	1.1	0
2600	Prediction of therapeutic response of advanced hepatocellular carcinoma to combined targeted immunotherapy by MRI. Magnetic Resonance Imaging, 2023, 96, 1-7.	1.0	3
2601	Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle. Cancers, 2022, 14, 4896.	1.7	4
2602	Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma. Clinical Radiology, 2023, 78, e37-e44.	0.5	1
2603	Application of nanomaterials in combined thermal ablation and immunotherapy for liver tumors. World Chinese Journal of Digestology, 2022, 30, 829-837.	0.0	0
2604	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 583-705.	4.5	102
2605	Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. Cancers, 2022, 14, 5013.	1.7	12
2607	Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. Vaccines, 2022, 10, 1673.	2.1	1
2608	A composite indicator of derived neutrophilâ€“lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors. Frontiers in Oncology, 0, 12, .	1.3	1
2609	Tumor microenvironment: barrier or opportunity towards effective cancer therapy. Journal of Biomedical Science, 2022, 29, .	2.6	67
2610	Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Cancer, 2022, 22, .	1.1	3
2611	Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. Frontiers in Immunology, 0, 13, .	2.2	13
2614	A novel risk score based on immune-related genes for hepatocellular carcinoma as a reliable prognostic biomarker and correlated with immune infiltration. Frontiers in Immunology, 0, 13, .	2.2	7
2615	Engineered anti-PDL1 with IFNÎ± targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut, 2023, 72, 1544-1554.	6.1	11
2616	Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. , 2022, 10, e005414.		18
2617	An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2023, 32, 101-117.	0.6	4
2618	Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-ÎºB pathway. International Journal of Pharmaceutics, 2022, 628, 122361.	2.6	8
2619	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0

#	Article	IF	Citations
2620	Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211348.	0.6	2
2621	Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study. Anticancer Research, 2022, 42, 5465-5473.	0.5	2
2622	Advances in Targeted Immunotherapy for Hepatobiliary Cancers. International Journal of Molecular Sciences, 2022, 23, 13961.	1.8	10
2623	A radiomics-based model can predict recurrence-free survival of hepatocellular carcinoma after curative ablation. Asian Journal of Surgery, 2023, 46, 2689-2696.	0.2	2
2624	Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 203-222.	8.2	113
2625	Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World Journal of Transplantation, 0, 12, 331-346.	0.6	2
2626	Quantitative Radiological Features and Deep Learning for the Non-Invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: A Digital Biopsy Study. Academic Radiology, 2023, 30, 1317-1328.	1.3	4
2627	Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data. Expert Opinion on Therapeutic Targets, 2022, 26, 767-780.	1.5	1
2628	Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. Frontiers in Immunology, 0, 13, .	2.2	9
2629	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Aheadâ€"A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 14117.	1.8	7
2630	Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma. Frontiers in Medicine, 0, 9, .	1.2	1
2631	Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Frontiers in Oncology, 0, 12, .	1.3	1
2632	Enzyme-induced morphological transformation of self-assembled peptide nanovehicles potentiates intratumoral aggregation and inhibits tumour immunosuppression. Chemical Engineering Journal, 2023, 454, 140466.	6.6	12
2633	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	0
2634	Low-dose nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 2022, 22, .	1.1	5
2635	Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma. Liver Cancer International, 2023, 4, 13-27.	0.2	0
2636	Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis. Medicine (United States), 2022, 101, e31479.	0.4	2
2637	CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways. Cancers, 2022, 14, 5610.	1.7	5

#	Article	IF	Citations
2638	Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review. , 2022, 1, 225-234.		3
2639	Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis. Clinical and Experimental Medicine, 0, , .	1.9	1
2640	The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints. Biomedicines, 2022, 10, 2827.	1.4	4
2641	Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. BMC Gastroenterology, 2022, 22, .	0.8	1
2642	Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World Journal of Gastroenterology, 0, 28, 6034-6044.	1.4	6
2643	Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study. International Immunopharmacology, 2022, 113, 109401.	1.7	0
2644	Folate Receptorâ€Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells. Small, 2023, 19, .	5.2	12
2645	Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Advances in Therapy, 0, , .	1.3	1
2646	Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncology, 2022, 18, 3769-3782.	1.1	11
2647	<scp>KCNQ1OT1</scp> sponges <scp>miR</scp>â€34a to promote malignant progression of malignant melanoma via upregulation of the <scp>STAT3</scp>/<scp>PDâ€L1</scp> axis. Environmental Toxicology, 2023, 38, 368-380.	2.1	6
2648	Molecular subtyping and IMScore based on immune-related pathways, oncogenic pathways, and DNA damage repair pathways for guiding immunotherapy in hepatocellular carcinoma patients. Journal of Gastrointestinal Oncology, 2022, .	0.6	1
2649	Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review. Journal of Cancer, 2022, 13, 3539-3553.	1.2	2
2650	A powerful antitumor â€œtridentâ€: the combination of radio-, immuno- and anti-angiogenesis therapy based on mesoporous silica single coated gold nanoparticles. Journal of Materials Chemistry B, 2023, 11, 879-889.	2.9	2
2651	Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188841.	3.3	0
2652	Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188848.	3.3	3
2653	The role of circadian gene timeless in gastrointestinal cancers. Gene Reports, 2023, 30, 101722.	0.4	0
2654	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2022, 23, 1126.	1.5	44
2655	Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies. Cancers, 2022, 14, 4380.	1.7	10

#	Article	IF	Citations
2656	Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Frontiers in Oncology, 0, 12, .	1.3	3
2657	Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs. Frontiers in Immunology, 0, 13, .	2.2	2
2659	Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis. Expert Opinion on Drug Safety, 2023, 22, 323-329.	1.0	0
2660	Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. , 2022, 10, e005457.		19
2661	Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. Journal of Hepatology, 2023, 78, 376-389.	1.8	13
2662	Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an antiâ€“PDâ€“1 antibody. Frontiers in Immunology, 0, 13, .	2.2	1
2663	Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. Expert Opinion on Investigational Drugs, 2022, 31, 1151-1167.	1.9	3
2664	Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis. Frontiers in Oncology, 0, 12, .	1.3	2
2665	Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1187-1200.	1.8	2
2666	Highlighting novel targets in immunotherapy for liver cancer. Expert Review of Gastroenterology and Hepatology, 2022, 16, 1029-1041.	1.4	3
2667	ACR AppropriatenessÂ® Management of Liver Cancer: 2022 Update. Journal of the American College of Radiology, 2022, 19, S390-S408.	0.9	1
2668	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Journal of Liver Cancer, 2023, 23, 1-120.	0.3	24
2669	State of the art and perspectives in liver transplantation. Hepatobiliary and Pancreatic Diseases International, 2023, 22, 1-3.	0.6	3
2671	Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future. Current Pharmaceutical Design, 2023, 29, 2-14.	0.9	2
2672	Macrophage GSK3Î²-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. , 2022, 10, e005655.		10
2673	Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Biomaterialia, 2023, 157, 337-351.	4.1	3
2674	Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. Frontiers in Medicine, 0, 9, .	1.2	1
2675	Inflammation and Fibrosis in Patients with Non-Cirrhotic Hepatitis B Virus-Associated Hepatocellular Carcinoma: Impact on Prognosis after Hepatectomy and Mechanisms Involved. Current Oncology, 2023, 30, 196-218.	0.9	2

#	Article	IF	Citations
2676	An overview: Management of patients with advanced hepatocellular carcinoma. BioScience Trends, 2022, 16, 405-425.	1.1	7
2677	Nanomedicineâ€boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma. Military Medical Research, 2022, 9, .	1.9	7
2678	Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation. Frontiers in Immunology, 0, 13, .	2.2	3
2679	Epidemiology, presentation, and therapeutic approaches for hepatitis D infections. Expert Review of Anti-Infective Therapy, 2023, 21, 127-142.	2.0	2
2680	Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1263-1278.	1.8	2
2681	The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. Cancers, 2022, 14, 6151.	1.7	3
2682	Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma. Aging, 0, , .	1.4	0
2683	Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
2684	Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncology, 2023, 9, 102.	3.4	11
2685	Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey. JTO Clinical and Research Reports, 2023, 4, 100446.	0.6	0
2686	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	36
2687	Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. Journal of Clinical Oncology, 0, , .	0.8	21
2688	Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers, 2023, 15, 50.	1.7	5
2689	Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines, 2022, 10, 3202.	1.4	26
2690	Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. European Journal of Cell Biology, 2023, 102, 151284.	1.6	8
2691	Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience. In Vivo, 2023, 37, 233-241.	0.6	1
2692	Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis. CardioVascular and Interventional Radiology, 0, , .	0.9	0
2693	Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211480.	1.4	10

#	Article	IF	Citations
2694	PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma. Cancers, 2023, 15, 447.	1.7	2
2695	Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts. Modern Pathology, 2023, 36, 100042.	2.9	2
2696	Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. Current Oncology, 2023, 30, 1363-1380.	0.9	1
2697	Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World Journal of Gastrointestinal Surgery, 0, 15, 19-31.	0.8	4
2698	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Frontiers in Pharmacology, 0, 13, .	1.6	13
2699	Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. Cancers, 2023, 15, 348.	1.7	3
2700	The upregulation of CLGN in hepatocellular carcinoma is potentially regulated by hsa-miR-194-3p and associated with patient progression. Frontiers in Oncology, 0, 12, .	1.3	0
2701	Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. Frontiers in Oncology, 0, 12, .	1.3	1
2702	A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinoma. Cell Discovery, 2023, 9, .	3.1	8
2703	Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 1417.	1.8	10
2704	YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity. Frontiers in Pharmacology, 0, 13, .	1.6	2
2705	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Frontiers in Immunology, 0, 13, .	2.2	9
2706	SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma. BMC Gastroenterology, 2023, 23, .	0.8	0
2707	Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	3
2708	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis. Journal of Oncology, 2023, 2023, 1-13.	0.6	0
2709	Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	6
2710	Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current Oncology, 2023, 30, 749-757.	0.9	4
2711	Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis. Hepatology, 2023, 77, 1139-1149.	3.6	7

#	Article	IF	Citations
2712	Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy. Hepatology International, 2023, 17, 406-416.	1.9	10
2713	In situ Vaccination Followed by Intramuscular poly-ICLC Injections for the Treatment of Hepatocellular Carcinoma in Mouse Models. Pharmacological Research, 2023, , 106646.	3.1	0
2714	Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management. Hepatology, 2024, 79, 213-223.	3.6	3
2715	A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Antiâ€“PD-1 Immunotherapy against Hepatocarcinoma. Journal of Immunology, 2023, 210, 681-695.	0.4	2
2716	Soluble programmed death ligandâ€1â€induced immunosuppressive effects on chimeric antigen receptorâ€natural killer cells targeting Glypicanâ€3 in hepatocellular carcinoma. Immunology, 2023, 169, 204-218.	2.0	4
2717	Peripheral and tumorâ€infiltrating immune cells are correlated with patient outcomes in ovarian cancer. Cancer Medicine, 2023, 12, 10045-10061.	1.3	1
2718	Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2023, 35, 191-197.	0.8	2
2719	Immune checkpoint inhibitors in kidney transplantation. Current Opinion in Organ Transplantation, 2023, 28, 46-54.	0.8	4
2720	Clinical features and management issues of NAFLD-related HCC: what we know so far. Expert Review of Gastroenterology and Hepatology, 2023, 17, 31-43.	1.4	4
2721	Microbiome and Metabolomics in Liver Cancer: Scientific Technology. International Journal of Molecular Sciences, 2023, 24, 537.	1.8	13
2722	Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. European Journal of Internal Medicine, 2023, 111, 37-46.	1.0	3
2723	Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis. Cancers, 2023, 15, 260.	1.7	1
2724	Network Analysis for the Discovery of Common Oncogenic Biomarkers in Liver Cancer Experimental Models. Biomedicines, 2023, 11, 342.	1.4	1
2726	Fibrosis and Immunotherapy in Hepatocellular Carcinoma. , 2023, , 255-281.		1
2727	Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment. Cancers, 2023, 15, 913.	1.7	3
2728	Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. Frontiers in Immunology, 0, 14, .	2.2	1
2729	Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma. Cancers, 2023, 15, 654.	1.7	7
2730	Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). Journal of Thoracic Disease, 2023, .	0.6	1

#	Article	IF	Citations
2731	Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. International Journal of Molecular Sciences, 2023, 24, 2358.	1.8	5
2732	The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	4
2733	A DNA/DMXAA/Metalâ€“Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity. Advanced Materials, 0, , 2210440.	11.1	16
2734	Tumor immunology. , 2023, , 245-452.		0
2736	The phospholipid flippase <scp>ATP9A</scp> enhances macropinocytosis to promote nutrient starvation tolerance in hepatocellular carcinoma. Journal of Pathology, 2023, 260, 17-31.	2.1	3
2737	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective. Clinical and Molecular Hepatology, 2023, 29, 230-241.	4.5	8
2738	Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Cancers, 2023, 15, 854.	1.7	2
2739	Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	3
2740	Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma. Pharmacogenomics and Personalized Medicine, 0, Volume 16, 39-58.	0.4	1
2741	Analysis of the potential association between ferroptosis and immune in hepatocellular carcinoma and their relationship with prognosis. Frontiers in Oncology, 0, 12, .	1.3	1
2742	Radiation therapy in the era of immune treatment for hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	5
2743	Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. Cancers, 2023, 15, 852.	1.7	6
2744	Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus. , 2023, 1, 5-10.		0
2745	Novel Computed-Tomography-Based Transformer Models for the Noninvasive Prediction of PD-1 in Pre-Operative Settings. Cancers, 2023, 15, 658.	1.7	4
2746	Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. Journal of Hepatology, 2023, 78, 770-782.	1.8	96
2747	Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer. Pathology Research and Practice, 2023, 244, 154338.	1.0	3
2748	Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 2023, 15, 600.	1.7	3
2749	Novel insights into the impact of liver inflammatory responses on primary liver cancer development. Liver Research, 2023, 7, 26-34.	0.5	1

#	Article	IF	Citations
2750	HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	8
2751	The application of nanoparticles in immunotherapy for hepatocellular carcinoma. Journal of Controlled Release, 2023, 355, 85-108.	4.8	3
2752	Cancer Immunology: Impact of Radioembolization of Hepatocellular Carcinoma on Immune Response Modulation. American Journal of Roentgenology, 2023, 220, 863-872.	1.0	5
2753	Immunotherapy: Targeting Cancer Cells. Biological and Medical Physics Series, 2023, , 179-217.	0.3	0
2754	Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma. Magnetic Resonance in Medical Sciences, 2023, 22, 209-220.	1.1	2
2755	Plant-derived natural products and combination therapy in liver cancer. Frontiers in Oncology, 0, 13, .	1.3	0
2756	Biomarker discovery and applicationâ€"An opportunity to resolve the challenge of liver cancer diagnosis and treatment. Pharmacological Research, 2023, 189, 106674.	3.1	5
2757	Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment. European Journal of Radiology, 2023, 162, 110784.	1.2	1
2758	A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma. Journal of Pharmacological Sciences, 2023, 152, 69-75.	1.1	1
2759	Magnetic Resonance Imaging Predictors of Hepatocellular Carcinoma Progression and Dropout in Patients in Liver Transplantation Waiting List. Transplantation Direct, 2022, 8, e1365.	0.8	0
2760	Immunotherapy for recurrent hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 2261-2271.	1.4	1
2762	Liver Stereotactic Body Radiotherapy (SBRT). , 2022, , 349-362.		0
2763	Evaluation of transcriptomic molecular classification, biological behavior, and clinicopathological features in hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2023, 23, 71-84.	1.5	0
2764	Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-Î³/NSDHL/SREBP1/TGF-Î²1 axis in hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2023, 159, 114254.	2.5	4
2765	YAP1 suppression inhibits autophagy and improves the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma. Experimental Cell Research, 2023, 424, 113486.	1.2	3
2766	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. Biology, 2023, 12, 218.	1.3	27
2768	Construction of a DDR-related signature for predicting of prognosis in metastatic colorectal carcinoma. Frontiers in Oncology, 0, 13, .	1.3	2
2771	Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images. Oncology Research, 2022, 30, 243-258.	0.6	0

#	Article	IF	Citations
2772	Hypoxia-associated circPRDM4 promotes immune escape via HIF-1Î± regulation of PD-L1 in hepatocellular carcinoma. Experimental Hematology and Oncology, 2023, 12, .	2.0	12
2773	Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	44
2774	Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1. Frontiers in Pharmacology, 0, 14, .	1.6	1
2775	Association of Multi-Phasic MR-Based Radiomic and Dosimetric Features with Treatment Response in Unresectable Hepatocellular Carcinoma Patients following Novel Sequential TACE-SBRT-Immunotherapy. Cancers, 2023, 15, 1105.	1.7	5
2776	Tumor Cellâ€"Derived Microparticles Induced by Methotrexate Augment T-cell Antitumor Responses by Downregulating Expression of PD-1 in Neutrophils. Cancer Immunology Research, 2023, 11, 501-514.	1.6	4
2777	Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	19
2778	Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World Journal of Gastroenterology, 0, 29, 1054-1075.	1.4	18
2779	A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Investigational New Drugs, 2023, 41, 162-167.	1.2	4
2780	Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells. Clinical and Experimental Medicine, 2023, 23, 1881-1899.	1.9	1
2781	Therapeutic options in hepatocellular carcinoma: a comprehensive review. Clinical and Experimental Medicine, 2023, 23, 1901-1916.	1.9	11
2782	Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 3625.	1.8	1
2784	Liver Cancer and the Curative Potential of Nanomedicine. , 2023, , 283-306.		0
2785	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2023, 12, 309-320.	4.2	5
2786	HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma. Biomolecules, 2023, 13, 360.	1.8	0
2787	Identification of Drug Targets and Agents Associated with Hepatocellular Carcinoma through Integrated Bioinformatics Analysis. Current Cancer Drug Targets, 2023, 23, 547-563.	0.8	2
2788	Association between HMGA1 and immunosuppression in hepatocellular carcinoma: A comprehensive bioinformatics analysis. Medicine (United States), 2023, 102, e32707.	0.4	1
2789	Effectiveness and safety of lenvatinib plus antiâ€programmed deathâ€1 antibodies in patients with hepatocellular carcinoma: A <scp>realâ€world</scp> cohort study. Cancer Medicine, 2023, 12, 9202-9212.	1.3	3
2790	XCR1+ DCs are critical for TÂcell-mediated immunotherapy of chronic viral infections. Cell Reports, 2023, 42, 112123.	2.9	1

#	Article	IF	Citations
2791	Management of Hepatocellular Carcinoma. JAMA Surgery, 2023, 158, 410.	2.2	72
2792	Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. Journal of Hepatocellular Carcinoma, 0, Volume 10, 267-279.	1.8	1
2794	Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview. Cancers, 2023, 15, 1310.	1.7	4
2795	Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment. Hepatology, 2023, 78, 1402-1417.	3.6	4
2796	Alpha fetoprotein promotes polarization of macrophages towards M2-like phenotype and inhibits macrophages to phagocytize hepatoma cells. Frontiers in Immunology, 0, 14, .	2.2	5
2798	Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. Frontiers in Oncology, 0, 13, .	1.3	1
2799	Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
2800	Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC. Cancer Immunology, Immunotherapy, 2023, 72, 2137-2149.	2.0	2
2801	Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, 0, Volume 10, 303-313.	1.8	3
2802	Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients. Anticancer Research, 2023, 43, 1377-1384.	0.5	1
2804	Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis. Immunotherapy, 2023, 15, 353-365.	1.0	3
2805	Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. Oncogene, 2023, 42, 1051-1057.	2.6	4
2806	Abnormally primed CD8 T cells: The Achillesâ€™ heel of CHB. Frontiers in Immunology, 0, 14, .	2.2	0
2807	Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer. Cancers, 2023, 15, 1532.	1.7	6
2808	The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2023, 22, 153303382311597.	0.8	3
2809	Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation. Frontiers in Pharmacology, 0, 14, .	1.6	0
2810	Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 10, 357-367.	1.8	2
2811	Self-supervised contrastive learning using CT images for PD-1/PD-L1 expression prediction in hepatocellular carcinoma. Frontiers in Oncology, 0, 13, .	1.3	4

#	Article	IF	Citations
2812	Immune Strategies for Gastrointestinal Cancer: HCC. , 2023, , 163-176.		0
2813	An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. International Journal of Molecular Sciences, 2023, 24, 5002.	1.8	6
2814	Identification of fatty acid metabolism-related clusters and immune infiltration features in hepatocellular carcinoma. Aging, 0, , .	1.4	0
2815	A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Gastroenterology, 2023, 164, 1279-1292.	0.6	8
2817	Disruption of SLFN11 Deficiencyâ€“Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Antiâ€“PD-1 Therapy Efficacy in Hepatocellular Carcinoma. Gastroenterology, 2023, 164, 1261-1278.	0.6	17
2818	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
2819	A prognostic risk model, tumor immune environment modulation, and drug prediction of ferroptosis and amino acid metabolism-related genes in hepatocellular carcinoma. Human Cell, 2023, 36, 1173-1189.	1.2	3
2820	Body mass index and serum alpha-fetoprotein level associated with PD1 expression and prognosis in patients with hepatocellular carcinoma. Heliyon, 2023, 9, e14460.	1.4	0
2821	Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 1407-1424.	1.4	0
2822	FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. Journal of Hepatology, 2023, 79, 109-125.	1.8	20
2823	The Multifaceted Roles of Macrophages in NAFLD Pathogenesis. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 1311-1324.	2.3	13
2824	Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. Livers, 2023, 3, 121-160.	0.8	2
2825	Immunotherapy for advanced or recurrent hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 405-424.	0.8	0
2826	Analysis of factors influencing the distribution of 131-I in combined treatment of Licartin with transcatheter arterial chemoembolization in primary hepatic carcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
2827	Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 1551-1568.	1.4	5
2828	Bioorthogonal Activation of TLR7 Agonists Provokes Innate Immunity to Reinforce Aptamer-Based Checkpoint Blockade. ACS Nano, 2023, 17, 5808-5820.	7.3	8
2829	Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma. Clinical Immunology, 2023, 249, 109290.	1.4	0
2830	A key driver to promote HCC: Cellular crosstalk in tumor microenvironment. Frontiers in Oncology, 0, 13, .	1.3	4

#	Article	IF	Citations
2831	Combination immunotherapy for hepatocellular carcinoma. Journal of Hepatology, 2023, 79, 506-515.	1.8	46
2832	Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab. Journal of Liver Cancer, 2023, 23, 225-229.	0.3	2
2833	Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review. , 2023, , .		0
2834	Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 487-503.	8.2	55
2835	Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies. International Immunopharmacology, 2023, 118, 110019.	1.7	15
2836	Exosome-derived circCCAR1 promotes CD8â€‰+â€‰T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Molecular Cancer, 2023, 22, .	7.9	47
2837	Immunotherapies for advanced hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	4
2838	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12
2839	Applications of immune checkpoint inhibitors (ICIs) in the medical fields. , 0, 36, 321-330.		0
2840	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist, 2023, 28, 714-721.	1.9	2
2841	Progress in the Study of Hepatocellular Carcinoma Microenvironment and Its Clinical Significance. Advances in Clinical Medicine, 2023, 13, 4415-4420.	0.0	0
2843	The predictive value of <scp>PDâ€L1</scp> expression in patients with advanced hepatocellular carcinoma treated with <scp>PD</scp>â€1/<scp>PDâ€L1</scp> inhibitors: A systematic review and metaâ€analysis. Cancer Medicine, 2023, 12, 9282-9292.	1.3	8
2844	T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. Liver Cancer International, 2023, 4, 58-72.	0.2	0
2845	Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration. Cell Death Discovery, 2023, 9, .	2.0	7
2846	Management of hepatocellular carcinomaÂfrom diagnosis in routine clinical practice. Hepatic Oncology, 2022, 9, .	4.2	0
2847	Comprehensive characterization of ferroptosis in hepatocellular carcinoma revealing the association with prognosis and tumor immune microenvironment. Frontiers in Oncology, 0, 13, .	1.3	1
2848	Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellularâ€“cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
2849	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. Biomedicines, 2023, 11, 1020.	1.4	6

#	Article	IF	Citations
2850	Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	0
2851	Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma. Frontiers in Oncology, 0, 13, .	1.3	1
2852	The Regulatory Axis of PD-L1 Isoform 2/TNF/T Cell Proliferation Is Required for the Canonical Immune-Suppressive Effects of PD-L1 Isoform 1 in Liver Cancer. International Journal of Molecular Sciences, 2023, 24, 6314.	1.8	0
2853	Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion. Advanced Science, 2023, 10, .	5.6	18
2854	Case Report: Solitary metastasis to the appendix after curative treatment of HCC. Frontiers in Surgery, 0, 10, .	0.6	0
2856	Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment. International Journal of Molecular Sciences, 2023, 24, 6495.	1.8	6
2857	Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. BMC Gastroenterology, 2023, 23, .	0.8	0
2858	Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors. Digestive and Liver Disease, 2023, 55, 938-944.	0.4	2
2859	Another prognostic marker for hepatocellular carcinoma. Hepatology International, 2023, 17, 279-280.	1.9	0
2860	Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives. Radiology, 2023, 307, .	3.6	16
2861	Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. Therapeutics and Clinical Risk Management, 0, Volume 19, 329-339.	0.9	2
2862	Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression. Human Genomics, 2023, 17, .	1.4	1
2863	Combining immunotherapy and radiotherapy in hepatocellular carcinoma: the importance of irradiated tumor burden and the possible role of a low dose radiotherapy induction strategy. Translational Cancer Research, 2023, .	0.4	0
2864	Role of CD147 in the development and diagnosis of hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	8
2865	Immune Responses to Solid Tumors and Immune Checkpoint Therapy. , 2023, , 1028-1041.		0
2866	TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. International Journal of Surgery, 2023, 109, 1222-1230.	1.1	6
2867	Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents. Journal of Hepatocellular Carcinoma, 0, Volume 10, 587-598.	1.8	1
2868	Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma. Cell Reports Medicine, 2023, 4, 101009.	3.3	1

#	Article	IF	Citations
2870	A tumor microenvironment-based prognostic index for osteosarcoma. Journal of Biomedical Science, 2023, 30, .	2.6	6
2871	Normalization of Tumor Vessels by Lenvatinibâ€Based Metalloâ€Nanodrugs Alleviates Hypoxia and Enhances Calreticulinâ€Mediated Immune Responses in Orthotopic HCC and Organoids. Small, 2023, 19, .	5.2	5
2872	Role of ferroptosis and its non-coding RNA regulation in hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	1
2873	Enhancedanti-tumor efficacy through a combination of intramuscularly expressed DNA vaccine and plasmid-encoded PD-1 antibody. Frontiers in Immunology, 0, 14, .	2.2	1
2874	Role of Î²-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma. Cancers, 2023, 15, 2311.	1.7	6
2875	Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2023, 22, 737-750.	1.9	3
2876	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. Pathology Research and Practice, 2023, 247, 154473.	1.0	1
2877	Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer. Oncogenesis, 2023, 12, .	2.1	1
2878	Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma. , 0, , .		0
2879	Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma. Mediators of Inflammation, 2023, 2023, 1-23.	1.4	3
2880	The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma. Advanced Science, 2023, 10, .	5.6	5
2881	The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis. Medicine (United States), 2023, 102, e32591.	0.4	0
2882	Histone chaperone SSRP1 is required for apoptosis inhibition and mitochondrial function in HCC via transcriptional promotion of TRAP1. Biochemistry and Cell Biology, 0, , .	0.9	0
2883	Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease. Journal of Hepatology, 2023, 79, e73-e76.	1.8	14
2884	Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma. Cancer Letters, 2023, 563, 216192.	3.2	4
2886	Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment. , 2023, , 1-34.		0
2893	Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment. , 2023, , 1-33.		0
2901	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0

#	Article	IF	Citations
2948	New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma. Drugs, 2023, 83, 1091-1109.	4.9	2
2968	Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab. Frontiers in Immunology, 0, 14, .	2.2	1
2982	Case report: Predictability of clinical response and rejection risk after immune checkpoint inhibition in liver transplantation. , 0, 2, .		0
3001	Biomarkers for immunotherapy of hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2023, 20, 780-798.	12.5	5
3013	Detailed review on phytosomal formulation attenuating new pharmacological therapies. Advances in Traditional Medicine, 0, , .	1.0	0
3028	Hepatitis Viruses: Hepatocellular Carcinoma. , 2023, , 1-36.		0
3060	Computational immunogenomic approaches to predict response to cancer immunotherapies. Nature Reviews Clinical Oncology, 2024, 21, 28-46.	12.5	1
3119	Immune System, Redox Signaling, and Cancer Immunity. , 2023, , 207-235.		0
3202	Importance of targeting various cell signaling pathways in solid cancers. International Review of Cell and Molecular Biology, 2024, , .	1.6	0
3219	Molecular Imaging of PD-1 Unveils Unknown Characteristics of PD-1 Itself by Visualizing â€œPD-1 Microclustersâ€• Advances in Experimental Medicine and Biology, 2024, , 197-205.	0.8	0